


**CUMULATIVE
SUPPLEMENT 5
MAY 2018**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2018

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

**Cumulative Supplement 5
May 2018**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	x
1.7 Cumulative Supplement Legend.....	xi
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

38th EDITION

CUMULATIVE SUPPLEMENT 5
May 2018

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 38th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
IDT AUSTRALIA LTD (IDT AUSTRALIA LTD)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
KREMERS URBAN PHARMACEUTICALS INC (KREMERS URBAN PHARMS)	LANNETT CO INC (LANNETT CO INC)
LANNETT HOLDINGS INC (LANNETT)	LANNETT CO INC (LANNETT CO INC)
LANNETT HOLDINGS INC (LANNETT HOLDINGS INC)	LANNETT CO INC (LANNETT CO INC)
SILARX PHARMACEUTICALS INC (SILARX)	LANNETT CO INC (LANNETT CO INC)

SILARX PHARMACEUTICALS INC
(SILARX PHARMS INC)

LANNETT CO INC
(LANNETT CO INC)

SAGENT AGILA LLIC
(SAGENT AGILA)

MYLAN ASI LLC
(MYLAN ASI)

SAGENT AGILA LLC
(SAGENT AGILA LLC)

MYLAN ASI LLC
(MYLAN ASI)

SAGENT STRIDES LLC
(SAGENT STRIDESC)

MYLAN ASI LLC
(MYLAN ASI)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001

LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2017</u>	<u>MAR 2018</u>	<u>JUN 2018</u>	<u>SEP 2018</u>	<u>DEC 2018</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	19294	19359			
	2758	2763			
	(14.3%)	(14.3%)			
MULTISOURCE	16536	16596			
	(85.7%)	(85.7%)			
THERAPEUTICALLY EQUIVALENT	16431	16501			
	(85.2%)	(85.2%)			
NOT THERAPEUTICALLY EQUIVALENT	105	95			
	(0.5%)	(0.5%)			
EXCEPTIONS ¹	73	72			
	(0.4%)	(0.4%)			
NEW MOLECULAR ENTITIES APPROVED	25	6			
NUMBER OF APPLICANTS	1075	1084			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**Note:

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full

applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

SOLUTION;ORAL
ABACAVIR SULFATE
AA AUROBINDO PHARMA LTD EQ 20MG BASE/ML A 077950 001 Mar 14, 2018 Feb NEWA

ABIRATERONE ACETATE

TABLET;ORAL
>A> YONSA
>A> +! SUN PHARMA GLOBAL 125MG N 210308 001 May 22, 2018 May NEWA
ZYTIGA
+ JANSSEN BIOTECH 250MG N 202379 001 Apr 28, 2011 Feb CHRS
+! 500MG N 202379 002 Apr 14, 2017 Feb CHRS

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL
APADAZ
+ KEMPHARM 325MG;EQ 6.12MG BASE N 208653 001 Feb 23, 2018 Feb NEWA

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL
BUTALBITAL AND ACETAMINOPHEN
MAYNE PHARMA INC 300MG;50MG A 207313 001 Dec 27, 2017 Mar CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
AA NUVO PHARM INC 300MG;50MG;40MG A 207118 001 Oct 28, 2016 Apr CTEC
AA TEDOR PHARMA INC 300MG;50MG;40MG A 206615 001 Aug 04, 2017 Apr CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
>A> AA LANNETT CO INC 120MG/5ML;12MG/5ML A 091238 001 Nov 10, 2011 May CAHN
>D> AA VINTAGE PHARMS 120MG/5ML;12MG/5ML A 091238 001 Nov 10, 2011 May CAHN
TABLET;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
@ FOSUN PHARMA 300MG;30MG A 081250 001 Jul 16, 1992 Jan CAHN
@ 300MG;60MG A 081249 001 Jul 16, 1992 Jan CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
AA EPIC PHARMA LLC 325MG;5MG A 203863 001 Mar 30, 2018 Mar NEWA
AA 325MG;7.5MG A 203863 002 Mar 30, 2018 Mar NEWA
AA 325MG;10MG A 203863 003 Mar 30, 2018 Mar NEWA
AA RHODES PHARMS 300MG;5MG A 207808 001 Mar 30, 2018 Mar NEWA
AA 300MG;7.5MG A 207808 002 Mar 30, 2018 Mar NEWA
AA 300MG;10MG A 207808 003 Mar 30, 2018 Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL
OXYCODONE AND ACETAMINOPHEN
@ SPECGX LLC 325MG/5ML;5MG/5ML A 040680 001 Sep 29, 2006 Jan DISC
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN
@ VINTAGE PHARMS 325MG/5ML;5MG/5ML A 203573 001 Dec 18, 2014 Jan DISC
TABLET;ORAL
OXYCODONE AND ACETAMINOPHEN
AA ABHAI LLC 325MG;2.5MG A 210644 001 Feb 09, 2018 Jan NEWA
AA 325MG;5MG A 210644 002 Feb 09, 2018 Jan NEWA
AA 325MG;7.5MG A 210644 003 Feb 09, 2018 Jan NEWA
AA 325MG;10MG A 210644 004 Feb 09, 2018 Jan NEWA
AA WES PHARMA INC 325MG;5MG A 207510 001 Mar 21, 2018 Mar NEWA
AA 325MG;7.5MG A 207510 002 Mar 21, 2018 Mar NEWA
AA 325MG;10MG A 207510 003 Mar 21, 2018 Mar NEWA

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	+	ICU MEDICAL INC	250MG/100ML	N017656	001			Mar	CRLD
SOLUTION/DROPS;OTIC									
ACETIC ACID									
>A>	AT	LANNETT CO INC	2%	A040607	001	Feb 24, 2005	May	CAHN	
	AT	RISING PHARMS INC	2%	A207280	001	Mar 09, 2018	Feb	NEWA	
>D>	AT	VINTAGE	2%	A040607	001	Feb 24, 2005	May	CAHN	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC
HYDROCORTISONE AND ACETIC ACID

>D>	AT	TARO	2%;1%	A088759	001	Mar 04, 1985	May	CAHN	
>A>	AT	TARO PHARM INDS LTD	2%;1%	A088759	001	Mar 04, 1985	May	CAHN	

ACYCLOVIR

CAPSULE;ORAL
ACYCLOVIR

AB		HERITAGE PHARMS INC	200MG	A074889	001	Oct 31, 1997	Mar	CMFD	
----	--	---------------------	-------	---------	-----	--------------	-----	------	--

OINTMENT;TOPICAL

AB		ALEMBIC PHARMS LTD	5%	A209000	001	Apr 06, 2018	Mar	NEWA	
----	--	--------------------	----	---------	-----	--------------	-----	------	--

TABLET;ORAL

AB		YILING PHARM LTD	400MG	A210401	001	Mar 07, 2018	Feb	NEWA	
AB			800MG	A210401	002	Mar 07, 2018	Feb	NEWA	

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL
ADAPALENE AND BENZOYL PEROXIDE

AB		PERRIGO ISRAEL	0.1%;2.5%	A205033	001	Jan 23, 2018	Jan	NEWA	
AB		TARO	0.1%;2.5%	A206959	001	Jan 24, 2018	Jan	NEWA	
>A>	AB	TOLMAR	0.1%;2.5%	A206164	001	May 23, 2018	May	NEWA	

ADENOSINE

INJECTABLE;INJECTION
ADENOCARD

>D>	AP	+	ASTELLAS	3MG/ML	N019937	002	Oct 30, 1989	May	DISC
>A>		+	@	3MG/ML	N019937	002	Oct 30, 1989	May	DISC

ADENOSINE

>D>	AP		AKORN	3MG/ML	A078076	001	Oct 31, 2008	May	CHRS
>A>	AP	!		3MG/ML	A078076	001	Oct 31, 2008	May	CHRS
	AP		FRESENIUS KABI USA	3MG/ML	A205568	001	Apr 16, 2018	Apr	NEWA
	AP		GLAND PHARMA LTD	3MG/ML	A206778	001	Feb 16, 2018	Feb	NEWA

ALBUTEROL SULFATE

SYRUP;ORAL
ALBUTEROL SULFATE

>A>	AA		LANNETT CO INC	EQ 2MG BASE/5ML	A078105	001	Dec 27, 2006	May	CAHN
>D>	AA		VINTAGE	EQ 2MG BASE/5ML	A078105	001	Dec 27, 2006	May	CAHN

TABLET;ORAL

ALBUTEROL SULFATE

>A>	AB		AMNEAL PHARMS CO	EQ 2MG BASE	A208804	001	May 21, 2018	May	NEWA
>A>	AB			EQ 4MG BASE	A208804	002	May 21, 2018	May	NEWA
		@	YAOPHARMA CO LTD	EQ 2MG BASE	A072151	001	Dec 05, 1989	Jan	CAHN
		@		EQ 4MG BASE	A072152	001	Dec 05, 1989	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

ALBUTEROL SULFATE

>D>	AB		MYLAN	EQ 8MG BASE	A078092	001	Jan 29, 2007	May	CTEC
>A>		!		EQ 8MG BASE	A078092	001	Jan 29, 2007	May	CTEC
			VOSPIRE ER						
>D>	AB	!	DAVA PHARMS INC	EQ 8MG BASE	A076130	003	Sep 26, 2002	May	DISC
>A>		@		EQ 8MG BASE	A076130	003	Sep 26, 2002	May	DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ FOSUN PHARMA EQ 0.083% BASE; 0.017% A076867 001 Dec 21, 2006 Jan CAHN

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB HANGZHOU BINJIANG EQ 5MG BASE A090258 001 Sep 24, 2009 Jan CAHN
 AB EQ 10MG BASE A090258 002 Sep 24, 2009 Jan CAHN
 AB EQ 35MG BASE A090258 003 Sep 24, 2009 Jan CAHN
 AB EQ 70MG BASE A090258 004 Sep 24, 2009 Jan CAHN
 @ MYLAN EQ 35MG BASE A076584 003 Aug 04, 2008 Apr DISC
 @ EQ 70MG BASE A076584 004 Aug 04, 2008 Apr DISC

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

@ FOSUN PHARMA 100MG A070268 001 Dec 31, 1985 Jan CAHN

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB PAR PHARM INC EQ 0.5MG BASE A206113 001 Feb 23, 2018 Feb NEWA
 AB EQ 1MG BASE A206113 002 Feb 23, 2018 Feb NEWA

AMANTADINE HYDROCHLORIDE

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

AB JUBILANT GENERICS 100MG A210403 001 Feb 07, 2018 Jan NEWA
 TABLET, EXTENDED RELEASE; ORAL
 OSMOLEX ER
 + OSMOTICA PHARM EQ 129MG BASE N209410 001 Feb 16, 2018 Feb NEWA
 + EQ 193MG BASE N209410 002 Feb 16, 2018 Feb NEWA
 +! EQ 258MG BASE N209410 003 Feb 16, 2018 Feb NEWA

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ YAOPHARMA CO LTD EQ 5MG ANHYDROUS; 50MG A073357 001 Nov 27, 1991 Jan CAHN

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN-HF 8%

@ ICU MEDICAL INC 8% (8GM/100ML) A020345 001 Apr 04, 1996 Mar DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 8.5% W/ ELECTROLYTES

>D> ICU MEDICAL INC 8.5%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML N019437 005 Apr 03, 1986 May DISC
 >A> @ 8.5%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML N019437 005 Apr 03, 1986 May DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

>A> ICU MEDICAL INC 8.5%; 102MG/100ML; 487MG/100ML; 28MG/100ML; 425MG/100ML N017673 009 Oct 25, 2002 May NEWA
 >A> AMINOSYN II 8.5% W/ELECTROLYTES
 ICU MEDICAL INC 8.5%; 102MG/100ML; 492MG/100ML; 60MG/100ML; 425MG/100ML N019437 008 Oct 25, 2002 May NEWA

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ ELECTROLYTES

>D> ICU MEDICAL INC 8.5%; 102MG/100ML; 522MG/100ML; 410MG/100ML N017673 005 May DISC
 >A> @ 8.5%; 102MG/100ML; 522MG/100ML; 410MG/100ML N017673 005 May DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	10MG	A 089399	002	Jul 14, 1987	Jan	CMFD
AB		25MG	A 089399	001	Jul 14, 1987	Jan	CMFD
AB		50MG	A 089399	003	Jul 14, 1987	Jan	CMFD
AB		75MG	A 089399	004	Jul 14, 1987	Jan	CMFD
AB		100MG	A 089399	005	Jul 14, 1987	Jan	CMFD
AB		150MG	A 089399	006	Jul 14, 1987	Jan	CMFD

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@	FOSUN PHARMA	10MG;2MG	A 071062	001	Nov 27, 1987	Jan	CAHN
@		10MG;4MG	A 071862	001	Dec 21, 1987	Jan	CAHN
@		25MG;2MG	A 071063	001	Nov 27, 1987	Jan	CAHN
@		25MG;4MG	A 071064	001	Nov 27, 1987	Jan	CAHN
@		50MG;4MG	A 071863	001	Dec 21, 1987	Jan	CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	SUNSHINE LAKE	EQ 2.5MG BASE	A 206524	001	May 04, 2018	Apr	NEWA
AB		EQ 5MG BASE	A 206524	002	May 04, 2018	Apr	NEWA
AB		EQ 10MG BASE	A 206524	003	May 04, 2018	Apr	NEWA
@	YAOPHARMA CO LTD	EQ 2.5MG BASE	A 076859	001	Sep 10, 2007	Jan	CAHN
@		EQ 5MG BASE	A 076859	002	Sep 10, 2007	Jan	CAHN
@		EQ 10MG BASE	A 076859	003	Sep 10, 2007	Jan	CAHN

>A> AMLODIPINE BESYLATE; CELECOXIB

>A> TABLET;ORAL

>A> CONSENSI

>A>	+	KITOV PHARMS LTD	EQ 2.5MG BASE;200MG	N 210045	001	May 31, 2018	May	NEWA
>A>	+		EQ 5MG BASE;200MG	N 210045	002	May 31, 2018	May	NEWA
>A>	+	!	EQ 10MG BASE;200MG	N 210045	003	May 31, 2018	May	NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	SOFIE	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A 204667	001	Apr 22, 2015	Feb	CAHN
----	-------	--------------------------------------	----------	-----	--------------	-----	------

AMMONIUM LACTATE

CREAM;TOPICAL

LAC-HYDRIN

@	SUN PHARM INDS INC	EQ 12% BASE	N 020508	001	Aug 29, 1996	Feb	CAHN
---	--------------------	-------------	----------	-----	--------------	-----	------

LOTION;TOPICAL

LAC-HYDRIN

+	@ SUN PHARM INDS INC	EQ 12% BASE	N 019155	001	Apr 24, 1985	Feb	CAHN
---	----------------------	-------------	----------	-----	--------------	-----	------

AMOXAPINE

TABLET;ORAL

AMOXAPINE

	WATSON LABS	25MG	A 072691	002	Aug 28, 1992	Mar	CMS1
		50MG	A 072691	003	Aug 28, 1992	Mar	CMS1
		100MG	A 072691	004	Aug 28, 1992	Mar	CMS1

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MYDAYIS

>D>	+	SHIRE DEV LLC	12.5MG;12.5MG;12.5MG;12.5MG	N 022063	004	Jun 20, 2017	May	CHRS
>A>	+	!	12.5MG;12.5MG;12.5MG;12.5MG	N 022063	004	Jun 20, 2017	May	CHRS

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

@	ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A 062797	001	Jul 12, 1993	Mar	DISC
---	----------------------	--------------------	----------	-----	--------------	-----	------

ANASTROZOLETABLET; ORAL
ARIMIDEX

AB +! ANI PHARMS INC 1MG N020541 001 Dec 27, 1995 Jan CAHN

APALUTAMIDETABLET; ORAL
ERLEADA

+! JANSSEN BIOTECH 60MG N210951 001 Feb 14, 2018 Feb NEWA

APREPITANTCAPSULE; ORAL
APREPITANTAB GLENMARK PHARMS SA 40MG A207777 001 Oct 12, 2017 Jan CAHN
AB 80MG A207777 002 Oct 12, 2017 Jan CAHN
AB 125MG A207777 003 Oct 12, 2017 Jan CAHNARGATROBANINJECTABLE; INJECTION
ARGATROBAN

AP AMNEAL PHARMS CO 250MG/2.5ML (100MG/ML) A206698 001 Jan 26, 2018 Jan NEWA

ARIPIPIRAZOLETABLET, ORALLY DISINTEGRATING; ORAL
ARIPIPIRAZOLEAB SCIEGEN PHARMS INC 10MG A207240 001 Apr 18, 2018 Apr NEWA
AB 15MG A207240 002 Apr 18, 2018 Apr NEWAARMODAFINILTABLET; ORAL
ARMODAFINILAB AUROBINDO PHARMA LTD 50MG A206069 001 Mar 06, 2018 Feb NEWA
AB 150MG A206069 002 Mar 06, 2018 Feb NEWA
AB 250MG A206069 003 Mar 06, 2018 Feb NEWAASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

>A> PLENVU
>A> +! SALIX PHARMS INC 7.54GM; 140GM; 2.2GM; 48.11GM; 5.2GM; 9 GM N209381 001 May 04, 2018 May NEWAASPIRIN; BUTALBITAL; CAFFEINETABLET; ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE
@ FOSUN PHARMA 325MG; 50MG; 40MG

A086398 002 Apr 06, 1984 Jan CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATETABLET; ORAL
ORPHENGESIC
@ GALT PHARMS 385MG; 30MG; 25MG
ORPHENGESIC FORTE
@ GALT PHARMS 770MG; 60MG; 50MG

A075141 001 May 29, 1998 Feb CAHN

A075141 002 May 29, 1998 Feb CAHN

ASPIRIN; DIPYRIDAMOLECAPSULE, EXTENDED RELEASE; ORAL
ASPIRIN AND DIPYRIDAMOLE>A> AB ANI PHARMS INC 25MG; 200MG A206964 001 Jan 18, 2017 May CAHN
>D> AB IMPAX LABS INC 25MG; 200MG A206964 001 Jan 18, 2017 May CAHNASPIRIN; OMEPRAZOLETABLET, DELAYED RELEASE; ORAL
YOSPRALA+ @ ARALEZ PHARMS 81MG; 40MG N205103 001 Sep 14, 2016 Apr DISC
+ @ 325MG; 40MG N205103 002 Sep 14, 2016 Apr DISC

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	10MG	A 090609	001	Feb 23, 2018	Feb	NEWA
AB		18MG	A 090609	002	Feb 23, 2018	Feb	NEWA
AB		25MG	A 090609	003	Feb 23, 2018	Feb	NEWA
AB		40MG	A 090609	004	Feb 23, 2018	Feb	NEWA
AB		60MG	A 090609	005	Feb 23, 2018	Feb	NEWA
AB		80MG	A 090609	006	Feb 23, 2018	Feb	NEWA
AB		100MG	A 090609	007	Feb 23, 2018	Feb	NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	ACCORD HLTHCARE	EQ 10MG BASE	A 207687	001	Mar 30, 2018	Mar	NEWA
AB		EQ 20MG BASE	A 207687	002	Mar 30, 2018	Mar	NEWA
AB		EQ 40MG BASE	A 207687	003	Mar 30, 2018	Mar	NEWA
AB		EQ 80MG BASE	A 207687	004	Mar 30, 2018	Mar	NEWA

ATROPINE SULFATE

SOLUTION;IV (INFUSTION), INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N 209260	001	Jan 26, 2018	Jan	NEWA
	SOLUTION/DROPS;OPHTHALMIC						
	ISOPTO ATROPINE						
@	ALCON LABS INC	1%	N 208151	001	Dec 01, 2016	Apr	DISC
		1%	N 208151	001	Dec 01, 2016	Feb	CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@	FOSUN PHARMA	0.025MG;2.5MG	A 086173	001		Jan	CAHN
	LONOX						
@	FOSUN PHARMA	0.025MG;2.5MG	A 085311	002		Jan	CAHN

>A> AVATROMBOPAG MALEATE

>A> TABLET;ORAL

>A> DOPTELET

>A>	+	AKARX INC	EQ 20MG BASE	N 210238	001	May 21, 2018	May	NEWA
-----	---	-----------	--------------	----------	-----	--------------	-----	------

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

+	ALLERGAN SALES LLC	EQ 0.5GM BASE;2GM/VIAL	N 206494	001	Feb 25, 2015	Jan	CAHN
---	--------------------	------------------------	----------	-----	--------------	-----	------

AZACITIDINE

>A> POWDER;INTRAVENOUS, SUBCUTANEOUS

>A> AZACITIDINE

>A>	AP	ACTAVIS LLC	100MG/VIAL	N 208216	001	Apr 29, 2016	May	CDFR
>A>	AP	CIPLA LTD	100MG/VIAL	A 209540	001	May 04, 2018	May	CDFR
>A>	AP	DR REDDYS LABS LTD	100MG/VIAL	A 201537	001	Sep 16, 2013	May	CDFR
>A>	AP	MYLAN INSTITUTIONAL	100MG/VIAL	A 204949	001	Apr 28, 2016	May	CDFR
>A>	AP	NATCO PHARMA LTD	100MG/VIAL	A 207234	001	Jun 23, 2017	May	CDFR
>A>	AP	SHILPA MEDICARE	100MG/VIAL	A 207518	001	Sep 29, 2016	May	CDFR

>A> VIDAZA

>A>	AP	+	CELGENE	100MG/VIAL	N 050794	001	May 19, 2004	May	CDFR
-----	----	---	---------	------------	----------	-----	--------------	-----	------

>D> POWDER;IV (INFUSION), SUBCUTANEOUS

>D> AZACITIDINE

>D>	AP	ACTAVIS LLC	100MG/VIAL	N 208216	001	Apr 29, 2016	May	CDFR
>D>	AP	CIPLA LTD	100MG/VIAL	A 209540	001	May 04, 2018	May	CDFR
	AP		100MG/VIAL	A 209540	001	May 04, 2018	Apr	NEWA
>D>	AP	DR REDDYS LABS LTD	100MG/VIAL	A 201537	001	Sep 16, 2013	May	CDFR
>D>	AP	MYLAN INSTITUTIONAL	100MG/VIAL	A 204949	001	Apr 28, 2016	May	CDFR
>D>	AP	NATCO PHARMA LTD	100MG/VIAL	A 207234	001	Jun 23, 2017	May	CDFR
>D>	AP	SHILPA MEDICARE	100MG/VIAL	A 207518	001	Sep 29, 2016	May	CDFR

>D> VIDAZA

>D>	AP	+	CELGENE	100MG/VIAL	N 050794	001	May 19, 2004	May	CDFR
-----	----	---	---------	------------	----------	-----	--------------	-----	------

AZITHROMYCIN

	FOR SUSPENSION;ORAL						
	AZITHROMYCIN						
AB	EPIC PHARMA LLC	EQ 100MG BASE/5ML	A207531	001	Apr 09, 2018	Mar	NEWA
AB		EQ 200MG BASE/5ML	A207531	002	Apr 09, 2018	Mar	NEWA
	TABLET;ORAL						
	AZITHROMYCIN						
	@ APOTEX CORP	EQ 250MG BASE	A065507	001	Jul 13, 2011	Mar	DISC
	@	EQ 500MG BASE	A065509	001	Jul 13, 2011	Mar	DISC
	@	EQ 600MG BASE	A065508	001	Jul 13, 2011	Mar	DISC

BACITRACIN

	INJECTABLE;INJECTION						
	BACITRACIN						
	@ MYLAN ASI	50,000 UNITS/VIAL	A090211	001	May 11, 2010	Jan	DISC

BACLOFEN

	INJECTABLE;INTRATHECAL						
	BACLOFEN						
AP	MYLAN LABS LTD	0.5MG/ML	A209592	001	Mar 21, 2018	Mar	NEWA
AP		1MG/ML	A209594	001	Mar 06, 2018	Feb	NEWA
AP		2MG/ML	A209592	002	Mar 21, 2018	Mar	NEWA
	GABLOFEN						
AP	+! PIRAMAL CRITICAL	1MG/ML	N022462	004	Jun 22, 2012	Feb	CFTG

>A> BARICITINIB

>A>	TABLET;ORAL						
>A>	OLUMIANT						
>A>	+! ELI LILLY AND CO	2MG	N207924	001	May 31, 2018	May	NEWA

BARIUM SULFATE

	FOR SUSPENSION;ORAL						
	E-Z-HD						
+!	BRACCO	98% (334GM/BOT)	N208036	001	Jan 11, 2016	Apr	CPOT
	E-Z-PAQUE						
+!	BRACCO	96% (169GM/BOT)	N208036	002	Apr 07, 2017	Apr	CPOT
	SUSPENSION;ORAL						
	LIQUID E-Z-PAQUE						
+!	BRACCO	60% (213GM/BOT)	N208143	003	Mar 01, 2017	Apr	CPOT
	READI-CAT 2						
+!	BRACCO	2% (9GM/BOT)	N208143	001	Jan 15, 2016	Apr	CPOT
	READI-CAT 2 SMOOTHIES						
+!	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016	Apr	CPOT
	TAGITOL V						
+!	BRACCO	40% (8GM/BOT)	N208143	005	Aug 04, 2017	Apr	CPOT
	VARIBAR HONEY						
+!	BRACCO	40% (100GM/250ML)	N208143	007	Mar 26, 2018	Mar	NEWA
	VARIBAR THIN HONEY						
+!	BRACCO	40% (100GM/250ML)	N208143	006	Jan 23, 2018	Jan	NEWA

BECLOMETHASONE DIPROPIONATE

	AEROSOL, METERED;INHALATION						
	QVAR REDIHALER						
+!	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017	Jan	CHRS

BENAZEPRIL HYDROCHLORIDE

	TABLET;ORAL						
	BENAZEPRIL HYDROCHLORIDE						
AB	CASI PHARMS INC	5MG	A076402	001	Feb 11, 2004	Mar	CAHN
AB		10MG	A076402	002	Feb 11, 2004	Mar	CAHN
AB		20MG	A076402	003	Feb 11, 2004	Mar	CAHN
AB		40MG	A076402	004	Feb 11, 2004	Mar	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

	TABLET;ORAL						
	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE						
	@ SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005	Mar	DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	MYLAN LABS LTD	25MG/VIAL	A204104	001	Apr 26, 2018	Apr	NEWA
AP		100MG/VIAL	A204104	002	Apr 26, 2018	Apr	NEWA

SOLUTION; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

>A>	+	EAGLE PHARMS	100MG/4ML (25MG/ML)	N205580	001	May 15, 2018	May	NEWA
>D>		TREANDA						
>D>	+	CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013	May	DISC
>A>	+	@	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013	May	DISC
>D>	+	!	180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013	May	DISC
>A>	+	@	180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013	May	DISC

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	CSPC NBP PHARM CO	100MG	A202765	002	Aug 25, 2017	Mar	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>A>	AB	TARO	3.75%;EQ 1.2% BASE	A208683	001	Jun 05, 2018	May	NEWA
>A>	AB		5%;EQ 1% BASE	A208776	001	May 25, 2018	May	NEWA
>D>	AB		5%;1.2%	A206218	001	Dec 15, 2017	May	CAHN
>A>	AB	TARO PHARMS	5%;1.2%	A206218	001	Dec 15, 2017	May	CAHN
		ONEXTON						
>D>	+	DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	May	CTEC
>A>	AB	+	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	May	CTEC

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

@ CHARTWELL RX

1MG

A081264 001 Jan 23, 1992 Jan CAHN

@

2MG

A081265 001 Jan 23, 1992 Jan CAHN

>A>		<u>BETAINE</u>						
>A>		FOR SOLUTION; ORAL						
>A>		CYSTADANE						
>A>	+	ORPHAN EUROPE	1GM/SCOOPFUL	N020576	001	Oct 25, 1996	May	CAIN

>D>		<u>BETAINE HYDROCHLORIDE</u>						
>D>		FOR SOLUTION; ORAL						
>D>		CYSTADANE						
>D>	+	ORPHAN EUROPE	1GM/SCOOPFUL	N020576	001	Oct 25, 1996	May	CAIN

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	HI-TECH PHARMACAL	EQ 0.05% BASE	A209896	001	Feb 06, 2018	Jan	NEWA
----	-------------------	---------------	---------	-----	--------------	-----	------

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	TELGENT PHARMA INC	EQ 0.05% BASE	A206389	001	Feb 13, 2018	Jan	NEWA
----	--------------------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETA-VAL

@ G AND W LABS INC

EQ 0.1% BASE

A070072 001 Jun 27, 1985 Jan DISC

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETOPTIC

AT	+	SANDOZ INC	EQ 0.5% BASE	N019270	001	Aug 30, 1985	Jan	CAHN
----	---	------------	--------------	---------	-----	--------------	-----	------

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

AB	AMERIGEN PHARMS LTD	75MG	A209861	001	May 08, 2018	Apr	NEWA
----	---------------------	------	---------	-----	--------------	-----	------

BICALUTAMIDETABLET;ORAL
CASODEX

AB +! ANI PHARMS INC 50MG N020498 001 Oct 04, 1995 Jan CAHN

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATETABLET;ORAL
BIKTARVY

+! GILEAD SCIENCES INC EQ 50MG BASE;200MG;EQ 25MG BASE N210251 001 Feb 07, 2018 Feb NEWA

>D> BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

>D> FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL

>D> PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL

>D> ! NOVEL LABS INC 5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2 .86GM;N/A,5.6GM A202217 001 Aug 20, 2014 May DISC

>A> @ 5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2 .86GM;N/A,5.6GM A202217 001 Aug 20, 2014 May DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINECAPSULE;ORAL
PYLERA

+! ALLERGAN SALES LLC 140MG;125MG;125MG N050786 001 Sep 28, 2006 Jan CAHN

BISOPROLOL FUMARATETABLET;ORAL
BISOPROLOL FUMARATE

AB CASI PHARMS INC 5MG A075643 001 Nov 16, 2000 Mar CAHN

AB 10MG A075643 002 Nov 16, 2000 Mar CAHN

BIVALIRUDININJECTABLE;INTRAVENOUS
BIVALIRUDIN

>A> AP MYLAN INSTITUTIONAL 250MG/VIAL A202471 001 Jun 01, 2018 May NEWA

SOLUTION;IV (INFUSION)
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

+! BAXTER HLTHCARE CORP 250MG/50ML (5MG/ML) N208374 001 Dec 21, 2017 Jan CAHN

+! 500MG/100ML (5MG/ML) N208374 002 Dec 21, 2017 Jan CAHN

BLEOMYCIN SULFATEINJECTABLE;INJECTION
BLEOMYCIN SULFATE

AP HONG KONG EQ 15 UNITS BASE/VIAL A205030 001 Apr 20, 2018 Apr NEWA

AP EQ 30 UNITS BASE/VIAL A205030 002 Apr 20, 2018 Apr NEWA

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDESYRUP;ORAL
BROMFED-DM

AA ! WOCKHARDT BIO AG 2MG/5ML;10MG/5ML;30MG/5ML A088811 001 Jun 07, 1985 Apr CAHN

BUMETANIDEINJECTABLE;INJECTION
BUMETANIDE

AP @ ATHENEX INC 0.25MG/ML A074441 001 Jan 27, 1995 Apr DISC

AP ! WEST-WARD PHARMS INT 0.25MG/ML A079196 001 Apr 30, 2008 Apr CHRS

TABLET;ORAL
BUMETANIDE

AB UPSHER-SMITH LABS 0.5MG A209916 001 Jan 23, 2018 Jan NEWA

AB 1MG A209916 002 Jan 23, 2018 Jan NEWA

AB 2MG A209916 003 Jan 23, 2018 Jan NEWA

AB ZYDUS PHARMS USA INC 0.5MG A202900 001 Apr 30, 2018 Apr NEWA

AB 1MG A202900 002 Apr 30, 2018 Apr NEWA

AB 2MG A202900 003 Apr 30, 2018 Apr NEWA

BUPRENORPHINE HYDROCHLORIDETABLET;SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE

AB CASI PHARMS INC EQ 2MG BASE A090279 001 Jun 10, 2015 Mar CAHN

AB EQ 8MG BASE A090279 002 Jun 10, 2015 Mar CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

>A>	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
>A>	DR REDDYS LABS SA	EQ 2MG BASE;EQ 0.5MG BASE	A205299	001	Jun 14, 2018	May	NEWA	
>A>		EQ 4MG BASE;EQ 1MG BASE	A205806	001	Jun 14, 2018	May	NEWA	
>A>		EQ 8MG BASE;EQ 2MG BASE	A205299	002	Jun 14, 2018	May	NEWA	
>A>		EQ 12MG BASE;EQ 3MG BASE	A205806	002	Jun 14, 2018	May	NEWA	
>A>	MYLAN TECHNOLOGIES	EQ 8MG BASE;EQ 2MG BASE	A207607	001	Jun 14, 2018	May	NEWA	
>A>		EQ 12MG BASE;EQ 3MG BASE	A207607	002	Jun 14, 2018	May	NEWA	
	SUBOXONE							
>D>	+ INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	May	CFTG	
>A>	AB +	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	May	CFTG	
>D>	+	EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	May	CFTG	
>A>	AB +	EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	May	CFTG	
>D>	+	EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	May	CFTG	
>A>	AB +	EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	May	CFTG	
>D>	+!	EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	May	CFTG	
>A>	AB +!	EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	May	CFTG	

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

>A>	AB	ALEMBIC PHARMS LTD	75MG	A203013	001	Jun 08, 2018	May	NEWA
>A>	AB		100MG	A203013	002	Jun 08, 2018	May	NEWA

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB2		SCIEGEN PHARMS INC	150MG	A206122	001	Aug 17, 2016	Jan	CAHN
-----	--	--------------------	-------	---------	-----	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	5MG	A078246	001	Feb 27, 2009	Feb	CAHN
AB			10MG	A078246	002	Feb 27, 2009	Feb	CAHN
AB			15MG	A078246	003	Feb 27, 2009	Feb	CAHN
AB			30MG	A078246	004	Feb 27, 2009	Feb	CAHN
		@ FOSUN PHARMA	5MG	A075413	001	Mar 19, 2002	Jan	CAHN
		@	10MG	A075413	002	Mar 19, 2002	Jan	CAHN
		@	15MG	A075413	003	Mar 19, 2002	Jan	CAHN
AB		INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Apr	NEWA
AB			7.5MG	A209696	002	May 03, 2018	Apr	NEWA
AB			10MG	A209696	003	May 03, 2018	Apr	NEWA
AB			15MG	A209696	004	May 03, 2018	Apr	NEWA
AB			30MG	A209696	005	May 03, 2018	Apr	NEWA

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	!	HOSPIRA	1MG/ML	A074626	001	Jan 23, 1997	Mar	CHRS
AP	!		2MG/ML	A074626	002	Jan 23, 1997	Mar	CHRS
		STADOL						
	+	@ APOTHECON	2MG/ML	N017857	004		Mar	CRLD
		STADOL PRESERVATIVE FREE						
	+	@ APOTHECON	1MG/ML	N017857	001		Mar	CRLD
	+	@	2MG/ML	N017857	002		Mar	CRLD

CABERGOLINE

TABLET;ORAL

CABERGOLINE

@	APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013	Mar	DISC
---	-------------	-------	---------	-----	--------------	-----	------

CALCIUM ACETATE

TABLET;ORAL

ELIPHOS

@	CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008	Apr	DISC
---	---------------	-------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

AP		INTL MEDICATION SYS	100MG/ML	A203477	001	May 09, 2018	Apr	NEWA
----	--	---------------------	----------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION							
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER							
+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685	005	Oct 17, 1988	Jan	CRLD
+ @		20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019685	006	Oct 17, 1988	Jan	CRLD
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER							
+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685	007	Oct 17, 1988	Jan	CRLD
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER							
AP +	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019685	002	Oct 17, 1988	Jan	CRLD
+ @		20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685	008	Oct 17, 1988	Jan	DISC
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER							
+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685	003	Oct 17, 1988	Jan	CRLD
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER							
+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685	004	Oct 17, 1988	Jan	DISC
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER							
+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685	001	Oct 17, 1988	Jan	CRLD

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS								
CALCIUM GLUCONATE								
>A>	+	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017	May	CDFR
>A>	+		5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017	May	CDFR
>A>	+		10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017	May	CDFR
SOLUTION; IV (INFUSION)								
CALCIUM GLUCONATE								
>D>	+	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017	May	CDFR
>D>	+		5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017	May	CDFR
>D>	+		10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017	May	CDFR

CANDESARTAN CILEXETIL

TABLET; ORAL							
ATACAND							
AB +	ANI PHARMS INC	4MG	N020838	001	Jun 04, 1998	Jan	CAHN
AB +		8MG	N020838	002	Jun 04, 1998	Jan	CAHN
AB +		16MG	N020838	003	Jun 04, 1998	Jan	CAHN
AB +!		32MG	N020838	004	Jun 04, 1998	Jan	CAHN
CANDESARTAN CILEXETIL							
@	APOTEX INC	4MG	A202079	001	Jan 10, 2014	Mar	DISC
@		8MG	A202079	002	Jan 10, 2014	Mar	DISC
@		16MG	A202079	003	Jan 10, 2014	Mar	DISC
@		32MG	A202079	004	Jan 10, 2014	Mar	DISC
AB	MYLAN PHARMS INC	4MG	A078702	001	May 03, 2013	Apr	CAHN
AB		8MG	A078702	002	May 03, 2013	Apr	CAHN
AB		16MG	A078702	003	May 03, 2013	Apr	CAHN
AB		32MG	A078702	004	May 03, 2013	Apr	CAHN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL							
ATACAND HCT							
AB +	ANI PHARMS INC	16MG; 12.5MG	N021093	001	Sep 05, 2000	Feb	CAHN
AB +		32MG; 12.5MG	N021093	002	Sep 05, 2000	Feb	CAHN
AB +!		32MG; 25MG	N021093	003	May 16, 2008	Feb	CAHN
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE							
@	APOTEX INC	16MG; 12.5MG	A202884	001	Dec 04, 2012	Mar	DISC
@		32MG; 12.5MG	A202884	002	Dec 04, 2012	Mar	DISC
@		32MG; 25MG	A202884	003	Jun 03, 2013	Mar	DISC
AB	PRINSTON INC	16MG; 12.5MG	A207455	001	Apr 11, 2018	Mar	NEWA
AB		32MG; 12.5MG	A207455	002	Apr 11, 2018	Mar	NEWA
AB		32MG; 25MG	A207455	003	Apr 11, 2018	Mar	NEWA

CAPECITABINE

TABLET;ORAL		CAPECITABINE					
AB	EUGIA PHARMA	150MG	A210604	001	Apr 17, 2018	Apr	NEWA
AB		500MG	A210604	002	Apr 17, 2018	Apr	NEWA

CAPTOPRIL

TABLET;ORAL		CAPTOPRIL					
	@ YAOPHARMA CO LTD	12.5MG	A074363	001	Nov 09, 1995	Jan	CAHN
	@	12.5MG	A074519	001	Feb 13, 1996	Jan	CAHN
	@	25MG	A074363	002	Nov 09, 1995	Jan	CAHN
	@	25MG	A074519	002	Feb 13, 1996	Jan	CAHN
	@	50MG	A074363	003	Nov 09, 1995	Jan	CAHN
	@	50MG	A074519	003	Feb 13, 1996	Jan	CAHN
	@	100MG	A074363	004	Nov 09, 1995	Jan	CAHN
	@	100MG	A074519	004	Feb 13, 1996	Jan	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL		CAPTOPRIL AND HYDROCHLOROTHIAZIDE					
	@ G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Jan	DISC
	@	25MG;25MG	A074827	002	Dec 29, 1997	Jan	DISC
	@	50MG;15MG	A074827	004	Dec 29, 1997	Jan	DISC
	@	50MG;25MG	A074827	003	Dec 29, 1997	Jan	DISC
	MYLAN	25MG;15MG	A074896	001	Dec 29, 1997	Jan	CTEC
!		25MG;25MG	A074896	002	Dec 29, 1997	Jan	CTEC
!		50MG;15MG	A074896	004	Dec 29, 1997	Jan	CTEC
		50MG;25MG	A074896	003	Dec 29, 1997	Jan	CTEC

CARBIDOPA

TABLET;ORAL		CARBIDOPA					
AB	ZYDUS PHARMS USA INC	25MG	A209910	001	May 07, 2018	Apr	NEWA

CARBINOXAMINE MALEATE

SOLUTION;ORAL		CARBINOXAMINE MALEATE					
	@ CYPRESS PHARM	4MG/5ML	A090418	001	May 04, 2010	Apr	DISC
TABLET;ORAL		CARBINOXAMINE MALEATE					
	@ CYPRESS PHARM	4MG	A090417	001	Aug 23, 2010	Apr	DISC

CARBOPLATIN

INJECTABLE;IV (INFUSION)		CARBOPLATIN					
AP	EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Apr	CAHN
AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Apr	CAHN
AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Apr	CAHN
>D>	!	MYLAN LABS LTD	A091478	001	Nov 23, 2011	May	DISC
>A>	@		A091478	001	Nov 23, 2011	May	DISC

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL		VRAYLAR					
+	ALLERGAN SALES LLC	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan	CAHN
+		EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan	CAHN
+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Jan	CAHN
+	!	EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan	CAHN

CARISOPRODOL

TABLET;ORAL		CARISOPRODOL					
	@ FOSUN PHARMA	350MG	A081025	001	Apr 13, 1989	Jan	CAHN

CARVEDILOL

TABLET;ORAL		CARVEDILOL					
AB	CHARTWELL MOLECULAR	3.125MG	A077474	001	Sep 05, 2007	Mar	CAHN
AB		6.25MG	A077474	002	Sep 05, 2007	Mar	CAHN
AB		12.5MG	A077474	003	Sep 05, 2007	Mar	CAHN

TABLET;ORAL
CARVEDILOL

AB 25MG A077474 004 Sep 05, 2007 Mar CAHN

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL
CARVEDILOL PHOSPHATE

AB IMPAX LABS INC 10MG A204717 001 May 07, 2018 Apr NEWA
 AB 20MG A204717 002 May 07, 2018 Apr NEWA
 AB 40MG A204717 003 May 07, 2018 Apr NEWA
 AB 80MG A204717 004 May 07, 2018 Apr NEWA

CASPOFUNGIN ACETATE

>A> POWDER; INTRAVENOUS
>A> CANCIDAS

>A> AP +! MERCK 50MG/VIAL N021227 001 Jan 26, 2001 May CDFR
 >A> AP +! 70MG/VIAL N021227 002 Jan 26, 2001 May CDFR
 >A> CASPOFUNGIN ACETATE
 >A> AP FRESENIUS KABI USA 50MG/VIAL N206110 001 Dec 30, 2016 May CDFR
 >A> AP 70MG/VIAL N206110 002 Dec 30, 2016 May CDFR
 >A> AP GLAND PHARMA LTD 50MG/VIAL A207092 001 Sep 29, 2017 May CDFR
 >A> AP 70MG/VIAL A207092 002 Sep 29, 2017 May CDFR
 >A> AP MYLAN LABS LTD 50MG/VIAL A207650 001 Sep 29, 2017 May CDFR
 >A> AP 70MG/VIAL A207650 002 Sep 29, 2017 May CDFR

>D> POWDER; IV (INFUSION)
>D> CANCIDAS

>D> AP +! MERCK 50MG/VIAL N021227 001 Jan 26, 2001 May CDFR
 >D> AP +! 70MG/VIAL N021227 002 Jan 26, 2001 May CDFR
 >D> CASPOFUNGIN ACETATE
 >D> AP FRESENIUS KABI USA 50MG/VIAL N206110 001 Dec 30, 2016 May CDFR
 >D> AP 70MG/VIAL N206110 002 Dec 30, 2016 May CDFR
 >D> AP GLAND PHARMA LTD 50MG/VIAL A207092 001 Sep 29, 2017 May CDFR
 >D> AP 70MG/VIAL A207092 002 Sep 29, 2017 May CDFR
 >D> AP MYLAN LABS LTD 50MG/VIAL A207650 001 Sep 29, 2017 May CDFR
 >D> AP 70MG/VIAL A207650 002 Sep 29, 2017 May CDFR

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

@ FOSUN PHARMA EQ 500MG BASE/VIAL A090291 001 Dec 21, 2010 Jan CAHN
 @ EQ 1GM BASE/VIAL A090291 002 Dec 21, 2010 Jan CAHN
 @ EQ 2GM BASE/VIAL A090291 003 Dec 21, 2010 Jan CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME

AP ! HIKMA EQ 500MG BASE/VIAL A065072 001 Nov 20, 2002 Apr CHRS
 AP ! EQ 1GM BASE/VIAL A065072 002 Nov 20, 2002 Apr CHRS
 AP ! EQ 2GM BASE/VIAL A065072 003 Nov 20, 2002 Apr CHRS
 AP ! EQ 10GM BASE/VIAL A065071 001 Nov 20, 2002 Apr CHRS
 CLAFORAN
 + @ US PHARM HOLDINGS EQ 500MG BASE/VIAL N050547 001 Apr DISC
 + @ EQ 1GM BASE/VIAL N050547 002 Apr DISC
 + @ EQ 2GM BASE/VIAL N050547 003 Apr DISC
 + @ EQ 10GM BASE/VIAL N050547 004 Dec 29, 1983 Apr DISC

CEFPROZIL

TABLET; ORAL
CEFPROZIL

AB CASI PHARMS INC 250MG A065235 001 Nov 14, 2005 Mar CAHN
 AB 500MG A065235 002 Nov 14, 2005 Mar CAHN

CEFTAROLINE FOSAMIL

POWDER; IV (INFUSION)
TEFLARO

+ ALLERGAN SALES LLC 400MG/VIAL N200327 001 Oct 29, 2010 Jan CAHN
 +! 600MG/VIAL N200327 002 Oct 29, 2010 Jan CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
 >D> FORTAZ IN PLASTIC CONTAINER
 >D> +! TELIGENT EQ 20MG BASE/ML N050634 002 Apr 28, 1989 May DISC
 >A> + @ EQ 20MG BASE/ML N050634 002 Apr 28, 1989 May DISC
 >D> +! EQ 40MG BASE/ML N050634 003 Apr 28, 1989 May DISC
 >A> + @ EQ 40MG BASE/ML N050634 003 Apr 28, 1989 May DISC

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL
 CEDAX
 @ SI PHARMS EQ 400MG BASE N050685 002 Dec 20, 1995 Jan CAHN
 FOR SUSPENSION; ORAL
 CEDAX
 + @ SI PHARMS EQ 90MG BASE/5ML N050686 001 Dec 20, 1995 Jan CAHN
 + @ EQ 180MG BASE/5ML N050686 002 Dec 20, 1995 Jan CAHN

CEFTRIAZONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
 CEFTRIAZONE
 >A> AP SAGENT PHARMS EQ 250MG BASE/VIAL A091049 001 Jun 11, 2018 May NEWA
 >A> AP EQ 500MG BASE/VIAL A091049 002 Jun 11, 2018 May NEWA
 >A> AP EQ 1GM BASE/VIAL A091049 003 Jun 11, 2018 May NEWA
 >A> AP EQ 2GM BASE/VIAL A091049 004 Jun 11, 2018 May NEWA

CEFUROXIME AXETIL

TABLET; ORAL
 CEFTIN
 >D> AB + GLAXOSMITHKLINE EQ 125MG BASE N050605 001 Dec 28, 1987 May DISC
 >A> + @ EQ 125MG BASE N050605 001 Dec 28, 1987 May DISC
 >D> AB + EQ 250MG BASE N050605 002 Dec 28, 1987 May DISC
 >A> + @ EQ 250MG BASE N050605 002 Dec 28, 1987 May DISC
 >D> AB +! EQ 500MG BASE N050605 003 Dec 28, 1987 May DISC
 >A> + @ EQ 500MG BASE N050605 003 Dec 28, 1987 May DISC
 CEFUROXIME AXETIL
 @ FOSUN PHARMA EQ 250MG BASE A065126 001 Oct 28, 2003 Jan CAHN
 @ EQ 500MG BASE A065126 002 Oct 28, 2003 Jan CAHN
 >D> AB LUPIN EQ 500MG BASE A065135 002 Jul 25, 2003 May CHRS
 >A> AB ! EQ 500MG BASE A065135 002 Jul 25, 2003 May CHRS

CEFUROXIME SODIUM

INJECTABLE; INJECTION
 >D> ZINACEF IN PLASTIC CONTAINER
 >D> +! TELIGENT EQ 30MG BASE/ML N050643 002 Apr 28, 1989 May DISC
 >A> + @ EQ 30MG BASE/ML N050643 002 Apr 28, 1989 May DISC

CELECOXIB

CAPSULE; ORAL
 CELECOXIB
 >A> AB AMNEAL PHARMS 50MG A208833 001 May 31, 2018 May NEWA
 >A> AB 100MG A208833 002 May 31, 2018 May NEWA
 >A> AB 200MG A208833 003 May 31, 2018 May NEWA
 >A> AB 400MG A208833 004 May 31, 2018 May NEWA
 AB CSPC OUYI PHARM CO 50MG A210071 001 Jan 23, 2018 Jan NEWA
 AB 100MG A210071 002 Jan 23, 2018 Jan NEWA
 AB 200MG A210071 003 Jan 23, 2018 Jan NEWA
 AB MICRO LABS 50MG A204776 001 Apr 30, 2018 Apr NEWA
 AB 100MG A204776 002 Apr 30, 2018 Apr NEWA
 AB 200MG A204776 003 Apr 30, 2018 Apr NEWA
 AB 400MG A204776 004 Apr 30, 2018 Apr NEWA

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL
 CETIRIZINE HYDROCHLORIDE
 >A> AA LANNETT CO INC 5MG/5ML A078496 001 Sep 25, 2009 May CAHN
 >D> AA VINTAGE 5MG/5ML A078496 001 Sep 25, 2009 May CAHN

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

@ APOTEX INC 30MG A091260 001 Aug 25, 2011 Mar DISC

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB ! NEOS THERAP INC EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML A091671 001 Jun 29, 2012 Apr CHRS

TUSSIONEX PENNKINETIC

+ @ UCB INC EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML N019111 001 Dec 31, 1987 Apr DISC

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

SONAZINE

@ FOSUN PHARMA 30MG/ML A080983 004 Jan CAHN

@ 100MG/ML A080983 005 Jan CAHN

SYRUP;ORAL

SONAZINE

@ FOSUN PHARMA 10MG/5ML A083040 001 Jan CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

>A> AB UMEDICA LABS PVT LTD 25MG A207222 001 May 24, 2018 May NEWA

>A> AB 50MG A207222 002 May 24, 2018 May NEWA

THALITONE

+ @ CASPER PHARMA LLC 15MG N019574 001 Dec 20, 1988 Apr CRLD

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLORPRES

@ MYLAN 15MG;0.1MG A071325 003 Feb 09, 1987 Mar DISC

@ 15MG;0.2MG A071325 002 Feb 09, 1987 Mar DISC

@ 15MG;0.3MG A071325 001 Feb 09, 1987 Mar DISC

CICLOPIROX

SHAMPOO;TOPICAL

CICLOPIROX

AT TELIGENT PHARMA INC 1% A209975 001 Apr 05, 2018 Mar NEWA

SOLUTION;TOPICAL

CICLOPIROX

AT INGENUS PHARMS LLC 8% A078124 001 Sep 18, 2007 Jan CAHN

CILASTATIN SODIUM; IMIPENEM

POWDER;INTRAVENOUS

IMIPENEM AND CILASTATIN

! ACS DOBFAR EQ 250MG BASE/VIAL;250MG/VIAL A090577 001 Dec 21, 2011 Apr CHRS

@ HOSPIRA INC EQ 250MG BASE/VIAL;250MG/VIAL A090825 001 Nov 16, 2011 Apr DISC

PRIMAXIN

+ @ MERCK EQ 250MG BASE/VIAL;250MG/VIAL N050587 001 Nov 26, 1985 Apr DISC

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

AB CASI PHARMS INC 50MG A077310 001 Nov 08, 2005 Mar CAHN

AB 100MG A077021 001 Nov 23, 2004 Mar CAHN

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@ CHARTWELL MOLECULES 200MG A074329 002 May 17, 1994 Jan CMS1

@ 300MG A074329 003 May 17, 1994 Jan CMS1

@ 400MG A074329 004 May 17, 1994 Jan CMS1

@ YAOPHARMA CO LTD 200MG A074100 001 Jan 31, 1995 Jan CAHN

@ 300MG A074100 002 Jan 31, 1995 Jan CAHN

@ 400MG A074100 003 Jan 31, 1995 Jan CAHN

@ 800MG A074100 004 Jan 31, 1995 Jan CAHN

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

>A>	@ LANNETT CO INC	EQ 300MG BASE/5ML	A074251	001	Dec 22, 1994	May	CAHN
>D>	@ VINTAGE PHARMS LLC	EQ 300MG BASE/5ML	A074251	001	Dec 22, 1994	May	CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 30MG BASE	A206125	001	Mar 08, 2018	Feb	NEWA
AB		EQ 60MG BASE	A206125	002	Mar 08, 2018	Feb	NEWA
AB		EQ 90MG BASE	A206125	003	Mar 08, 2018	Feb	NEWA
AB	CIPLA LTD	EQ 30MG BASE	A208915	001	Mar 08, 2018	Feb	NEWA
AB		EQ 60MG BASE	A208915	002	Mar 08, 2018	Feb	NEWA
AB		EQ 90MG BASE	A208915	003	Mar 08, 2018	Feb	NEWA
AB	STRIDES PHARMA	EQ 30MG BASE	A209226	001	Apr 30, 2018	Apr	NEWA
AB		EQ 60MG BASE	A209226	002	Apr 30, 2018	Apr	NEWA
AB		EQ 90MG BASE	A209226	003	Apr 30, 2018	Apr	NEWA
AB	ZYDUS PHARMS USA INC	EQ 30MG BASE	A208971	001	Apr 23, 2018	Apr	NEWA
AB		EQ 60MG BASE	A208971	002	Apr 23, 2018	Apr	NEWA
AB		EQ 90MG BASE	A208971	003	Apr 23, 2018	Apr	NEWA
	SENSIPAR						
AB	+ AMGEN	EQ 30MG BASE	N021688	001	Mar 08, 2004	Feb	CFTG
AB	+	EQ 60MG BASE	N021688	002	Mar 08, 2004	Feb	CFTG
AB	+	EQ 90MG BASE	N021688	003	Mar 08, 2004	Feb	CFTG

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	INFORLIFE	200MG/100ML	A078252	001	Mar 18, 2008	Jan	CAHN
AP		400MG/200ML	A078252	002	Mar 18, 2008	Jan	CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

AT	ALTAIRE PHARMS INC	EQ 0.3% BASE	A204613	001	May 03, 2018	Apr	NEWA
	TABLET;ORAL						
	CIPRO						
	+ @ BAYER HLTHCARE	EQ 100MG BASE	N019537	001	Apr 08, 1996	Mar	DISC
	+ @	EQ 750MG BASE	N019537	004	Oct 22, 1987	Mar	DISC
	CIPROFLOXACIN HYDROCHLORIDE						
	@ FOSUN PHARMA	EQ 250MG BASE	A076593	002	Jun 09, 2004	Jan	CAHN
	@	EQ 500MG BASE	A076593	003	Jun 09, 2004	Jan	CAHN
	@	EQ 750MG BASE	A076593	004	Jun 09, 2004	Jan	CAHN
>D>	AB SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004	May	DISC
>A>	@	EQ 250MG BASE	A075747	001	Jun 09, 2004	May	DISC
>D>	AB	EQ 500MG BASE	A075747	002	Jun 09, 2004	May	DISC
>A>	@	EQ 500MG BASE	A075747	002	Jun 09, 2004	May	DISC
>D>	AB	EQ 750MG BASE	A075747	003	Jun 09, 2004	May	DISC
>A>	@	EQ 750MG BASE	A075747	003	Jun 09, 2004	May	DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

	@ FOSUN PHARMA	212.6MG;EQ 287.5MG BASE	A078712	001	Dec 11, 2007	Jan	CAHN
--	----------------	-------------------------	---------	-----	--------------	-----	------

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP	HOSPIRA INC	EQ 2MG BASE/ML	A203236	001	Mar 30, 2018	Mar	NEWA
AP		EQ 2MG BASE/ML	A203238	001	Mar 30, 2018	Mar	NEWA
AP		EQ 10MG BASE/ML	A203236	002	Mar 30, 2018	Mar	NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB	+ ALLERGAN SALES LLC	EQ 10MG BASE	N020822	001	Apr 27, 2000	Jan	CAHN
AB	+	EQ 20MG BASE	N020822	002	Jul 17, 1998	Jan	CAHN
AB	+	EQ 40MG BASE	N020822	003	Jul 17, 1998	Jan	CAHN
	@	EQ 60MG BASE	N020822	004	Jul 17, 1998	Jan	CAHN

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB	CHARTWELL MOLECULAR	EQ 10MG BASE	A077044	001	Nov 05, 2004	Mar	CAHN
AB		EQ 20MG BASE	A077044	002	Nov 05, 2004	Mar	CAHN
AB		EQ 40MG BASE	A077044	003	Nov 05, 2004	Mar	CAHN
	@ FOSUN PHARMA	EQ 10MG BASE	A077035	001	Oct 28, 2004	Jan	CAHN
	@	EQ 10MG BASE	A077040	001	Aug 17, 2005	Jan	CAHN
	@	EQ 20MG BASE	A077035	002	Oct 28, 2004	Jan	CAHN
	@	EQ 20MG BASE	A077040	002	Aug 17, 2005	Jan	CAHN
	@	EQ 40MG BASE	A077035	003	Oct 28, 2004	Jan	CAHN
	@	EQ 40MG BASE	A077040	003	Aug 17, 2005	Jan	CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

SOLUTION;ORAL

CLENPIQ

+!	FERRING PHARMS INC	12GM/BOT;3.5GM/BOT;10MG/BOT	N209589	001	Nov 28, 2017	Apr	CPOT
----	--------------------	-----------------------------	---------	-----	--------------	-----	------

CLARITHROMYCIN

FOR SUSPENSION;ORAL

BIAXIN

+ @	ABBVIE	125MG/5ML	N050698	001	Dec 23, 1993	Apr	DISC	
+ @		250MG/5ML	N050698	002	Dec 23, 1993	Apr	DISC	
	CLARITHROMYCIN							
AB	! SANDOZ	250MG/5ML	A065283	003	Sep 04, 2007	Apr	CHRS	
>D>	AB	SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007	May	DISC
>A>	@	125MG/5ML	A065382	001	Aug 30, 2007	May	DISC	
>D>	AB	250MG/5ML	A065382	002	Aug 30, 2007	May	DISC	
>A>	@	250MG/5ML	A065382	002	Aug 30, 2007	May	DISC	

TABLET;ORAL

CLARITHROMYCIN

>D>	AB	SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004	May	DISC
>A>	@	250MG	A065174	001	Sep 24, 2004	May	DISC	
>D>	AB	500MG	A065174	002	Sep 24, 2004	May	DISC	
>A>	@	500MG	A065174	002	Sep 24, 2004	May	DISC	

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

>D>	AA	! TEVA	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994	May	CTEC
>A>		!	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994	May	CTEC
>D>	AA	WOCKHARDT	EQ 0.5MG BASE/5ML	A074863	001	Mar 13, 1998	May	CAHN
>A>	@	WOCKHARDT BIO AG	EQ 0.5MG BASE/5ML	A074863	001	Mar 13, 1998	May	DISC
>A>	AA		EQ 0.5MG BASE/5ML	A074863	001	Mar 13, 1998	May	CAHN

TABLET;ORAL

TAVIST

>D>	@	NOVARTIS	2.68MG	N017661	001		May	CRLD
>A>	+ @		2.68MG	N017661	001		May	CRLD

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	APPCO PHARMA LLC	EQ 75MG BASE/5ML	A207047	001	May 11, 2018	Apr	NEWA
----	------------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	@	ABBOTT LABS	EQ 6MG BASE/ML	A065027	001	Jun 29, 2001	Mar	CAHN
	@		EQ 12MG BASE/ML	A065027	002	Jun 29, 2001	Mar	CAHN
	@		EQ 18MG BASE/ML	A065027	003	Jun 29, 2001	Mar	CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT	GLASSHOUSE PHARMS	EQ 1% BASE	A209846	001	Feb 08, 2018	Jan	NEWA	
>D>	AT	WOCKHARDT	EQ 1% BASE	A063304	001	Jul 15, 1997	May	CAHN
>A>	@	WOCKHARDT BIO AG	EQ 1% BASE	A063304	001	Jul 15, 1997	May	DISC
>A>	AT		EQ 1% BASE	A063304	001	Jul 15, 1997	May	CAHN

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1	GLENMARK PHARMS	0.05%	A209095	001	May 10, 2018	Apr	NEWA
AB1	LUPIN LTD	0.05%	A210208	001	Jan 30, 2018	Jan	NEWA
AB1	TELIGENT PHARMA INC	0.05%	A209974	001	Apr 17, 2018	Apr	NEWA

CREAM;TOPICAL
IMPOYZ

+!	ENCORE DERMAT	0.025%	N209483	001	Nov 28, 2017	Jan CAHN
OINTMENT;TOPICAL						
CLOBETASOL PROPIONATE						
AB	CHEMO RESEARCH SL	0.05%	A209701	001	Apr 17, 2018	Apr NEWA
AB	NOVEL LABS INC	0.05%	A208841	001	May 04, 2018	Apr NEWA
SOLUTION;TOPICAL						
CLOBETASOL PROPIONATE						
AT	GLENMARK PHARMS LTD	0.05%	A210190	001	Apr 18, 2018	Apr NEWA
SPRAY;TOPICAL						
CLOBETASOL PROPIONATE						
AT	APOTEX INC	0.05%	A210446	001	Apr 17, 2018	Apr NEWA
AT	GLENMARK PHARMS	0.05%	A209004	001	Mar 26, 2018	Mar NEWA
AT	LUPIN LTD	0.05%	A208125	001	Mar 26, 2018	Mar NEWA
AT	TARO	0.05%	A208842	001	Mar 26, 2018	Mar NEWA

CLOFARABINE

>D>	INJECTABLE;IV (INFUSION)					
>D>	CLOFARABINE					
>D>	AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017 May CDFR
>D>	AP	AMNEAL PHARMS CO	20MG/20ML (1MG/ML)	A208857	001	Nov 06, 2017 May CDFR
>D>	AP	DR REDDYS LABS LTD	20MG/20ML (1MG/ML)	A205375	001	Nov 06, 2017 May CDFR
>D>	AP	MSN LABS PVT LTD	20MG/20ML (1MG/ML)	A209775	001	Dec 06, 2017 May CDFR
>D>	AP	MYLAN LABS LTD	20MG/20ML (1MG/ML)	A208860	001	Nov 06, 2017 May CDFR
>D>	CLOLAR					
>D>	AP	+! GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004 May CDFR
>A>	SOLUTION;INTRAVENOUS					
>A>	CLOFARABINE					
>A>	AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017 May CDFR
>A>	AP	AMNEAL PHARMS CO	20MG/20ML (1MG/ML)	A208857	001	Nov 06, 2017 May CDFR
>A>	AP	DR REDDYS LABS LTD	20MG/20ML (1MG/ML)	A205375	001	Nov 06, 2017 May CDFR
>A>	AP	MSN LABS PVT LTD	20MG/20ML (1MG/ML)	A209775	001	Dec 06, 2017 May CDFR
>A>	AP	MYLAN LABS LTD	20MG/20ML (1MG/ML)	A208860	001	Nov 06, 2017 May CDFR
>A>	CLOLAR					
>A>	AP	+! GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004 May CDFR

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION						
CLONIDINE HYDROCHLORIDE						
>D>	AP	EXELA PHARMA SCS LLC	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013 May CAHN
>D>	AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013 May CAHN
>A>	AP	X-GEN PHARMS INC	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013 May CAHN
>A>	AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013 May CAHN
TABLET;ORAL						
CLONIDINE HYDROCHLORIDE						
	@	AUROLIFE PHARMA LLC	0.1MG	A070886	002	Aug 31, 1988 Jan CMS1
	@		0.3MG	A070886	003	Aug 31, 1988 Jan CMS1
	@	CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988 Apr CMS1
	@		0.2MG	A071785	003	Apr 05, 1988 Apr CMS1
TABLET, EXTENDED RELEASE;ORAL						
CLONIDINE HYDROCHLORIDE						
AB1		JUBILANT GENERICS	0.1MG	A210338	001	Jan 29, 2018 Jan NEWA
AB1		MAYNE PHARMA INC	0.1MG	A210680	001	Apr 30, 2018 Apr NEWA

CLOPIDOGREL BISULFATE

TABLET;ORAL						
CLOPIDOGREL BISULFATE						
AB		PRINSTON INC	EQ 75MG BASE	A206376	001	May 07, 2018 Apr NEWA
AB			EQ 300MG BASE	A206376	002	May 07, 2018 Apr NEWA

CLOZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL						
CLOZAPINE						
AB		BARR LABS INC	12.5MG	A090308	003	Apr 09, 2018 Mar NEWA
AB	+	JAZZ PHARMS III	12.5MG	N021590	004	May 30, 2007 Mar CTEC

COLESEVELAM HYDROCHLORIDE

TABLET; ORAL

COLESEVELAM HYDROCHLORIDE

>A>	AB	GLENMARK PHARMS LTD	625MG	A203480	001	May 18, 2018	May	NEWA
	AB	IMPAX LABS INC	625MG	A091600	001	May 16, 2018	Apr	NEWA
		WELCHOL						
	AB	+! DAIICHI SANKYO	625MG	N021176	001	May 26, 2000	Apr	CFTG

CROFELEMER

TABLET, DELAYED RELEASE; ORAL

MYTESI

	+!	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012	Mar	CTNA
--	----	-----------------	-------	---------	-----	--------------	-----	------

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

@ FERA PHARMS LLC 10MG/ML

A075437	001	Apr 21, 2000	Mar	CAHN
---------	-----	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

AT		SANDOZ INC	4%	A075282	001	Jun 16, 1999	Jan	CAHN
----	--	------------	----	---------	-----	--------------	-----	------

CROTAMITON

CREAM; TOPICAL

EURAX

	+!	SUN PHARM INDS INC	10%	N006927	001		Feb	CAHN
--	----	--------------------	-----	---------	-----	--	-----	------

LOTION; TOPICAL

EURAX

AT	+!	SUN PHARM INDS INC	10%	N009112	003		Feb	CAHN
----	----	--------------------	-----	---------	-----	--	-----	------

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOGYL

AT	!	ALCON LABS INC	0.5%	A084109	001		Feb	CAHN
AT	!		1%	A084110	001		Feb	CAHN
	!		2%	A084108	001		Feb	CAHN

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL

	!	ALCON LABS INC	0.2%;1%	A084300	001		Feb	CAHN
--	---	----------------	---------	---------	-----	--	-----	------

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

AB		AMERIGEN PHARMS LTD	25MG	A207014	001	Mar 19, 2018	Mar	NEWA
AB			50MG	A207014	002	Mar 19, 2018	Mar	NEWA
AB		STI PHARMA LLC	25MG	A209872	001	May 07, 2018	Apr	NEWA
AB			50MG	A209872	002	May 07, 2018	Apr	NEWA
AB	+	WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Mar	CFTG
AB	+!		50MG	N203856	002	Sep 16, 2013	Mar	CFTG

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

>A>	AP	AMNEAL PHARMS CO	500MG/VIAL	A210046	001	May 25, 2018	May	NEWA
>A>	AP		1GM/VIAL	A210046	002	May 25, 2018	May	NEWA
>A>	AP		2GM/VIAL	A210046	003	May 25, 2018	May	NEWA

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

>D>	AB1	IVAX SUB TEVA PHARMS	50MG	A065110	001	Mar 29, 2005	May	CTEC
>A>			50MG	A065110	001	Mar 29, 2005	May	CTEC
		GENGRAF						
>D>	AB1	ABBVIE	50MG	A065003	002	May 12, 2000	May	DISC
>A>		@	50MG	A065003	002	May 12, 2000	May	DISC

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL		CYPROHEPTADINE HYDROCHLORIDE					
AA	APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Apr	CAHN
	@ FOSUN PHARMA	4MG	A086808	001		Jan	CAHN
AA	MOUNTAIN	4MG	A040537	001	Sep 30, 2003	Jan	CAHN
AA	STRIDES PHARMA	4MG	A209172	001	Apr 11, 2018	Mar	NEWA

CYTARABINE

INJECTABLE; INJECTION		CYTARABINE					
AP	MYLAN LABS LTD	20MG/ML	A200916	001	Dec 13, 2011	Jan	CAHN

DAPAGLIFLOZIN

TABLET; ORAL		FARXIGA					
+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Mar	CAIN
+	!	10MG	N202293	002	Jan 08, 2014	Mar	CAIN

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL		XIGDUO XR					
+	ASTRAZENECA AB	2.5MG; 1GM	N205649	005	Jul 28, 2017	Mar	CAIN
+		5MG; 500MG	N205649	001	Oct 29, 2014	Mar	CAIN
+		5MG; 1GM	N205649	002	Oct 29, 2014	Mar	CAIN
+		10MG; 500MG	N205649	003	Oct 29, 2014	Mar	CAIN
+	!	10MG; 1GM	N205649	004	Oct 29, 2014	Mar	CAIN

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL		QTERN						
+	!	ASTRAZENECA AB	10MG; EQ 5MG BASE	N209091	001	Feb 27, 2017	Mar	CAIN

DAPTOMYCIN

POWDER; INTRAVENOUS		DAPTOMYCIN						
AP	FRESENIUS KABI USA	500MG/VIAL	A206077	001	Apr 11, 2018	Mar	NEWA	
>A>	AP	MYLAN LABS LTD	500MG/VIAL	A205037	001	Jun 05, 2018	May	NEWA
AP	TEVA PHARMS USA	500MG/VIAL	A091039	001	Mar 25, 2016	Feb	CAHN	

DECITABINE

INJECTABLE; INTRAVENOUS		DECITABINE					
AP	SAGENT PHARMS	50MG/VIAL	A207100	001	Mar 16, 2018	Mar	NEWA

DEFERIPRONE

SOLUTION; ORAL		FERRIPROX					
+	AOPHARMA INC	80MG/ML	N208030	002	Apr 20, 2018	Apr	NEWA

DESFLURANE

LIQUID; INHALATION		DESFLURANE							
AN	SHANGHAI HENGRUI	100%	A208234	001	Feb 26, 2018	Feb	NEWA		
AN	+	!	BAXTER HLTHCARE	100%	N020118	001	Sep 18, 1992	Feb	CFTG

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL		DESIPRAMINE HYDROCHLORIDE						
>A>	AB	ANI PHARMS INC	10MG	A205153	001	Oct 28, 2016	May	CAHN
		@	25MG	A071803	002	Dec 08, 1987	Apr	CMS1
>A>	AB		25MG	A205153	002	Oct 28, 2016	May	CAHN
		@	50MG	A071803	003	Dec 08, 1987	Apr	CMS1
>A>	AB		50MG	A205153	003	Oct 28, 2016	May	CAHN
		@	75MG	A071803	004	Dec 08, 1987	Apr	CMS1
>A>	AB		75MG	A205153	004	Oct 28, 2016	May	CAHN
>A>	AB		100MG	A205153	005	Oct 28, 2016	May	CAHN
		@	150MG	A071803	005	May 29, 1997	Apr	CMS1
>A>	AB		150MG	A205153	006	Oct 28, 2016	May	CAHN
>D>	AB	MOUNTAIN	10MG	A205153	001	Oct 28, 2016	May	CAHN

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB		10MG	A205153	001	Oct 28, 2016	Feb	CAHN
>D>	AB	25MG	A205153	002	Oct 28, 2016	May	CAHN
	AB	25MG	A205153	002	Oct 28, 2016	Feb	CAHN
>D>	AB	50MG	A205153	003	Oct 28, 2016	May	CAHN
	AB	50MG	A205153	003	Oct 28, 2016	Feb	CAHN
>D>	AB	75MG	A205153	004	Oct 28, 2016	May	CAHN
	AB	75MG	A205153	004	Oct 28, 2016	Feb	CAHN
>D>	AB	100MG	A205153	005	Oct 28, 2016	May	CAHN
	AB	100MG	A205153	005	Oct 28, 2016	Feb	CAHN
>D>	AB	150MG	A205153	006	Oct 28, 2016	May	CAHN
	AB	150MG	A205153	006	Oct 28, 2016	Feb	CAHN

DESOXIMETASONE

CREAM;TOPICAL

TOPICORT

>D>	AB	! TARO	0.05%	A073210	001	Nov 30, 1990	May	CAHN
>D>	AB	!	0.25%	A073193	001	Nov 30, 1990	May	CAHN
>D>		+ @	0.25%	N017856	001		May	CAHN
>A>	AB	! TARO PHARM INDS LTD	0.05%	A073210	001	Nov 30, 1990	May	CAHN
>A>	AB	!	0.25%	A073193	001	Nov 30, 1990	May	CAHN
>A>		+ @	0.25%	N017856	001		May	CAHN

TOPICORT LP

>D>		+ @ TARO	0.05%	N018309	001		May	CAHN
>A>		+ @ TARO PHARM INDS LTD	0.05%	N018309	001		May	CAHN

GEL;TOPICAL

TOPICORT

>D>	AB	! TARO	0.05%	A074904	001	Jul 14, 1998	May	CAHN
>D>		+ @	0.05%	N018586	001	Mar 29, 1982	May	CAHN
>A>	AB	! TARO PHARM INDS LTD	0.05%	A074904	001	Jul 14, 1998	May	CAHN
>A>		+ @	0.05%	N018586	001	Mar 29, 1982	May	CAHN

OINTMENT;TOPICAL

TOPICORT

>D>	AB	+! TARO	0.05%	N018594	001	Jan 17, 1985	May	CAHN
>D>	AB	!	0.25%	A074286	001	Jun 07, 1996	May	CAHN
>D>		+ @	0.25%	N018763	001	Sep 30, 1983	May	CAHN
>A>	AB	+! TARO PHARM INDS LTD	0.05%	N018594	001	Jan 17, 1985	May	CAHN
>A>	AB	!	0.25%	A074286	001	Jun 07, 1996	May	CAHN
>A>		+ @	0.25%	N018763	001	Sep 30, 1983	May	CAHN

SPRAY;TOPICAL

DESOXIMETASONE

AT		LUPIN ATLANTIS	0.25%	A208124	001	Mar 16, 2018	Mar	NEWA
		TOPICORT						
>D>	AT	+! TARO	0.25%	N204141	001	Apr 11, 2013	May	CAHN
>A>	AT	+! TARO PHARMS	0.25%	N204141	001	Apr 11, 2013	May	CAHN

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB		CASI PHARMS INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Mar	CAHN
AB			EQ 100MG BASE	A204028	002	Jun 29, 2015	Mar	CAHN

DEXAMETHASONE

ELIXIR;ORAL

DEXAMETHASONE

>A>	AA	LANNETT CO INC	0.5MG/5ML	A091188	001	May 11, 2011	May	CAHN
>D>	AA	VINTAGE PHARMS	0.5MG/5ML	A091188	001	May 11, 2011	May	CAHN

HEXADROL

		@ ASPEN GLOBAL INC	0.5MG/5ML	N012674	001		Feb	CAHN
--	--	--------------------	-----------	---------	-----	--	-----	------

SUSPENSION;INTRAOCULAR

DEXYCU KIT

		+! EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018	Apr	CAHN
		+! ICON BIOSCIENCE	9%	N208912	001	Feb 09, 2018	Feb	NEWA

TABLET;ORAL

DEXAMETHASONE

>A>	BP	FERA PHARMS LLC	0.5MG	A088481	002	Apr 28, 1983	May	CMS1
>A>	BP		0.75MG	A088481	003	Apr 28, 1983	May	CMS1
>A>	BP		4MG	A088481	004	Apr 28, 1983	May	CMS1
	BP		6MG	A088481	001	Nov 28, 1983	Jan	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

		INJECTABLE; INJECTION		DEXAMETHASONE SODIUM PHOSPHATE	
>A>	AP	SOMERSET THERAPS LLC	EQ 4MG PHOSPHATE/ML	A207521 001	Jun 08, 2018 May NEWA
		DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE			
	AP	SOMERSET THERAPS LLC	EQ 10MG PHOSPHATE/ML	A207442 001	Apr 19, 2018 Apr NEWA
		HEXADROL			
	+ @	ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML	N014694 002	Feb CAHN
	+ @		EQ 10MG PHOSPHATE/ML	N014694 003	Feb CAHN
	@		EQ 20MG PHOSPHATE/ML	N014694 004	Feb CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

		INJECTABLE; INJECTION		DEXMEDETOMIDINE HYDROCHLORIDE	
	AP	ZYDUS PHARMS USA INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A206798 001	Feb 27, 2018 Feb NEWA

DEXTROAMPHETAMINE SULFATE

		TABLET; ORAL		DEXTROAMPHETAMINE SULFATE	
	AA	ARBOR PHARMS LLC	2.5MG	A090533 001	Oct 25, 2011 Apr CAHN
			5MG	A090533 002	Oct 25, 2011 Apr CAHN
			7.5MG	A090533 003	Oct 25, 2011 Apr CAHN
	AA		10MG	A090533 004	Oct 25, 2011 Apr CAHN
			15MG	A090533 005	Oct 25, 2011 Apr CAHN
			20MG	A090533 006	Oct 25, 2011 Apr CAHN
			30MG	A090533 007	Oct 25, 2011 Apr CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

		SYRUP; ORAL		PROMETH W/ DEXTROMETHORPHAN	
		@ G AND W LABS INC	15MG/5ML; 6.25MG/5ML	A088762 001	Oct 31, 1984 Jan DISC

DEXTROSE

		INJECTABLE; INJECTION		DEXTROSE 5% IN PLASTIC CONTAINER	
	AP	+ @	ICU MEDICAL INC 50MG/ML	N019222 001	Jul 13, 1984 Mar DISC
		+!	50MG/ML	N019222 001	Jul 13, 1984 Feb CAHN
		DEXTROSE 70% IN PLASTIC CONTAINER			
	AP	+!	B BRAUN 70GM/100ML	N019626 005	Feb 18, 2015 Feb NEWA

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

		INJECTABLE; INJECTION		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
	AP	+!	ICU MEDICAL INC 5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362 009	Jul 05, 1983 Mar CHRS
	AP	+!	5GM/100ML; 149MG/100ML; 450MG/100ML	N018362 005	Mar 28, 1988 Mar CPOT
		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
			BAXTER HLTHCARE 5GM/100ML; 75MG/100ML; 900MG/100ML	N019308 004	Apr 05, 1985 Mar CTEC
			5GM/100ML; 150MG/100ML; 900MG/100ML	N019308 002	Apr 05, 1985 Mar CTEC
		+ @	ICU MEDICAL INC 5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691 002	Mar 24, 1988 Mar DISC
		+ @	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691 004	Mar 24, 1988 Mar DISC
		POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
		+ @	ICU MEDICAL INC 5GM/100ML; 224MG/100ML; 450MG/100ML	N018362 006	Mar 28, 1988 Mar DISC
		POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
		+ @	ICU MEDICAL INC 5GM/100ML; 224MG/100ML; 900MG/100ML	N019691 006	Mar 24, 1988 Mar DISC
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
	AP	+!	ICU MEDICAL INC 5GM/100ML; 149MG/100ML; 450MG/100ML	N018362 010	Jul 05, 1983 Mar CHRS
		+ @	5GM/100ML; 298MG/100ML; 450MG/100ML	N018362 007	Mar 28, 1988 Mar DISC
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	AP	+!	ICU MEDICAL INC 5GM/100ML; 300MG/100ML; 900MG/100ML	N019308 003	Apr 05, 1985 Mar CTEC
		+ @	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691 005	Mar 24, 1988 Mar CRLD
		+ @	5GM/100ML; 298MG/100ML; 900MG/100ML	N019691 008	Mar 24, 1988 Mar DISC
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
	AP	+!	ICU MEDICAL INC 5GM/100ML; 224MG/100ML; 450MG/100ML	N018362 002	Mar CHRS
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
			BAXTER HLTHCARE 5GM/100ML; 224MG/100ML; 900MG/100ML	N019308 006	Apr 05, 1985 Mar CTEC
		+ @	ICU MEDICAL INC 5GM/100ML; 224MG/100ML; 900MG/100ML	N019691 007	Mar 24, 1988 Mar DISC
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
	AP	+!	ICU MEDICAL INC 5GM/100ML; 298MG/100ML; 450MG/100ML	N018362 003	Mar CHRS

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	+	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	009	Mar 24, 1988	Mar CRLD
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
		BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 450MG/100ML	N018008	004		Mar CTEC
	+	@ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	008	Mar 28, 1988	Mar DISC
	+	@	5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	004	Mar 28, 1988	Mar DISC
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
		BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 900MG/100ML	N019308	001	Apr 05, 1985	Mar CTEC
	+	@ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	001	Mar 24, 1988	Mar DISC
	+	@	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	003	Mar 24, 1988	Mar DISC

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP	+	ICU MEDICAL INC	5GM/100ML; 450MG/100ML	N017607	001		Jan CRLD

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

>D> INJECTABLE; INJECTION

>D>	RENOGRAFIN-76						
>D>	+	BRACCO	66%; 10%	N010040	001		May DISC
>A>	+	@	66%; 10%	N010040	001		May DISC

>D> DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

>D>	SOLUTION; INTRAUTERINE						
>D>	SINOGRAFIN						
>D>	+	BRACCO	52.7%; 26.8%	N011324	002		May DISC
>A>	+	@	52.7%; 26.8%	N011324	002		May DISC

DIAZEPAM

TABLET; ORAL

	DIAZEPAM						
	@	DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	Apr CMS1
	@		5MG	A070228	003	Sep 26, 1985	Apr CMS1

DICLOFENAC POTASSIUM

TABLET; ORAL

	DICLOFENAC POTASSIUM						
AB		CASI PHARMS INC	50MG	A075229	001	Nov 20, 1998	Mar CAHN

DICLOFENAC SODIUM

SOLUTION; TOPICAL

	DICLOFENAC SODIUM						
AT		ZYDUS PHARMS USA INC	1.5%	A206411	001	Apr 17, 2018	Apr NEWA

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM						
AB	!	CASI PHARMS INC	25MG	A074376	001	Sep 28, 1995	Mar CAHN
AB	!		50MG	A074376	002	Sep 28, 1995	Mar CAHN
AB	!		75MG	A074394	001	Nov 30, 1995	Mar CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	BENTYL						
AB	+	ALLERGAN SALES LLC	10MG	N007409	003	Oct 15, 1984	Jan CAHN

INJECTABLE; INJECTION

	BENTYL						
AP	+	ALLERGAN SALES LLC	10MG/ML	N008370	001	Oct 15, 1984	Jan CAHN
	BENTYL PRESERVATIVE FREE						
AP	+	ALLERGAN SALES LLC	10MG/ML	N008370	002	Oct 15, 1984	Jan CAHN

DICYCLOMINE HYDROCHLORIDE

AP		AKORN INC	10MG/ML	A207084	001	May 04, 2018	Apr NEWA
----	--	-----------	---------	---------	-----	--------------	----------

TABLET; ORAL

	BENTYL						
AB	+	ALLERGAN SALES LLC	20MG	N007409	001	Oct 15, 1984	Jan CAHN

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

	DIDANOSINE						
	@	BARR	200MG	A077167	001	Dec 03, 2004	Mar DISC
	@		250MG	A077167	002	Dec 03, 2004	Mar DISC
	@		400MG	A077167	003	Dec 03, 2004	Mar DISC

DIFLORASONE DIACETATE

OINTMENT;TOPICAL
DIFLORASONE DIACETATE

>A> AB TELIGENT PHARMA INC 0.05% A210753 001 Jun 12, 2018 May NEWA

DIGOXIN

TABLET;ORAL
LANOXIN

>D> + CONCORDIA PHARMS INC 0.1875MG N020405 003 Sep 30, 1997 May DISC
>A> + @ 0.1875MG N020405 003 Sep 30, 1997 May DISC

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

>A> AB3 PAR PHARM 360MG A209766 001 May 30, 2018 May NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

@ FOSUN PHARMA 25MG A080832 001 Jan CAHN
@ 25MG A080845 002 Jan CAHN
@ 50MG A080832 002 Jan CAHN
@ 50MG A080845 001 Jan CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

AB APOTEX INC EQ 125MG VALPROIC ACID A077615 003 Jul 29, 2008 Apr CAHN
AB EQ 250MG VALPROIC ACID A077615 002 Jul 29, 2008 Apr CAHN
AB EQ 500MG VALPROIC ACID A077615 001 Jul 29, 2008 Apr CAHN

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

AP AMNEAL PHARMS CO 20MG/ML (20MG/ML) A209640 001 Jan 19, 2018 Jan NEWA
AP 80MG/4ML (20MG/ML) A209640 002 Jan 19, 2018 Jan NEWA
AP 160MG/8ML (20MG/ML) A209640 003 Jan 19, 2018 Jan NEWA

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

AP MYLAN LABS LTD 160MG/16ML (10MG/ML) A208859 001 Apr 30, 2018 Apr NEWA

DOFETILIDE

CAPSULE;ORAL
DOFETILIDE

>D> AB APICORE US 0.125MG A208625 001 Apr 10, 2018 May CAHN
AB 0.125MG A208625 001 Apr 10, 2018 Mar NEWA
>D> AB 0.25MG A208625 002 Apr 10, 2018 May CAHN
AB 0.25MG A208625 002 Apr 10, 2018 Mar NEWA
>D> AB 0.5MG A208625 003 Apr 10, 2018 May CAHN
AB 0.5MG A208625 003 Apr 10, 2018 Mar NEWA
>A> AB BIONPHARMA INC 0.125MG A208625 001 Apr 10, 2018 May CAHN
>A> AB 0.25MG A208625 002 Apr 10, 2018 May CAHN
>A> AB 0.5MG A208625 003 Apr 10, 2018 May CAHN
AB SIGMAPHARM LABS LLC 0.125MG A207746 001 Mar 26, 2018 Mar NEWA
AB 0.25MG A207746 002 Mar 26, 2018 Mar NEWA
AB 0.5MG A207746 003 Mar 26, 2018 Mar NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
DONEPEZIL HYDROCHLORIDE

@ APOTEX 5MG A078841 001 Jun 02, 2011 Mar DISC
@ 10MG A078841 002 Jun 02, 2011 Mar DISC
@ SUN PHARM INDS LTD 5MG A076786 001 Nov 26, 2010 Apr DISC
@ 10MG A076786 002 Nov 26, 2010 Apr DISC

DOPAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOPAMINE HYDROCHLORIDE

AP	HIKMA INTL PHARMS	40MG/ML	A207707	001	Apr 11, 2018	Mar	NEWA
AP		80MG/ML	A207707	002	Apr 11, 2018	Mar	NEWA

DORZOLAMIDE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

>D>	AT	WATSON LABS INC	EQ 2% BASE	A202053	001	Sep 11, 2014	May	DISC
>A>		@	EQ 2% BASE	A202053	001	Sep 11, 2014	May	DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>D>	AT	WATSON LABS INC	EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014	May	DISC
>A>		@	EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014	May	DISC

DOXAZOSIN MESYLATETABLET; ORAL
DOXAZOSIN MESYLATE

AB	APPCO PHARMA LLC	EQ 1MG BASE	A209013	001	Apr 17, 2018	Apr	NEWA
AB		EQ 2MG BASE	A209013	002	Apr 17, 2018	Apr	NEWA
AB		EQ 4MG BASE	A209013	003	Apr 17, 2018	Apr	NEWA
AB		EQ 8MG BASE	A209013	004	Apr 17, 2018	Apr	NEWA
AB	HERITAGE PHARMA	EQ 1MG BASE	A205210	001	Feb 13, 2018	Jan	NEWA
AB		EQ 2MG BASE	A205210	002	Feb 13, 2018	Jan	NEWA
AB		EQ 4MG BASE	A205210	003	Feb 13, 2018	Jan	NEWA
AB		EQ 8MG BASE	A205210	004	Feb 13, 2018	Jan	NEWA
AB	@ YAOPHARMA CO LTD	EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan	CAHN
	@	EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan	CAHN
	@	EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan	CAHN
	@	EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan	CAHN

DOXEPIIN HYDROCHLORIDETABLET; ORAL
DOXEPIIN HYDROCHLORIDE@ ACTAVIS ELIZABETH EQ 3MG BASE
@ EQ 6MG BASE

SILENOR

+ PERNIX THERAPS LLC EQ 3MG BASE
+! EQ 6MG BASE

A201951	001	Jul 26, 2013	Jan	DISC
A201951	002	Jul 26, 2013	Jan	DISC
N022036	001	Mar 17, 2010	Jan	CTEC
N022036	002	Mar 17, 2010	Jan	CTEC

DOXYCYCLINE HYCLATECAPSULE; ORAL
ACTICLATE CAP

>D>	+!	AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	May	DISC
>A>	+ @		EQ 75MG BASE	N208253	001	Apr 26, 2016	May	DISC

DOXYCYCLINE HYCLATE

>A>	AB	ALEMBIC PHARMS LTD	EQ 50MG BASE	A210527	001	Jun 13, 2018	May	NEWA
>A>	AB		EQ 100MG BASE	A210527	002	Jun 13, 2018	May	NEWA
>A>	AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A207774	001	May 31, 2018	May	NEWA
>A>	AB		EQ 100MG BASE	A207774	002	May 31, 2018	May	NEWA

TABLET, DELAYED RELEASE; ORAL

DORYX

+ @ MAYNE PHARMA EQ 80MG BASE

DOXYCYCLINE HYCLATE

>A>	AB	ACTAVIS ELIZABETH	EQ 50MG BASE	A090134	003	May 22, 2018	May	NEWA
>A>	AB		EQ 200MG BASE	A090134	004	May 22, 2018	May	NEWA
		@ MYLAN	EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr	DISC

DRONABINOLCAPSULE; ORAL
DRONABINOL

>A>	AB	LANNETT CO INC	2.5MG	A201463	001	May 18, 2018	May	NEWA
>A>	AB		5MG	A201463	002	May 18, 2018	May	NEWA
>A>	AB		10MG	A201463	003	May 18, 2018	May	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL		DROSPIRENONE AND ETHINYL ESTRADIOL							
AB	JUBILANT CADISTA	3MG;0.02MG		A209423	001	Dec 22, 2017	Mar	CAHN	
TABLET;ORAL-28		ZUMANDIMINE							
AB	AUROBINDO PHARMA LTD	3MG;0.02MG		A209632	001	Feb 27, 2018	Feb	NEWA	
AB	AUROBINDO PHARMA LTD	3MG;0.03MG		A209407	001	Mar 26, 2018	Mar	NEWA	

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL		DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM							
>A> AB	LUPIN LTD	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG		A205947	001	Jun 13, 2018	May	NEWA	

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL		DULOXETINE HYDROCHLORIDE							
>A> AB	BRECKENRIDGE PHARM	EQ 40MG BASE		A203088	004	May 18, 2018	May	NEWA	
>D>	LUPIN LTD	EQ 40MG BASE		A090694	003	Dec 11, 2013	May	CTEC	
>A> AB		EQ 40MG BASE		A090694	003	Dec 11, 2013	May	CTEC	

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL		DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE							
>A> AB	ZYDUS PHARMS USA INC	0.5MG;0.4MG		A207769	001	May 24, 2018	May	NEWA	

ECONAZOLE NITRATE

CREAM;TOPICAL		ECONAZOLE NITRATE							
AB	CASI PHARMS INC	1%		A076075	001	Nov 26, 2002	Mar	CAHN	
AB	MYLAN PHARMS INC	1%		A210364	001	Apr 18, 2018	Apr	NEWA	

EFAVIRENZ

TABLET;ORAL		EFAVIRENZ							
AB	HETERO LABS LTD III	600MG		A078886	001	Apr 27, 2018	Apr	NEWA	
AB	STRIDES PHARMA	600MG		A204869	001	Mar 12, 2018	Feb	NEWA	

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL		ATRIPLA							
+	GILEAD SCIENCES	600MG;200MG;300MG		N021937	001	Jul 12, 2006	Mar	CAHN	

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL		SYMFI							
+	MYLAN LABS LTD	600MG;300MG;300MG		N022142	001	Mar 22, 2018	Mar	NEWA	
+	MYLAN PHARMS INC	400MG;300MG;300MG		N208255	001	Feb 05, 2018	Feb	NEWA	

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL		ELETRIPTAN HYDROBROMIDE							
>A> AB	AMNEAL PHARMS CO	EQ 20MG BASE		A206787	001	May 25, 2018	May	NEWA	
>A> AB		EQ 40MG BASE		A206787	002	May 25, 2018	May	NEWA	

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL		EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE							
AB	AUROBINDO PHARMA LTD	200MG;300MG		A090513	001	Jan 26, 2018	Jan	NEWA	
AB	MYLAN PHARMS INC	200MG;300MG		A206436	001	Apr 09, 2018	Mar	NEWA	

ENTECAVIR

TABLET;ORAL		ENTECAVIR							
AB	BRECKENRIDGE PHARM	0.5MG		A208721	001	Mar 15, 2018	Apr	NEWA	
AB		1MG		A208721	002	Mar 15, 2018	Apr	NEWA	
AB	CASI PHARMS INC	0.5MG		A206672	001	May 11, 2017	Mar	CAHN	
AB		1MG		A206672	002	May 11, 2017	Mar	CAHN	

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS
CORPHEDRA

AP PAR STERILE PRODUCTS 50MG/ML (50MG/ML) N208943 001 Jan 27, 2017 Apr CDFR

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

AT CASI PHARMS INC 0.05% A203384 001 Dec 07, 2016 Mar CAHN

EPINEPHRINE

SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

+! BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML) N205029 001 Jul 29, 2014 Apr CRLD

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
@ EASTMAN KODAK 0.01MG/ML;2%
@ 0.02MG/ML;2%

A040057 002 Feb 26, 1993 Mar DISC

A040057 001 Feb 26, 1993 Mar DISC

EPROSARTAN MESYLATE

TABLET;ORAL
EPROSARTAN MESYLATE

AB ! MYLAN PHARMS INC EQ 600MG BASE A202012 002 Nov 16, 2011 Mar CHRS

TEVETEN

+ @ ABBVIE EQ 400MG BASE N020738 005 Dec 22, 1997 Mar DISC

+ @ EQ 600MG BASE N020738 006 May 27, 1999 Mar DISC

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

AP SAGENT PHARMS 2MG/ML A204693 001 Mar 07, 2018 Feb NEWA

AP 75MG/100ML A204693 002 Mar 07, 2018 Feb NEWA

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, IV (INFUSION)
ERTAPENEM SODIUM

AP ACS DOBFAR SPA EQ 1GM BASE/VIAL A208790 001 Apr 16, 2018 Apr NEWA

INVANZ

AP +! MERCK SHARP DOHME EQ 1GM BASE/VIAL N021337 001 Nov 21, 2001 Apr CFTG

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL
STEGLUJAN

+ MERCK SHARP DOHME 5MG;EQ 100MG BASE N209805 001 Dec 19, 2017 Jan CMS1

+! 15MG;EQ 100MG BASE N209805 002 Dec 19, 2017 Jan CMS1

ERYTHROMYCIN

TABLET;ORAL
ERYTHROMYCIN

AB AMNEAL PHARMS CO 250MG A209720 001 Mar 09, 2018 Feb NEWA

AB 500MG A209720 002 Mar 09, 2018 Feb NEWA

AB ARBOR PHARMS LLC 250MG A061621 001 Feb CTEC

AB ! 500MG A061621 002 Feb CTEC

ESCITALOPRAM OXALATE

SOLUTION;ORAL
LEXAPRO

AA +! ALLERGAN SALES LLC EQ 5MG BASE/5ML N021365 001 Nov 27, 2002 Jan CAHN

TABLET;ORAL
LEXAPRO

AB + ALLERGAN SALES LLC EQ 5MG BASE N021323 001 Aug 14, 2002 Jan CAHN

AB + EQ 10MG BASE N021323 002 Aug 14, 2002 Jan CAHN

AB +! EQ 20MG BASE N021323 003 Aug 14, 2002 Jan CAHN

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
ESMOLOL HYDROCHLORIDE

>A>	AP	MYLAN LABS LTD	10MG/ML	A206608	001	Jun 08, 2018	May NEWA
>A>	AP		20MG/ML	A206608	002	Jun 08, 2018	May NEWA
>A>	AP	SAGENT PHARMS	10MG/ML	A207107	001	Jun 08, 2018	May NEWA
>A>	AP		20MG/ML	A207107	002	Jun 08, 2018	May NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL
ESOMEPRAZOLE MAGNESIUM

>A>	AB	HEC PHARM CO LTD	EQ 20MG BASE	A207265	002	May 18, 2018	May NEWA
>A>	AB		EQ 40MG BASE	A207265	001	May 18, 2018	May NEWA
	AB	SUN PHARM INDS LTD	EQ 20MG BASE	A209735	001	Apr 30, 2018	Apr NEWA
	AB		EQ 40MG BASE	A209735	002	Apr 30, 2018	Apr NEWA

ESTRADIOL

CREAM; VAGINAL
ESTRADIOL

	AB	ALVOGEN PINE BROOK	0.01%	A209767	001	Mar 05, 2018	Feb NEWA
	AB	PERRIGO UK FINCO	0.01%	A210194	001	Jan 22, 2018	Jan NEWA
	AB	TEVA PHARMS USA	0.01%	A210488	001	Mar 30, 2018	Mar NEWA
>A>		INSERT; VAGINAL					
>A>		IMVEXXY					
>A>	+	THERAPEUTICSMD INC	0.004MG	N208564	001	May 29, 2018	May NEWA
>A>	+	!	0.01MG	N208564	002	May 29, 2018	May NEWA

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL
FEMRING

>D>	+	APIL	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	May CAHN
>D>	+	!	EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	May CAHN
>A>	+	MILLICENT	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	May CAHN
>A>	+	!	EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	May CAHN

ESTRADIOL VALERATE

INJECTABLE; INJECTION
ESTRADIOL VALERATE

	@	FOSUN PHARMA	10MG/ML	A040628	001	Oct 04, 2007	Jan CAHN
	@		20MG/ML	A040628	002	Oct 04, 2007	Jan CAHN
	@		40MG/ML	A040628	003	Oct 04, 2007	Jan CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

	AB	ACCORD HLTHCARE	1MG; 0.5MG	A210233	001	Feb 28, 2018	Feb NEWA
--	----	-----------------	------------	---------	-----	--------------	----------

ETHACRYNIC ACID

TABLET; ORAL
ETHACRYNIC ACID

	AB	AMNEAL PHARMS CO	25MG	A208805	001	May 08, 2018	Apr NEWA
--	----	------------------	------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL
BALCOLTRA

		AVION PHARMS	0.02MG; 0.1MG	N208612	001	Jan 09, 2018	Feb CAHN
		NEUVOSYN LABS LLC	0.02MG; 0.1MG	N208612	001	Jan 09, 2018	Jan NEWA
		LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL					
	AB	LABS LEON FARMA	0.02MG, 0.1MG; 0.01MG, N/A	A205131	001	Dec 14, 2017	Apr CPOT
	AB	LUPIN LTD	0.02MG, 0.1MG; 0.01MG, N/A	A091674	001	Oct 26, 2011	Apr CPOT
	AB	MAYNE PHARMA	0.02MG, 0.1MG; 0.01MG, N/A	A200407	001	Oct 25, 2011	Apr CPOT
	AB	MYLAN LABS LTD	0.02MG, 0.1MG; 0.01MG, N/A	A200493	001	Jun 17, 2015	Apr CPOT
		LO SIMPESE					
	AB	AUROBINDO PHARMA LTD	0.02MG, 0.1MG; 0.01MG, N/A	A206852	001	Apr 28, 2017	Apr CPOT
		LOSEASONIQUE					
	AB	TEVA BRANDED PHARM	0.02MG, 0.1MG; 0.01MG, N/A	N022262	001	Oct 24, 2008	Apr CPOT
		TABLET; ORAL-21					
		ALESSE					
>D>	+	@ WYETH PHARMS	0.02MG; 0.1MG	N020683	001	Mar 27, 1997	May CAHN
>A>	+	@	0.02MG; 0.1MG	N020683	001	Mar 27, 1997	May CAHN

		TABLET;ORAL-21							
		TRIPHASIL-21							
>D>	+	@ WYETH PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N019192	001	Nov 01, 1984	May	CAHN	
>A>	+	@	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N019192	001	Nov 01, 1984	May	CAHN	
		TABLET;ORAL-28							
		ALESSE							
>D>	+	@ WYETH PHARMS	0.02MG;0.1MG	N020683	002	Mar 27, 1997	May	CAHN	
>A>	+	@	0.02MG;0.1MG	N020683	002	Mar 27, 1997	May	CAHN	
		LEVONORGESTREL AND ETHINYL ESTRADIOL							
AB		MYLAN LABS LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018	Mar	NEWA	
		<u>ETHINYL ESTRADIOL; NORETHINDRONE</u>							
		TABLET;ORAL-28							
		MODICON 28							
	+	@ JANSSEN PHARMS	0.035MG;0.5MG	N017735	001			Feb	DISC
		WERA							
AB	!	NOVAST LABS LTD	0.035MG;0.5MG	A091204	001	Mar 27, 2012	Feb	CHRS	
		<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>							
		TABLET;ORAL							
		LO LOESTRIN FE							
	+	! APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Apr	CTEC	
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	@	MYLAN LABS LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	Apr	DISC	
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB		APOTEX INC	0.02MG;1MG	A208639	001	Mar 21, 2018	Mar	NEWA	
		TABLET;ORAL-28							
>A>		HAILEY 1.5/30							
>A>	AB	GLENMARK PHARMS	0.03MG;1.5MG	A209297	001	Jun 05, 2018	May	NEWA	
>A>		HAILEY FE 1.5/30							
>A>	AB	GLENMARK PHARMS	0.03MG;1.5MG	A209031	001	Jun 05, 2018	May	NEWA	
		TABLET, CHEWABLE, TABLET;ORAL							
		LO MINASTRIN FE							
	+	@ APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan	DISC	
		<u>ETHIONAMIDE</u>							
		TABLET;ORAL							
		TRECTOR							
>A>	+	! WYETH PHARMS	250MG	N013026	002		May	CAHN	
>D>	+	! WYETH PHARMS INC	250MG	N013026	002		May	CAHN	
		<u>ETODOLAC</u>							
		TABLET;ORAL							
		ETODOLAC							
>A>	AB	AMNEAL PHARMS CO	400MG	A208834	001	Jun 07, 2018	May	NEWA	
>A>	AB		500MG	A208834	002	Jun 07, 2018	May	NEWA	
		<u>EVEROLIMUS</u>							
		TABLET;ORAL							
		EVEROLIMUS							
AB		WEST-WARD PHARMS INT	0.25MG	A206133	001	Apr 12, 2018	Apr	NEWA	
AB			0.5MG	A206133	002	Apr 12, 2018	Apr	NEWA	
AB			0.75MG	A206133	003	Apr 12, 2018	Apr	NEWA	
		ZORTRESS							
AB	+	NOVARTIS	0.25MG	N021560	001	Apr 20, 2010	Apr	CFTG	
AB	+		0.5MG	N021560	002	Apr 20, 2010	Apr	CFTG	
AB	+	!	0.75MG	N021560	003	Apr 20, 2010	Apr	CFTG	
		<u>EXEMESTANE</u>							
		TABLET;ORAL							
		EXEMESTANE							
AB		CIPLA LTD	25MG	A210323	001	Apr 27, 2018	Apr	NEWA	
		<u>EZETIMIBE; SIMVASTATIN</u>							
		TABLET;ORAL							
		EZETIMIBE AND SIMVASTATIN							
>A>	AB	ANI PHARMS INC	10MG;10MG	A201890	001	Apr 26, 2017	May	CAHN	
>A>	AB		10MG;20MG	A201890	002	Apr 26, 2017	May	CAHN	
>A>	AB		10MG;40MG	A201890	003	Apr 26, 2017	May	CAHN	

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

>A>	AB		10MG;80MG	A201890	004	Apr 26, 2017	May	CAHN
>D>	AB	IMPAX LABS INC	10MG;10MG	A201890	001	Apr 26, 2017	May	CAHN
>D>	AB		10MG;20MG	A201890	002	Apr 26, 2017	May	CAHN
>D>	AB		10MG;40MG	A201890	003	Apr 26, 2017	May	CAHN
>D>	AB		10MG;80MG	A201890	004	Apr 26, 2017	May	CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

@ PLD ACQUISITIONS

20MG

A075302 001 Apr 16, 2001 Feb CAHN

@

40MG

A075302 002 Apr 16, 2001 Feb CAHN

FELBAMATE

TABLET;ORAL

FELBAMATE

>A>	AB	ANI PHARMS INC	400MG	A202284	001	Nov 04, 2015	May	CAHN
>A>	AB		600MG	A202284	002	Nov 04, 2015	May	CAHN
>D>	AB	IMPAX LABS INC	400MG	A202284	001	Nov 04, 2015	May	CAHN
>D>	AB		600MG	A202284	002	Nov 04, 2015	May	CAHN

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

AB		AMERIGEN PHARMS LTD	67MG	A209504	001	Apr 30, 2018	Apr	NEWA
AB			134MG	A209504	002	Apr 30, 2018	Apr	NEWA
AB			200MG	A209504	003	Apr 30, 2018	Apr	NEWA

TABLET;ORAL

FENOFIBRATE

AB		AMNEAL PHARMS LLC	48MG	A209951	001	Feb 09, 2018	Jan	NEWA
AB			54MG	A209950	001	Mar 19, 2018	Mar	NEWA
AB			145MG	A209951	002	Feb 09, 2018	Jan	NEWA
AB			160MG	A209950	002	Mar 19, 2018	Mar	NEWA

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

DURAGESIC-37

+	JANSSSEN PHARMS	37.5MCG/HR	N019813	006	Jan 24, 2018	Jan	NEWA
---	-----------------	------------	---------	-----	--------------	-----	------

FERRIC PYROPHOSPHATE CITRATE

SOLUTION;IV (INFUSION)

TRIFERIC

>D>	+	ROCKWELL MEDICAL INC	272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015	May	DISC
>A>	+	@	272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015	May	DISC

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

ALLEGRA

>D>	AB	+	SANOFI AVENTIS US	30MG/5ML	N021963	001	Oct 16, 2006	May	DISC
>A>		+	@	30MG/5ML	N021963	001	Oct 16, 2006	May	DISC

FEXOFENADINE HYDROCHLORIDE

>D>	AB		ACTAVIS MID ATLANTIC	30MG/5ML	A201311	001	Jul 25, 2012	May	CHRS
>A>		!		30MG/5ML	A201311	001	Jul 25, 2012	May	CHRS

FINASTERIDE

TABLET;ORAL

FINASTERIDE

>D>	AB		GEDEON RICHTER USA	5MG	A077251	001	Dec 22, 2006	May	DISC
>A>			@	5MG	A077251	001	Dec 22, 2006	May	DISC

>D> FINGOLIMOD

CAPSULE;ORAL

GILENYA

>D>		+	NOVARTIS	0.5MG	N022527	001	Sep 21, 2010	May	CAIN
-----	--	---	----------	-------	---------	-----	--------------	-----	------

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL
GILENYA

>A>	+	NOVARTIS	EQ 0.25MG BASE	N022527	002	May 11, 2018	May NEWA
>A>	+	!	EQ 0.5MG BASE	N022527	001	Sep 21, 2010	May CAIN

FLUCONAZOLE

INJECTABLE; INJECTION
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	!	INFORLIFE	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Jan CAHN
AP	!		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Jan CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

>D>	AP	+	FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005	May DISC
>A>		+	@	20-200mCi/ML	N021870	001	Aug 19, 2005	May DISC
>D>	AP		MIDWEST MEDCL	20-200mCi/ML	A203736	001	Nov 19, 2015	May DISC
>A>			@	20-200mCi/ML	A203736	001	Nov 19, 2015	May DISC
>D>	AP		PETNET	20-200mCi/ML	A079086	001	Feb 25, 2011	May CHRS
>A>	AP		!	20-200mCi/ML	A079086	001	Feb 25, 2011	May CHRS

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

		@	G AND W LABS	0.025%	A089525	001	Jul 26, 1988	Jan DISC
--	--	---	--------------	--------	---------	-----	--------------	----------

OIL/DROPS; OTIC
FLAC

AT			PATRIN PHARMA INC	0.01%	A210736	001	Apr 11, 2018	Mar NEWA
----	--	--	-------------------	-------	---------	-----	--------------	----------

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE

		@	G AND W LABS INC	0.01%	A207441	001	Sep 28, 2016	Jan DISC
--	--	---	------------------	-------	---------	-----	--------------	----------

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

>A>	AB		AMNEAL PHARMS LLC	0.1%	A211111	001	Jun 04, 2018	May NEWA
-----	----	--	-------------------	------	---------	-----	--------------	----------

FLUOCINONIDE EMULSIFIED BASE

>D>	AB2	!	TARO	0.05%	A072494	001	Jan 19, 1989	May CAHN
>A>	AB2	!	TARO PHARM INDS LTD	0.05%	A072494	001	Jan 19, 1989	May CAHN

SOLUTION; TOPICAL
FLUOCINONIDE

AT			GLASSHOUSE PHARMS	0.05%	A209118	001	Apr 23, 2018	Apr NEWA
AT			MACLEODS PHARMS LTD	0.05%	A209283	001	Apr 23, 2018	Apr NEWA

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS
FLUORESCITE

AP	+	!	ALCON LABS INC	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Feb CAHN
----	---	---	----------------	--------------------------------------	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL
FLUOXETINE HYDROCHLORIDE

AB			DR REDDYS LABS LTD	EQ 10MG BASE	A076006	001	Jan 30, 2002	Apr CAHN
AB				EQ 20MG BASE	A076006	002	Apr 23, 2018	Apr NEWA
AB				EQ 20MG BASE	A076006	002	Apr 23, 2018	Apr CAHN
		@	FOSUN PHARMA	EQ 10MG BASE	A076024	001	Jan 29, 2002	Jan CAHN

FLUTAMIDE

CAPSULE; ORAL
FLUTAMIDE
@ YAOPHARMA CO LTD

			125MG	A075818	001	Sep 18, 2001	Jan CAHN
--	--	--	-------	---------	-----	--------------	----------

FLUTICASONE FUROATE

POWDER; INHALATION
ARNUITY ELLIPTA

>A>	+	!	GLAXOSMITHKLINE	0.05MG/INH	N205625	003	May 17, 2018	May NEWA
-----	---	---	-----------------	------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATESPRAY, METERED;NASAL
XHANCE

+! OPTINOSE US INC 0.093MG N209022 001 Sep 18, 2017 Jan CMS1

FONDAPARINUX SODIUMINJECTABLE;SUBCUTANEOUS
FONDAPARINUX SODIUM

AP	JIANGSU HENGRUI MED	2.5MG/0.5ML	A206812	001	May 15, 2018	Apr	NEWA
AP		5MG/0.4ML	A206812	002	May 15, 2018	Apr	NEWA
AP		7.5MG/0.6ML	A206812	003	May 15, 2018	Apr	NEWA
AP		10MG/0.8ML	A206812	004	May 15, 2018	Apr	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	EMCURE PHARMS LTD	10MG;12.5MG	A079025	001	Sep 17, 2010	Jan	CAHN
AB	!	20MG;12.5MG	A079025	002	Sep 17, 2010	Jan	CAHN

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDEPOWDER;INTRAVENOUS
AKYNZEO

+! HELSINN HLTHCARE EQ 235MG BASE;EQ 0.25MG BASE N210493 001 Apr 19, 2018 Apr NEWA

FOSTAMATINIB DISODIUM

TABLET;ORAL

TAVALLISSE

+	RIGEL PHARMS INC	EQ 100MG BASE	N209299	001	Apr 17, 2018	Apr	NEWA
+!		EQ 150MG BASE	N209299	002	Apr 17, 2018	Apr	NEWA

GABAPENTINCAPSULE;ORAL
GABAPENTIN

AB	ACI HEALTHCARE LTD	100MG	A206943	001	May 14, 2018	Apr	NEWA
AB		300MG	A206943	002	May 14, 2018	Apr	NEWA
AB		400MG	A206943	003	May 14, 2018	Apr	NEWA

GATIFLOXACINSOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

>A> AT MICRO LABS 0.5% A206446 001 Jun 08, 2018 May NEWA

GEMCITABINE HYDROCHLORIDEINJECTABLE;INJECTION
GEMCITABINE HYDROCHLORIDE@ HAMELN RDS GMBH EQ 200MG BASE/VIAL
@ EQ 1GM BASE/VIALA090663 001 Sep 10, 2012 Mar DISC
A090663 002 Sep 10, 2012 Mar DISCGEMFIBROZILTABLET;ORAL
GEMFIBROZIL

@ YAOPHARMA CO LTD 600MG

A074615 001 Sep 29, 1995 Jan CAHN

GENTAMICIN SULFATEOINTMENT;TOPICAL
GENTAMICIN SULFATE

AT G AND W LABS INC EQ 0.1% BASE A064054 001 Apr 29, 1994 Jan CMFD

GLATIRAMER ACETATEINJECTABLE;SUBCUTANEOUS
GLATOPIA

AP SANDOZ INC 40MG/ML A206921 001 Feb 12, 2018 Jan NEWA

GLUCAGONINJECTABLE;INJECTION
GLUCAGON

+! LILLY 1MG/VIAL N020928 001 Sep 11, 1998 Apr CAIN

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGEN

+! NOVO NORDISK EQ 1MG BASE/VIAL N020918 001 Jun 22, 1998 Apr CAIN

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

@ YAOPHARMA CO LTD 1.5MG A075174 001 Jun 22, 1998 Jan CAHN
@ 3MG A075174 002 Jun 22, 1998 Jan CAHN

GLYCINE

SOLUTION; IRRIGATION
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

AT +! BAXTER HLTHCARE 1.5GM/100ML N017865 001 Mar CRLD

GLYCOPYRROLATE

TABLET; ORAL
GLYCOPYRROLATE

>D> AA PAR PHARM 1MG A040653 001 Aug 31, 2006 May CHRS
>A> AA ! 1MG A040653 001 Aug 31, 2006 May CHRS
>D> AA 2MG A040653 002 Aug 31, 2006 May CHRS
>A> AA ! 2MG A040653 002 Aug 31, 2006 May CHRS
@ RENATA 1MG A040568 001 Dec 22, 2004 Apr CAHN
@ 2MG A040568 002 Dec 22, 2004 Apr CAHN
>D> ROBINUL
>D> AA +! CASPER PHARMA LLC 1MG N012827 001 May DISC
>A> + @ 1MG N012827 001 May DISC
>D> ROBINUL FORTE
>D> AA +! CASPER PHARMA LLC 2MG N012827 002 May DISC
>A> + @ 2MG N012827 002 May DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION
GRANISETRON HYDROCHLORIDE

@ TEVA PHARMS USA EQ 1MG BASE/ML (EQ 1MG BASE/ML) A077963 001 Jan 03, 2008 Feb DISC

TABLET; ORAL
GRANISETRON HYDROCHLORIDE

AB CHARTWELL MOLECULAR EQ 1MG BASE A078037 001 Feb 27, 2008 Mar CAHN

GRISEOFULVIN, ULTRAMICROSIZED

TABLET; ORAL
GRISEOFULVIN, ULTRAMICROSIZED

AB MOUNTAIN 125MG A204371 001 Jan 09, 2014 Jan CAHN
AB 250MG A204371 002 Jan 09, 2014 Jan CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL
FLOWTUSS

>A> BKK PHARMS 200MG/5ML; 2.5MG/5ML N022424 001 May 14, 2015 May CAHN
>D> MISSION PHARMACAL CO 200MG/5ML; 2.5MG/5ML N022424 001 May 14, 2015 May CAHN

TABLET; ORAL
HYDROCODONE BITARTRATE AND GUAIFENESIN

+! ECI PHARMS LLC 400MG; 5MG N208085 001 Apr 25, 2018 Apr NEWA

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL
HYCOFENIX

>A> +! BKK PHARMS 200MG/5ML; 2.5MG/5ML; 30MG/5ML N022279 001 May 14, 2015 May CAHN
>D> +! MISSION PHARMACAL CO 200MG/5ML; 2.5MG/5ML; 30MG/5ML N022279 001 May 14, 2015 May CAHN

GUANABENZ ACETATE

TABLET; ORAL
GUANABENZ ACETATE

@ YAOPHARMA CO LTD EQ 4MG BASE A074517 001 Sep 30, 1998 Jan CAHN
@ EQ 8MG BASE A074517 002 Sep 30, 1998 Jan CAHN

HALCINONIDECREAM;TOPICAL
HALOG

+! SUN PHARM INDS INC 0.1% N017556 001 Feb CAHN

HALOBETASOL PROPIONATEAEROSOL, FOAM;TOPICAL
HALOBETASOL PROPIONATE

>A> +! THERAPS INC 0.05% N210566 001 May 24, 2018 May NEWA

CREAM;TOPICAL
ULTRAVATE

AB + SUN PHARM INDS INC 0.05% N019967 001 Dec 27, 1990 Feb CAHN

OINTMENT;TOPICAL
HALOBETASOL PROPIONATE

AB TELIGENT PHARMA INC 0.05% A209978 001 Mar 20, 2018 Mar NEWA

ULTRAVATE

AB + SUN PHARM INDS INC 0.05% N019968 001 Dec 17, 1990 Feb CAHN

HALOPERIDOL LACTATEINJECTABLE;INJECTION
HALOPERIDOL

@ FOSUN PHARMA EQ 5MG BASE/ML A076464 001 Sep 29, 2004 Jan CAHN

HEPARIN SODIUMINJECTABLE;INJECTION
HEPARIN SODIUM

AP CASI PHARMS INC 5,000 UNITS/ML A091659 001 Jun 08, 2011 Mar CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA SCIEGEN PHARMS INC 10MG A205236 001 May 26, 2017 Feb CAHN

AA 25MG A205236 002 May 26, 2017 Feb CAHN

AA 50MG A205236 003 May 26, 2017 Feb CAHN

AA 100MG A205236 004 May 26, 2017 Feb CAHN

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

@ APOTEX 12.5MG A078389 001 May 16, 2008 Mar DISC

TABLET;ORAL

HYDROCHLOROTHIAZIDE

@ APOTEX 25MG A040774 001 Oct 03, 2007 Mar DISC

@ 50MG A040774 002 Oct 03, 2007 Mar DISC

AB SCIEGEN PHARMS INC 25MG A203018 001 Jul 23, 2014 Jan CAHN

AB 50MG A203018 002 Jul 23, 2014 Jan CAHN

@ YAOPHARMA CO LTD 25MG A087565 001 Mar 09, 1982 Jan CAHN

@ 50MG A084912 001 Jan CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET;ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

@ APOTEX INC 12.5MG;10MG A076674 001 Oct 05, 2004 Apr DISC

@ 12.5MG;20MG A076674 002 Oct 05, 2004 Apr DISC

@ 25MG;20MG A076674 003 Oct 05, 2004 Apr DISC

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

HYZAAR

+ @ MERCK SHARP DOHME 12.5MG;50MG N020387 001 Apr 28, 1995 Apr DISC

+ @ 25MG;100MG N020387 002 Nov 10, 1998 Apr DISC

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

@ APOTEX 12.5MG;50MG A090150 001 Oct 06, 2010 Mar DISC

@ 12.5MG;100MG A090150 002 Aug 11, 2010 Mar DISC

@ 25MG;100MG A090150 003 Oct 06, 2010 Mar DISC

AB ! AUROBINDO PHARMA 25MG;100MG A091629 003 Jan 06, 2010 Apr CHRS

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

@	YAOPHARMA CO LTD	15MG;250MG	A 070182	001	Jan 15, 1986	Jan	CAHN
@		25MG;250MG	A 070183	001	Jan 15, 1986	Jan	CAHN
@		30MG;500MG	A 070543	001	Jan 15, 1986	Jan	CAHN
@		50MG;500MG	A 070544	001	Jan 15, 1986	Jan	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	YAOPHARMA CO LTD	25MG;40MG	A 071060	001	Aug 26, 1987	Jan	CAHN
@		25MG;80MG	A 071061	001	Aug 26, 1987	Jan	CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

@	YAOPHARMA CO LTD	25MG;25MG	A 086881	001		Jan	CAHN
---	------------------	-----------	----------	-----	--	-----	------

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	!	CASI PHARMS INC	25MG;50MG	A 073191	001	Jul 31, 1991	Mar	CAHN
----	---	-----------------	-----------	----------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

@	APOTEX INC	12.5MG;80MG	A 203026	001	Mar 21, 2013	Mar	DISC
@		12.5MG;160MG	A 203026	002	Mar 21, 2013	Mar	DISC
@		12.5MG;320MG	A 203026	003	Mar 21, 2013	Mar	DISC
@		25MG;160MG	A 203026	004	Mar 21, 2013	Mar	DISC
@		25MG;320MG	A 203026	005	Mar 21, 2013	Mar	DISC

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

>A>	AT	LANNETT CO INC	2.5%	A 040503	001	Mar 12, 2004	May	CAHN
>D>		@ TARO	1%	A 086155	001		May	CAHN
>D>	AT		2.5%	A 088799	001	Nov 09, 1984	May	CAHN
>A>		@ TARO PHARM INDS LTD	1%	A 086155	001		May	CAHN
>A>	AT		2.5%	A 088799	001	Nov 09, 1984	May	CAHN
>A>	AT		2.5%	A 088799	001	Nov 09, 1984	May	CAHN
>D>	AT	VINTAGE PHARMS	2.5%	A 040503	001	Mar 12, 2004	May	CAHN

LOTION; TOPICAL

HYDROCORTISONE

>A>	AT	LANNETT CO INC	2.5%	A 040417	001	Jul 30, 2003	May	CAHN
>D>	AT	VINTAGE PHARMS	2.5%	A 040417	001	Jul 30, 2003	May	CAHN

HYDROCORTISONE VALERATE

CREAM; TOPICAL

WESTCORT

+	@	SUN PHARM INDS INC	0.2%	N 017950	001		Mar	CAHN
---	---	--------------------	------	----------	-----	--	-----	------

OINTMENT; TOPICAL

WESTCORT

+	@	SUN PHARM INDS INC	0.2%	N 018726	001	Aug 08, 1983	Feb	CAHN
---	---	--------------------	------	----------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

AP		EUROHLTH INTL SARL	2MG/ML	A 202159	001	Apr 27, 2018	Apr	NEWA
----	--	--------------------	--------	----------	-----	--------------	-----	------

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	2MG	A 210506	001	Jan 17, 2018	Jan	NEWA
AB			4MG	A 210506	002	Jan 17, 2018	Jan	NEWA
AB			8MG	A 210506	003	Jan 17, 2018	Jan	NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL		HYDROXYCHLOROQUINE SULFATE					
AB	ALKALOIDA ZRT	200MG	A201691	001	May 08, 2018	Apr	NEWA
AB	AMNEAL PHARMS CO	200MG	A210577	001	May 15, 2018	Apr	NEWA
AB	APPCO PHARMA LLC	200MG	A210441	001	May 01, 2018	Apr	NEWA

HYDROXYPROGESTERONE CAPROATE

SOLUTION;SUBCUTANEOUS		MAKENA (AUTOINJECTOR)					
+!	AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Feb	NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL		ATARAX					
+ @	PFIZER	10MG	N010392	001		Feb	CRLD
+ @		25MG	N010392	004		Feb	CRLD
+ @		50MG	N010392	006		Feb	CRLD
+ @		100MG	N010392	005		Feb	CRLD

IBRUTINIB

TABLET;ORAL		IMBRUVICA					
+	PHARMACYCLICS INC	140MG	N210563	001	Feb 16, 2018	Feb	NEWA
+		280MG	N210563	002	Feb 16, 2018	Feb	NEWA
+		420MG	N210563	003	Feb 16, 2018	Feb	NEWA
+!		560MG	N210563	004	Feb 16, 2018	Feb	NEWA

IBUPROFEN

SUSPENSION;ORAL		IBUPROFEN					
	AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018	Feb	NEWA

IBUTILIDE FUMARATE

INJECTABLE;INJECTION		IBUTILIDE FUMARATE					
@	MYLAN INSTITUTIONAL	0.1MG/ML	A090924	001	Jan 11, 2010	Jan	DISC

IMIQUIMOD

CREAM;TOPICAL		IMIQUIMOD					
@	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Jan	DISC

INDAPAMIDE

TABLET;ORAL		INDAPAMIDE					
@	YAOPHARMA CO LTD	1.25MG	A074594	001	May 23, 1996	Jan	CAHN
@		2.5MG	A074594	002	May 23, 1996	Jan	CAHN

INSULIN GLARGINE RECOMBINANT

SOLUTION;SUBCUTANEOUS		TOUJEO MAX SOLOSTAR					
+!	SANOFI US SERVICES	900 UNITS/3ML (300 UNITS/ML)	N206538	002	Mar 26, 2018	Mar	NEWA
+!	SANOFI US SERVICES	450 UNITS/1.5ML (300 UNITS/ML)	N206538	001	Feb 25, 2015	Mar	CPOT

IOHEXOL

SOLUTION;INJECTION, ORAL, RECTAL		OMNIPAQUE 240					
>D>	GE HEALTHCARE	51.8%	N020608	001	Oct 24, 1995	May	DISC
>A>	@	51.8%	N020608	001	Oct 24, 1995	May	DISC

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL		ATROVENT					
+	@ BOEHRINGER INGELHEIM	0.021MG/SPRAY	N020393	001	Oct 20, 1995	Jan	DISC
+	@	0.042MG/SPRAY	N020394	001	Oct 20, 1995	Jan	DISC
IPRATROPIUM BROMIDE							
AB	! WEST-WARD PHARMS INT	0.021MG/SPRAY	A076664	001	Nov 05, 2003	Jan	CHRS
AB	!	0.042MG/SPRAY	A076598	001	Nov 05, 2003	Jan	CHRS

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AB	AMNEAL PHARMS	75MG	A204740	001	Apr 17, 2018	Apr	NEWA
AB		150MG	A204740	002	Apr 17, 2018	Apr	NEWA
AB		300MG	A204740	003	Apr 17, 2018	Apr	NEWA
	@ APOTEX INC	75MG	A200832	001	Oct 15, 2012	Mar	DISC
	@	150MG	A200832	002	Oct 15, 2012	Mar	DISC
	@	300MG	A200832	003	Oct 15, 2012	Mar	DISC
AB	CHARTWELL MOLECULAR	75MG	A077205	001	Nov 14, 2012	Apr	CAHN
AB		150MG	A077205	002	Nov 14, 2012	Apr	CAHN
AB		300MG	A077205	003	Nov 14, 2012	Apr	CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

>A>	AP	CIPLA LTD	0.2MG/ML	A210322	001	Jun 12, 2018	May	NEWA
-----	----	-----------	----------	---------	-----	--------------	-----	------

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

	@ ACCORD HLTHCARE	30MG	A209684	001	Oct 24, 2017	Apr	DISC
	@	60MG	A209684	002	Oct 24, 2017	Apr	DISC
	@	120MG	A209684	003	Oct 24, 2017	Apr	DISC

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET, TABLET; ORAL

SYMDEKO (COPACKAGED)

+	!	VERTEX PHARMS INC	150MG,N/A;150MG, 100MG	N210491	001	Feb 12, 2018	Feb	NEWA
---	---	-------------------	------------------------	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

KETOROLAC TROMETHAMINE

AT		SANDOZ INC	0.4%	A078721	001	Nov 05, 2009	Jan	CAHN
----	--	------------	------	---------	-----	--------------	-----	------

LACTULOSE

SOLUTION; ORAL

LACTULOSE

>A>	AA	BIO-PHARM INC	10GM/15ML	A207786	001	Jun 11, 2018	May	NEWA
>A>	AA	LANNETT CO INC	10GM/15ML	A075993	001	Jul 26, 2001	May	CAHN
>D>	AA	VINTAGE PHARMS	10GM/15ML	A075993	001	Jul 26, 2001	May	CAHN

LAMIVUDINE

TABLET; ORAL

LAMIVUDINE

AB		STRIDES PHARMA	150MG	A090457	001	Apr 19, 2018	Apr	NEWA
AB			300MG	A090457	002	Apr 19, 2018	Apr	NEWA

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

CIMDUO

	+	!	MYLAN LABS LTD	300MG;300MG	N022141	001	Feb 28, 2018	Feb	NEWA
>A>			LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE						
>A>			AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018	May	NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB		SHANGHAI DESANO	150MG;300MG	A206375	001	Apr 10, 2018	Mar	NEWA
----	--	-----------------	-------------	---------	-----	--------------	-----	------

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

	@	FOSUN PHARMA	10MG	A077087	001	Sep 13, 2005	Jan	CAHN
	@		20MG	A077087	002	Sep 13, 2005	Jan	CAHN

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

FRESENIUS KABI USA EQ 10MG BASE/ML A207241 001 Mar 14, 2018 Mar NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON

+ @ ABBVIE ENDOCRINE INC 1MG/0.2ML N019010 001 Apr 09, 1985 Feb CRLD

LEVETIRACETAM

INJECTABLE; IV (INFUSION)
LEVETIRACETAM

AP AKORN 500MG/5ML (100MG/ML) A209934 001 May 04, 2018 Apr NEWA
AP HAINAN POLY PHARM 500MG/5ML (100MG/ML) A209781 001 Mar 20, 2018 Mar NEWA

SOLUTION; ORAL
LEVETIRACETAM

>A> AA ACI HEALTHCARE LTD 100MG/ML A078582 001 Jan 15, 2009 May CAHN
>D> AA ALLIED PHARMA INC 100MG/ML A078582 001 Jan 15, 2009 May CAHN
>A> AA LANNETT CO INC 100MG/ML A090079 001 Apr 11, 2012 May CAHN
>D> AA VINTAGE PHARMS 100MG/ML A090079 001 Apr 11, 2012 May CAHN

TABLET; ORAL
LEVETIRACETAM

@ FOSUN PHARMA 250MG A077324 001 Jan 15, 2009 Jan CAHN
@ 500MG A077324 002 Jan 15, 2009 Jan CAHN
@ 750MG A077324 003 Jan 15, 2009 Jan CAHN
@ 1GM A077324 004 Jan 15, 2009 Jan CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

@ FOSUN PHARMA 5MG A090486 001 Mar 26, 2013 Jan CAHN

LEVOFLOXACIN

INJECTABLE; INJECTION
LEVAQUIN

+ @ JANSSEN PHARMS EQ 500MG/20ML (EQ 25MG/ML) N020635 001 Dec 20, 1996 Feb DISC
+ @ EQ 750MG/30ML (EQ 25MG/ML) N020635 004 Dec 20, 1996 Feb DISC

LEVOFLOXACIN

AP ! AUROBINDO PHARMA LTD EQ 500MG/20ML (EQ 25MG/ML) A202328 001 Jan 24, 2013 Mar CHRS
AP ! EQ 750MG/30ML (EQ 25MG/ML) A202328 002 Jan 24, 2013 Mar CHRS
@ EMCURE PHARMS LTD EQ 500MG/20ML (EQ 25MG/ML) A202590 001 Jan 24, 2013 Mar DISC
@ EQ 750MG/30ML (EQ 25MG/ML) A202590 002 Jan 24, 2013 Mar DISC
@ ZYDUS PHARMS USA INC EQ 500MG/20ML (EQ 25MG/ML) A205968 001 Jun 01, 2017 Feb DISC
@ EQ 750MG/30ML (EQ 25MG/ML) A205968 002 Jun 01, 2017 Feb DISC

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP ! INFORLIFE EQ 250MG/50ML (EQ 5MG/ML) A090343 001 Jul 07, 2011 Jan CAHN
AP ! EQ 500MG/100ML (EQ 5MG/ML) A090343 002 Jul 07, 2011 Jan CAHN
AP ! EQ 750MG/150ML (EQ 5MG/ML) A090343 003 Jul 07, 2011 Jan CAHN

SOLUTION; ORAL

LEVOFLOXACIN

>D> ! HI TECH PHARMA 250MG/10ML A091678 001 Jun 20, 2011 May CTEC
>A> AA ! 250MG/10ML A091678 001 Jun 20, 2011 May CTEC
>A> AA LANNETT CO INC 250MG/10ML A205222 001 May 25, 2018 May NEWA

TABLET; ORAL

LEVAQUIN

+ @ JANSSEN PHARMS 250MG N020634 001 Dec 20, 1996 Feb DISC
+ @ 500MG N020634 002 Dec 20, 1996 Feb DISC
+ @ 750MG N020634 003 Sep 08, 2000 Feb DISC

LEVOFLOXACIN

AB ! AUROBINDO PHARMA LTD 750MG A201043 003 Jun 20, 2011 Feb CHRS

LEVOLEUCOVORIN CALCIUM

>A> POWDER; INTRAVENOUS
>A> FUSILEV

>A> AP +! SPECTRUM PHARMS EQ 50MG BASE/VIAL N020140 001 Mar 07, 2008 May CDFR
>A> LEVOLEUCOVORIN CALCIUM
>A> AP ACTAVIS LLC EQ 50MG BASE/VIAL A206516 001 Feb 13, 2017 May CDFR
>A> +! EQ 175MG BASE/VIAL N208723 001 Sep 29, 2016 May CDFR
>A> AP AMNEAL PHARMS CO EQ 50MG BASE/VIAL A207547 001 Feb 13, 2017 May CDFR
>A> AP WEST-WARD PHARMS INT EQ 50MG BASE/VIAL A206263 001 Jun 16, 2016 May CDFR

>D>	POWDER;IV (INFUSION)							
>D>	FUSILEV							
>D> AP	+! SPECTRUM PHARMS	EQ 50MG BASE/VIAL		N020140	001	Mar 07, 2008	May	CDFR
>D>	LEVOLEUCOVORIN CALCIUM							
>D> AP	ACTAVIS LLC	EQ 50MG BASE/VIAL		A206516	001	Feb 13, 2017	May	CDFR
>D>	+!	EQ 175MG BASE/VIAL		N208723	001	Sep 29, 2016	May	CDFR
>D> AP	AMNEAL PHARMS CO	EQ 50MG BASE/VIAL		A207547	001	Feb 13, 2017	May	CDFR
>D> AP	WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL		A206263	001	Jun 16, 2016	May	CDFR
>A>	SOLUTION;INTRAVENOUS							
>A>	FUSILEV							
>A>	+ @ SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		N020140	002	Apr 29, 2011	May	CDFR
>A>	+ @	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		N020140	003	Apr 29, 2011	May	CDFR
>A>	LEVOLEUCOVORIN CALCIUM							
>A> AP	AMNEAL PHARMS CO	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A207548	001	Sep 08, 2017	May	CDFR
>A> AP	INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A210623	001	May 03, 2018	May	CDFR
>A> AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A210623	002	May 03, 2018	May	CDFR
>A> AP	MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A203576	001	Oct 20, 2015	May	CDFR
>A> AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A203576	002	Oct 20, 2015	May	CDFR
>A> AP	SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A203563	001	Mar 09, 2015	May	CDFR
>A> AP	!	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A203563	002	Mar 09, 2015	May	CDFR
>D>	SOLUTION;IV (INFUSION)							
>D>	FUSILEV							
>D>	+ @ SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		N020140	002	Apr 29, 2011	May	CDFR
>D>	+ @	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		N020140	003	Apr 29, 2011	May	CDFR
>D>	LEVOLEUCOVORIN CALCIUM							
>D> AP	AMNEAL PHARMS CO	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A207548	001	Sep 08, 2017	May	CDFR
>D> AP	INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A210623	001	May 03, 2018	May	CDFR
AP		EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A210623	001	May 03, 2018	Apr	NEWA
>D> AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A210623	002	May 03, 2018	May	CDFR
AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A210623	002	May 03, 2018	Apr	NEWA
>D> AP	MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A203576	001	Oct 20, 2015	May	CDFR
>D> AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A203576	002	Oct 20, 2015	May	CDFR
>D> AP	SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A203563	001	Mar 09, 2015	May	CDFR
>D> AP	!	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A203563	002	Mar 09, 2015	May	CDFR

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
FETZIMA

+	ALLERGAN SALES LLC	EQ 20MG BASE		N204168	001	Jul 25, 2013	Jan	CAHN
+		EQ 40MG BASE		N204168	002	Jul 25, 2013	Jan	CAHN
+		EQ 80MG BASE		N204168	003	Jul 25, 2013	Jan	CAHN
+!		EQ 120MG BASE		N204168	004	Jul 25, 2013	Jan	CAHN

LEVOTHYROXINE SODIUM

CAPSULE;ORAL
TIROSINT

>D>	+!	INSTITUT BIOCHIMIQUE	0.15MG		N021924	007	Oct 13, 2006	May	CHRS
>A>	+		0.15MG		N021924	007	Oct 13, 2006	May	CHRS
>D>	+		0.200MG		N021924	012	Apr 25, 2017	May	CHRS
>A>	+!		0.200MG		N021924	012	Apr 25, 2017	May	CHRS

POWDER;INTRAVENOUS
LEVOTHYROXINE SODIUM

AP	PIRAMAL CRITICAL	100MCG/VIAL		A206163	001	Jun 29, 2016	Jan	CAHN
AP		500MCG/VIAL		A206163	002	Jun 29, 2016	Jan	CAHN

LIDOCAINE

OINTMENT;TOPICAL

		LIDOCAINE							
AT		TEVA PHARMS USA	5%		A210256	001	Jan 16, 2018	Jan	NEWA
		PATCH;TOPICAL							
		ZTLIDO							
	+	SCILEX PHARMS INC	1.8%		N207962	001	Feb 28, 2018	Feb	NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

		LIDOCAINE HYDROCHLORIDE							
AP		SPECTRA MDCL DEVICES	1%		A208017	001	Apr 18, 2018	Apr	NEWA

SOLUTION;ORAL

		LIDOCAINE HYDROCHLORIDE VISCOUS							
>A>	AT	!	LANNETT CO INC	2%	A040708	001	Feb 27, 2007	May	CAHN
>D>	AT	!	VINTAGE	2%	A040708	001	Feb 27, 2007	May	CAHN

SOLUTION;TOPICAL

		LIDOCAINE HYDROCHLORIDE							
>A>	AT		LANNETT CO INC	4%	A040710	001	Feb 27, 2007	May	CAHN
>D>	AT		VINTAGE	4%	A040710	001	Feb 27, 2007	May	CAHN

LINACLOTIDE

CAPSULE;ORAL

LINZESS

	+	ALLERGAN SALES LLC	72MCG		N202811	003	Jan 25, 2017	Jan	CAHN
	+		145MCG		N202811	001	Aug 30, 2012	Jan	CAHN
	+	!	290MCG		N202811	002	Aug 30, 2012	Jan	CAHN

LINEZOLID

>A>									
>A>			SOLUTION;INTRAVENOUS						
>A>			LINEZOLID						
>A>	AP		AUROBINDO PHARMA LTD	600MG/300ML (2MG/ML)	A206917	001	Aug 04, 2016	May	CDFR
>A>	AP		FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764	001	Mar 15, 2016	May	CDFR
>A>	AP		HOSPIRA INC	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015	May	CDFR
>A>	AP		HQ SPCLT PHARMA	200MG/100ML (2MG/ML)	A207001	001	Jul 07, 2017	May	CDFR
>A>	AP			600MG/300ML (2MG/ML)	A207001	002	Jul 07, 2017	May	CDFR
>A>	AP		MYLAN LABS LTD	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	May	CDFR
>A>	AP			600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	May	CDFR
>A>	AP		NANG KUANG PHARM CO	200MG/100ML (2MG/ML)	A207354	001	Dec 20, 2016	May	CDFR
>A>	AP			600MG/300ML (2MG/ML)	A207354	002	Dec 20, 2016	May	CDFR
>A>	AP		SAGENT PHARMS	200MG/100ML (2MG/ML)	A204696	001	Mar 02, 2017	May	CDFR
>A>	AP			600MG/300ML (2MG/ML)	A204696	002	Mar 02, 2017	May	CDFR
>A>	AP		SANDOZ INC	200MG/100ML (2MG/ML)	A200904	001	Jul 16, 2015	May	CDFR
>A>	AP			600MG/300ML (2MG/ML)	A200904	002	Jul 16, 2015	May	CDFR
>A>	AP		TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012	May	CDFR
>A>			LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
>A>		+	HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015	May	CDFR
>A>			ZYVOX						
>A>	AP	+	PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	May	CDFR
>A>		+		400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000	May	CDFR
>A>	AP	+		600MG/300ML (2MG/ML)	N021131	003	Apr 18, 2000	May	CDFR
>D>			SOLUTION;IV (INFUSION)						
>D>			LINEZOLID						
>D>	AP		AUROBINDO PHARMA LTD	600MG/300ML (2MG/ML)	A206917	001	Aug 04, 2016	May	CDFR
>D>	AP		FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764	001	Mar 15, 2016	May	CDFR
>D>	AP		HOSPIRA INC	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015	May	CDFR
>D>	AP		HQ SPCLT PHARMA	200MG/100ML (2MG/ML)	A207001	001	Jul 07, 2017	May	CDFR
>D>	AP			600MG/300ML (2MG/ML)	A207001	002	Jul 07, 2017	May	CDFR
>D>	AP		MYLAN LABS LTD	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	May	CDFR
>D>	AP			600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	May	CDFR
>D>	AP		NANG KUANG PHARM CO	200MG/100ML (2MG/ML)	A207354	001	Dec 20, 2016	May	CDFR
>D>	AP			600MG/300ML (2MG/ML)	A207354	002	Dec 20, 2016	May	CDFR
>D>	AP		SAGENT PHARMS	200MG/100ML (2MG/ML)	A204696	001	Mar 02, 2017	May	CDFR
>D>	AP			600MG/300ML (2MG/ML)	A204696	002	Mar 02, 2017	May	CDFR
>D>	AP		SANDOZ INC	200MG/100ML (2MG/ML)	A200904	001	Jul 16, 2015	May	CDFR
>D>	AP			600MG/300ML (2MG/ML)	A200904	002	Jul 16, 2015	May	CDFR
>D>	AP		TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012	May	CDFR
>D>			LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
>D>		+	HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015	May	CDFR
>D>			ZYVOX						
>D>	AP	+	PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	May	CDFR

>D> SOLUTION;IV (INFUSION)
 >D> ZYVOX
 >D> + 400MG/200ML (2MG/ML) N021131 002 Apr 18, 2000 May CDFR
 >D> AP +! 600MG/300ML (2MG/ML) N021131 003 Apr 18, 2000 May CDFR

LIOTRIX (T4;T3)

TABLET;ORAL

THYROLAR-0.25

+ ALLERGAN SALES LLC 0.0125MG;0.0031MG N016807 001 Apr CAHN

THYROLAR-0.5

+ ALLERGAN SALES LLC 0.025MG;0.0063MG N016807 005 Apr CAHN

THYROLAR-1

+ ALLERGAN SALES LLC 0.05MG;0.0125MG N016807 004 Apr CAHN

THYROLAR-2

+ ALLERGAN SALES LLC 0.1MG;0.025MG N016807 002 Apr CAHN

THYROLAR-3

+! ALLERGAN SALES LLC 0.15MG;0.0375MG N016807 003 Apr CAHN

THYROLAR-5

@ ALLERGAN SALES LLC 0.25MG;0.0625MG N016807 006 Apr CAHN

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB CASI PHARMS INC 2.5MG A075994 001 Jul 01, 2002 Mar CAHN

AB 5MG A075994 002 Jul 01, 2002 Mar CAHN

AB 10MG A075994 003 Jul 01, 2002 Mar CAHN

AB 20MG A075994 004 Jul 01, 2002 Mar CAHN

AB 30MG A075994 005 Jul 01, 2002 Mar CAHN

AB 40MG A075994 006 Jul 01, 2002 Mar CAHN

>A> LOFEXIDINE HYDROCHLORIDE

>A> TABLET;ORAL

>A> LUCEMYRA

>A> +! US WORLDMEDS LLC EQ 0.18MG BASE N209229 001 May 16, 2018 May NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

@ YAOPHARMA CO LTD 2MG A072993 001 Aug 28, 1992 Jan CAHN

LORAZEPAM

TABLET;ORAL

LORAZEPAM

>A> @ ANDA REPOSITORY 0.5MG A072555 002 Mar 29, 1991 May CMS1

>A> @ 1MG A072555 003 Mar 29, 1991 May CMS1

@ MYLAN 0.5MG A071591 002 Oct 13, 1987 Jan CMS1

@ 1MG A071591 003 Oct 13, 1987 Jan CMS1

>D> AB SUN PHARM INDS LTD 0.5MG A076045 001 Aug 29, 2001 May DISC

>A> @ 0.5MG A076045 001 Aug 29, 2001 May DISC

>D> AB 1MG A076045 002 Aug 29, 2001 May DISC

>A> @ 1MG A076045 002 Aug 29, 2001 May DISC

>D> AB 2MG A076045 003 Aug 29, 2001 May DISC

>A> @ 2MG A076045 003 Aug 29, 2001 May DISC

LOSARTAN POTASSIUM

TABLET;ORAL

COZAAR

+ @ MERCK SHARP DOHME 25MG N020386 001 Apr 14, 1995 Apr DISC

+ @ 50MG N020386 002 Apr 14, 1995 Apr DISC

LOSARTAN POTASSIUM

@ APOTEX CORP 25MG A090790 001 Oct 06, 2010 Mar DISC

@ 50MG A090790 002 Oct 06, 2010 Mar DISC

@ 100MG A090790 003 Oct 06, 2010 Mar DISC

LUTETIUM DOTATATE LU-177

SOLUTION;IV (INFUSION)

LUTATHERA

+! AAA USA INC 10mCi/ML N208700 001 Jan 26, 2018 Jan NEWA

MACIMORELIN ACETATE

FOR SOLUTION;ORAL
MACRILEN

>D>	+	STRONGBRIDGE IRELAND	EQ 60MG BASE/POUCH	N205598	001	Dec 21, 2017	May CMS1
>A>	+		EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017	May CMS1
	+		EQ 60MG BASE/POUCH	N205598	001	Dec 21, 2017	Jan CAHN

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017378	001			Apr CRLD
---	-----------------	---	---------	-----	--	--	----------

PLASMA-LYTE A IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982		Apr CRLD
---	-----------------	---	---------	-----	--------------	--	----------

MALATHION

LOTION;TOPICAL

OVIDE

>D> AT	+	TARO PHARM	0.5%	N018613	001	Aug 02, 1982	May CAHN
>A> AT	+	TARO PHARM INDS LTD	0.5%	N018613	001	Aug 02, 1982	May CAHN

MANGANESE CHLORIDE

INJECTABLE;INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986		Mar CRLD
---	---------	-----------------------	---------	-----	--------------	--	----------

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

+	ICU MEDICAL INC	540MG/100ML;2.7GM/100ML	N018316	001			Mar CRLD
---	-----------------	-------------------------	---------	-----	--	--	----------

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

VERMOX

+	@ JANSSEN PHARMS	500MG	N208398	001	Oct 19, 2016		Feb DISC
---	------------------	-------	---------	-----	--------------	--	----------

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

@	FOSUN PHARMA	EQ 50MG BASE	A072262	001	Nov 29, 1988		Jan CAHN
@		EQ 100MG BASE	A072263	001	Nov 29, 1988		Jan CAHN

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

AB	MICRO LABS	250MG	A090562	001	Nov 19, 2010		Feb CAHN
----	------------	-------	---------	-----	--------------	--	----------

MEMANTINE HYDROCHLORIDE

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA	APOTEX INC	2MG/ML	A209955	001	Feb 09, 2018		Jan NEWA
AA	! BIO-PHARM INC	2MG/ML	A205446	001	Dec 07, 2015		Apr CHRS
	NAMENDA						
	+ @ ALLERGAN SALES LLC	2MG/ML	N021627	001	Apr 18, 2005		Apr DISC
AA	+	2MG/ML	N021627	001	Apr 18, 2005		Jan CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB	CSPC OUYI PHARM CO	5MG	A209527	001	May 07, 2018		Apr NEWA
AB		10MG	A209527	002	May 07, 2018		Apr NEWA
	NAMENDA						
AB	+ ALLERGAN SALES LLC	5MG	N021487	001	Oct 16, 2003		Jan CAHN
AB	+	10MG	N021487	002	Oct 16, 2003		Jan CAHN

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

AP	ACS DOBFAR SPA	500MG/VIAL	A204139	001	Jun 09, 2016		Apr CAHN
AP		1GM/VIAL	A204139	002	Jun 09, 2016		Apr CAHN

MEROPENEM; VABORBACTAM

POWDER; IV (INFUSION)
VABOMERE

+! REMPEX PHARMS 1GM/VIAL;1GM/VIAL N209776 001 Aug 29, 2017 Jan CAHN

MESALAMINE

ENEMA; RECTAL
MESALAMINE

@ G AND W LABS INC 4GM/60ML A076841 001 Sep 30, 2004 Jan DISC

SUPPOSITORY; RECTAL
CANASA

@ ALLERGAN SALES LLC 500MG N021252 001 Jan 05, 2001 Jan CAHN
AB +! 1GM N021252 002 Nov 05, 2004 Jan CAHN

TABLET, DELAYED RELEASE; ORAL
MESALAMINE

AB ACTAVIS LABS FL 1.2GM A203817 001 Mar 23, 2018 Mar NEWA

MESNA

INJECTABLE; INTRAVENOUS
MESNA

@ MYLAN INSTITUTIONAL 100MG/ML A076488 001 Mar 08, 2012 Jan DISC

METARAMINOL BITARTRATE

INJECTABLE; INJECTION
METARAMINOL BITARTRATE

@ FRESENIUS KABI USA EQ 10MG BASE/ML A080722 001 Feb DISC

METAXALONE

TABLET; ORAL
METAXALONE

MOUNTAIN 400MG A040486 001 Feb 27, 2015 Jan CAHN
@ PRIMUS PHARMS 640MG N022503 001 Jun 01, 2015 Jan CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

@ SANDOZ 500MG A075985 001 Jan 25, 2002 Mar DISC
@ 850MG A075985 002 Jan 25, 2002 Mar DISC
@ 1GM A075985 003 Jan 25, 2002 Mar DISC

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

AB1 ALIGNSCIENCE PHARMA 500MG A209303 001 Mar 19, 2018 Mar NEWA
AB1 GRANULES INDIA LTD 500MG A209313 001 Mar 16, 2018 Mar NEWA
AB 750MG A209313 002 Mar 16, 2018 Mar NEWA

>D> METFORMIN HYDROCHLORIDE; REPAGLINIDE

>D> TABLET; ORAL

>D> REPAGLINIDE AND METFORMIN HYDROCHLORIDE

>D> LUPIN LTD 500MG;1MG A200624 001 Jul 15, 2015 May DISC
>A> @ 500MG;1MG A200624 001 Jul 15, 2015 May DISC
>D> ! 500MG;2MG A200624 002 Jul 15, 2015 May DISC
>A> @ 500MG;2MG A200624 002 Jul 15, 2015 May DISC

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

@ TEVA 500MG;EQ 2MG BASE A077337 001 May 07, 2014 Apr DISC
@ 500MG;EQ 1MG BASE A077337 005 May 19, 2017 Apr DISC
@ 500MG;EQ 4MG BASE A077337 002 May 07, 2014 Apr DISC
@ 1GM;EQ 4MG BASE A077337 004 May 07, 2014 Apr DISC
@ 1GM;EQ 2MG BASE A077337 003 May 07, 2014 Apr DISC

METHADONE HYDROCHLORIDE

TABLET; ORAL
METHADONE HYDROCHLORIDE

AA SUN PHARM INDUSTRIES 5MG A208305 001 Mar 30, 2018 Mar NEWA
AA 10MG A208305 002 Mar 30, 2018 Mar NEWA

METHIMAZOLE

TABLET; ORAL		METHIMAZOLE					
AB	CASI PHARMS INC	5MG	A040411	001	Mar 27, 2001	Mar	CAHN
AB		10MG	A040411	002	Mar 27, 2001	Mar	CAHN

METHOCARBAMOL

SOLUTION; IM-IV		METHOCARBAMOL					
AP	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	A209331	001	Apr 17, 2018	Apr	NEWA
TABLET; ORAL		METHOCARBAMOL					
>D>	AA	ALLIED PHARMA INC	500MG	A203550	001	Feb 08, 2017	May
	AA		500MG	A203550	001	Feb 08, 2017	Feb
>D>	AA		750MG	A203550	002	Feb 08, 2017	May
	AA		750MG	A203550	002	Feb 08, 2017	Feb
>A>	AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	May
>A>	AA		750MG	A203550	002	Feb 08, 2017	May
	@	FOSUN PHARMA	500MG	A084616	001		Jan
	@		750MG	A084615	001		Jan
AA		GRANULES INDIA LTD	500MG	A209312	001	May 07, 2018	Apr
AA			750MG	A209312	002	May 07, 2018	Apr

METHOTREXATE

SOLUTION; SUBCUTANEOUS		RASUVO					
+	!	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Apr
+	!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Apr
+	!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Apr
+	!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Apr
+	!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Apr
+	!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Apr
+	!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Apr
+	!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Apr
+	!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr

METHYCLOTHIAZIDE

TABLET; ORAL		METHYCLOTHIAZIDE					
	@	YAOPHARMA CO LTD	2.5MG	A089835	001	Aug 18, 1988	Jan
	@		5MG	A089837	001	Aug 18, 1988	Jan

METHYLDOPA

TABLET; ORAL		METHYLDOPA					
	@	YAOPHARMA CO LTD	125MG	A071700	001	Mar 02, 1988	Jan
	@		250MG	N018934	001	Jun 29, 1984	Jan
	@		500MG	N018934	002	Jun 29, 1984	Jan

METHYLERGONOVINE MALEATE

TABLET; ORAL		METHYLERGONOVINE MALEATE					
AB		GRANULES PHARMS	0.2MG	A210424	001	May 15, 2018	Apr
AB	!	NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Apr

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL		METADATE CD					
AB2	+	LANNETT CO INC	10MG	N021259	003	May 27, 2003	Mar
AB2	+		20MG	N021259	001	Apr 03, 2001	Mar
AB2	+		30MG	N021259	002	Jun 19, 2003	Mar
AB2	+		40MG	N021259	004	Feb 19, 2006	Mar
AB2	+		50MG	N021259	005	Feb 19, 2006	Mar
AB2	+		60MG	N021259	006	Feb 19, 2006	Mar
TABLET; ORAL		METHYLPHENIDATE HYDROCHLORIDE					
AB1		MAYNE PHARMA	10MG	A200886	001	Feb 26, 2018	Feb
FOR SUSPENSION, EXTENDED RELEASE; ORAL		METHYLPHENIDATE HYDROCHLORIDE					
AB		ACTAVIS LABS FL INC	5MG/ML	A206049	001	May 17, 2018	Apr
AB	+	QUILLIVANT XR	5MG/ML	N202100	001	Sep 27, 2012	Apr

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	BIONPHARMA INC	5MG	A209753	001	Mar 02, 2018	Feb	NEWA
AB		10MG	A209753	002	Mar 02, 2018	Feb	NEWA
AB		20MG	A209753	003	Mar 02, 2018	Feb	NEWA
AB	LANNETT CO INC	5MG	A086429	001		Mar	CAHN
AB		10MG	A085799	001		Mar	CAHN
AB		20MG	A086428	001		Mar	CAHN
AB	MOUNTAIN	5MG	A091159	001	Mar 12, 2014	Jan	CAHN
AB		10MG	A091159	002	Mar 12, 2014	Jan	CAHN
AB		20MG	A091159	003	Mar 12, 2014	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

	@ LANNETT CO INC	10MG	A040306	001	Oct 20, 1999	Mar	CAHN
AB	!	20MG	A089601	001	Jun 01, 1988	Mar	CAHN

METHYLPHENIDATE HYDROCHLORIDE

AB	ACTAVIS LABS FL	54MG	A076655	001	Mar 21, 2018	Mar	NEWA	
AB	AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018	Jan	NEWA	
AB		27MG	A207515	002	Feb 01, 2018	Jan	NEWA	
AB		36MG	A207515	003	Feb 01, 2018	Jan	NEWA	
AB		54MG	A207515	004	Feb 01, 2018	Jan	NEWA	
>A>	AB ANI PHARMS INC	18MG	A208607	001	Jul 14, 2017	May	CAHN	
>A>	AB	27MG	A208607	002	Jul 14, 2017	May	CAHN	
>A>	AB	36MG	A208607	003	Jul 14, 2017	May	CAHN	
>A>	AB	54MG	A208607	004	Jul 14, 2017	May	CAHN	
>D>	AB MOUNTAIN	18MG	A208607	001	Jul 14, 2017	May	CAHN	
	AB	18MG	A208607	001	Jul 14, 2017	Jan	CAHN	
>D>	AB	27MG	A208607	002	Jul 14, 2017	May	CAHN	
	AB	27MG	A208607	002	Jul 14, 2017	Jan	CAHN	
>D>	AB	36MG	A208607	003	Jul 14, 2017	May	CAHN	
	AB	36MG	A208607	003	Jul 14, 2017	Jan	CAHN	
>D>	AB	54MG	A208607	004	Jul 14, 2017	May	CAHN	
	AB	54MG	A208607	004	Jul 14, 2017	Jan	CAHN	
	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017	Jan	CHRS

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

AB	TIANJIN TIANYAO	4MG	A204072	001	May 14, 2018	Apr	NEWA
AB	ZYDUS PHARMS USA INC	4MG	A206751	001	Apr 23, 2018	Apr	NEWA
AB		8MG	A206751	002	Apr 23, 2018	Apr	NEWA
AB		16MG	A206751	003	Apr 23, 2018	Apr	NEWA
AB		32MG	A206751	004	Apr 23, 2018	Apr	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

	@ YAOPHARMA CO LTD	EQ 5MG BASE	A074478	001	Oct 05, 1995	Jan	CAHN
	@	EQ 10MG BASE	A072215	001	Jan 30, 1990	Jan	CAHN
	@	EQ 10MG BASE	A074478	002	Oct 05, 1995	Jan	CAHN

METOLAZONE

TABLET;ORAL

MYKROX

	@ LANNETT CO INC	0.5MG	N019532	001	Oct 30, 1987	Apr	CAHN
	ZAROXOLYN						
AB	+ LANNETT CO INC	2.5MG	N017386	001		Mar	CAHN
AB	+!	5MG	N017386	002		Mar	CAHN
AB	+!	10MG	N017386	003		Mar	CAHN

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018	Jan	NEWA
+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018	Jan	NEWA
+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018	Jan	NEWA
+	!	EQ 200MG TARTRATE	N210428	004	Jan 26, 2018	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB	ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Mar	CMS1
AB	NOVAST LABS LTD	EQ 25MG TARTRATE	A204106	001	Feb 06, 2018	Jan	NEWA
AB		EQ 50MG TARTRATE	A204106	002	Feb 06, 2018	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB		EQ 100MG TARTRATE	A204106	003	Feb 06, 2018	Jan NEWA
AB		EQ 200MG TARTRATE	A204106	004	Feb 06, 2018	Jan NEWA
AB	ZYDUS PHARMS USA INC	EQ 25MG TARTRATE	A203894	001	Mar 23, 2018	Mar NEWA
AB		EQ 50MG TARTRATE	A203894	002	Mar 23, 2018	Mar NEWA
AB		EQ 100MG TARTRATE	A203894	003	Mar 23, 2018	Mar NEWA
AB		EQ 200MG TARTRATE	A203894	004	Mar 23, 2018	Mar NEWA

METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE

@	RENATA	50MG	A074453	001	Apr 27, 1995	Jan CAHN
@		100MG	A074453	002	Apr 27, 1995	Jan CAHN
@	YAOPHARMA CO LTD	50MG	A073288	001	Mar 25, 1994	Jan CAHN
@		100MG	A073289	001	Mar 25, 1994	Jan CAHN

METRONIDAZOLE

TABLET;ORAL

METRONIDAZOLE

@	FOSUN PHARMA	250MG	N018620	001	Mar 04, 1982	Jan CAHN
@		250MG	N018740	001	Oct 22, 1982	Jan CAHN
@		500MG	N018620	002	Jun 02, 1983	Jan CAHN
@		500MG	N018740	002	Oct 22, 1982	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

>D>		FLAGYL ER					
>D>	AB	+! GD SEARLE LLC	750MG	N020868	001	Nov 26, 1997	May DISC
>A>		+ @	750MG	N020868	001	Nov 26, 1997	May DISC
		METRONIDAZOLE					
>D>	AB	ALEMBIC PHARMS LTD	750MG	A090222	001	May 05, 2010	May DISC
>A>		@	750MG	A090222	001	May 05, 2010	May DISC

MICAFUNGIN SODIUM

>A>		INJECTABLE;INTRAVENOUS					
>A>		MYCAMINE					
>A>		+! ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	May CDFR
>A>		+!	EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	May CDFR
>D>		INJECTABLE;IV (INFUSION)					
>D>		MYCAMINE					
>D>		+! ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	May CDFR
>D>		+!	EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	May CDFR

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB	APOTEX INC	2.5MG	A077746	001	Sep 12, 2006	Feb CTEC
AB		5MG	A077746	002	Sep 12, 2006	Feb CTEC
AB		10MG	A077746	003	Sep 12, 2006	Feb CTEC
AB	CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003	Mar CAHN
AB		5MG	A076514	002	Sep 11, 2003	Mar CAHN
AB		10MG	A076514	003	Jul 02, 2004	Mar CAHN

MIGLUSTAT

CAPSULE;ORAL

MIGLUSTAT

AB	AMERIGEN PHARMS LTD	100MG	A208342	001	Apr 17, 2018	Apr NEWA
AB	ZAVESCA					
AB	+! ACTELION PHARMS LTD	100MG	N021348	001	Jul 31, 2003	Apr CFTG

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

@	USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016	Mar CAHN
@		25MG	A205071	002	Jan 27, 2016	Mar CAHN
@		50MG	A205071	003	Jan 27, 2016	Mar CAHN
@		100MG	A205071	004	Jan 27, 2016	Mar CAHN

MINOCYCLINE HYDROCHLORIDE

INJECTABLE;INJECTION

MINOCIN

+! REMPEX PHARMS EQ 100MG BASE/VIAL N050444 001 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB ALKEM LABS LTD EQ 65MG BASE A204453 006 Mar 16, 2018 Mar NEWA

AB EQ 115MG BASE A204453 007 Mar 16, 2018 Mar NEWA

AB BARR LABS INC EQ 65MG BASE A065485 004 May 18, 2012 Jan CMFD

AB EQ 115MG BASE A065485 005 May 18, 2012 Jan CMFD

SOLODYN

AB + MEDICIS EQ 65MG BASE N050808 004 Jul 23, 2009 Mar CTEC

AB +! EQ 115MG BASE N050808 005 Jul 23, 2009 Mar CTEC

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

>D> AP WEST-WARD PHARMS INT 5MG/VIAL A064117 001 Apr 19, 1995 May DISC

>A> @ 5MG/VIAL A064117 001 Apr 19, 1995 May DISC

>D> AP 20MG/VIAL A064117 002 Apr 19, 1995 May DISC

>A> @ 20MG/VIAL A064117 002 Apr 19, 1995 May DISC

>A> @ 40MG/VIAL A064117 003 Jun 02, 1999 May CMS1

MONTELUKAST SODIUM

TABLET;ORAL

MONTELUKAST SODIUM

@ APOTEX CORP EQ 10MG BASE A201294 001 Aug 03, 2012 Mar DISC

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

@ APOTEX INC EQ 4MG BASE A201508 001 Aug 03, 2012 Mar DISC

@ EQ 5MG BASE A201508 002 Aug 03, 2012 Mar DISC

MORPHINE SULFATE

SOLUTION;ORAL

MORPHINE SULFATE

AA ANI PHARMS INC 10MG/5ML A205509 001 Apr 17, 2018 Apr NEWA

AA 20MG/5ML A205509 002 Apr 17, 2018 Apr NEWA

AA 100MG/5ML A205509 003 Apr 17, 2018 Apr NEWA

>A> AA LANNETT CO INC 10MG/5ML A202309 001 Nov 25, 2015 May CAHN

>A> AA 20MG/5ML A202310 001 Oct 30, 2015 May CAHN

>D> AA VINTAGE PHARMS LLC 10MG/5ML A202309 001 Nov 25, 2015 May CAHN

>D> AA 20MG/5ML A202310 001 Oct 30, 2015 May CAHN

MUPIROCIN CALCIUM

CREAM;TOPICAL

BACTROBAN

+ @ GLAXOSMITHKLINE EQ 2% BASE N050746 001 Dec 11, 1997 Apr DISC

MUPIROCIN

! GLENMARK PHARMS INC EQ 2% BASE A201587 001 Jan 24, 2013 Apr CHRS

>D> OINTMENT;NASAL

BACTROBAN

>D> +! GLAXOSMITHKLINE EQ 2% BASE N050703 001 Sep 18, 1995 May DISC

>A> + @ EQ 2% BASE N050703 001 Sep 18, 1995 May DISC

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

@ APOTEX CORP 250MG A090419 001 Apr 22, 2009 Mar DISC

TABLET;ORAL

MYCOPHENOLATE MOFETIL

@ APOTEX 500MG A090499 001 Apr 22, 2009 Mar DISC

NABUMETONE

TABLET;ORAL

NABUMETONE

AB CASI PHARMS INC 500MG A075280 001 Feb 25, 2002 Mar CAHN

AB 750MG A075280 002 Feb 25, 2002 Mar CAHN

NADOLOL

TABLET;ORAL

NADOLOL

>A>	AB	RICONPHARMA LLC	20MG	A210786	001	Jun 01, 2018	May NEWA
>A>	AB		40MG	A210786	002	Jun 01, 2018	May NEWA
>A>	AB		80MG	A210786	003	Jun 01, 2018	May NEWA

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

>D>	!	TARO	1%	A205975	001	Sep 08, 2016	May CAHN
	!		1%	A205975	001	Sep 08, 2016	Apr CHRS
>A>	!	TARO PHARMS	1%	A205975	001	Sep 08, 2016	May CAHN
		NAFTIN					
	+	@ SEBELA IRELAND LTD	1%	N019599	001	Feb 29, 1988	Apr DISC

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

NARCAN

+ @ ADAPT 2MG/SPRAY

N208411 002 Jan 24, 2017 Apr DISC

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

@ FOSUN PHARMA 50MG

A075434 001 Mar 08, 2000 Jan CAHN

NAPROXEN

TABLET;ORAL

NAPROXEN

@ FOSUN PHARMA 250MG

A074140 001 Dec 21, 1993 Jan CAHN

@ 375MG

A074140 002 Dec 21, 1993 Jan CAHN

@ 500MG

A074140 003 Dec 21, 1993 Jan CAHN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

@ FOSUN PHARMA 375MG

A075061 001 Feb 18, 1998 Jan CAHN

@ 500MG

A075061 002 Feb 18, 1998 Jan CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

AB AUROBINDO PHARMA LTD 500MG;EQ 85MG BASE

A207457 001 Feb 15, 2018 Feb NEWA

TREXIMET

AB +! PERNIX IRELAND LTD 500MG;EQ 85MG BASE

N021926 001 Apr 15, 2008 Feb CFTG

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

@ APOTEX CORP EQ 1MG BASE

A091373 001 Apr 22, 2011 Mar DISC

@ EQ 2.5MG BASE

A091373 002 Apr 22, 2011 Mar DISC

AB CASI PHARMS INC EQ 1MG BASE

A090288 001 Jul 07, 2010 Mar CAHN

AB EQ 2.5MG BASE

A090288 002 Jul 07, 2010 Mar CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

BYSTOLIC

AB + ALLERGAN SALES LLC EQ 2.5MG BASE

N021742 002 Dec 17, 2007 Feb CFTG

+ EQ 2.5MG BASE

N021742 002 Dec 17, 2007 Jan CAHN

AB + EQ 5MG BASE

N021742 003 Dec 17, 2007 Feb CFTG

+ EQ 5MG BASE

N021742 003 Dec 17, 2007 Jan CAHN

AB + EQ 10MG BASE

N021742 004 Dec 17, 2007 Feb CFTG

+ EQ 10MG BASE

N021742 004 Dec 17, 2007 Jan CAHN

AB +! EQ 20MG BASE

N021742 005 Oct 08, 2008 Feb CFTG

+! EQ 20MG BASE

N021742 005 Oct 08, 2008 Jan CAHN

NEBIVOLOL HYDROCHLORIDE

@ TORRENT PHARMS LTD EQ 2.5MG BASE

A203966 001 Mar 02, 2018 Mar DISC

AB EQ 2.5MG BASE

A203966 001 Mar 02, 2018 Feb NEWA

@ EQ 5MG BASE

A203966 002 Mar 02, 2018 Mar DISC

AB EQ 5MG BASE

A203966 002 Mar 02, 2018 Feb NEWA

@ EQ 10MG BASE

A203966 003 Mar 02, 2018 Mar DISC

AB EQ 10MG BASE

A203966 003 Mar 02, 2018 Feb NEWA

@ EQ 20MG BASE

A203966 004 Mar 02, 2018 Mar DISC

TABLET;ORAL
NEBIVOLOL HYDROCHLORIDE

AB EQ 20MG BASE A203966 004 Mar 02, 2018 Feb NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL
BYVALSON

+! ALLERGAN SALES LLC EQ 5MG BASE;80MG N206302 001 Jun 03, 2016 Jan CAHN

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL
NEFAZODONE HYDROCHLORIDE

@ FOSUN PHARMA 50MG A076302 001 Sep 16, 2003 Jan CAHN
 @ 100MG A076302 002 Sep 16, 2003 Jan CAHN
 @ 150MG A076302 003 Sep 16, 2003 Jan CAHN
 @ 200MG A076302 004 Sep 16, 2003 Jan CAHN
 @ 250MG A076302 005 Sep 16, 2003 Jan CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS
BLOXIVERZ

AP +! AVADEL LEGACY 5MG/10ML (0.5MG/ML) N204078 001 May 31, 2013 Feb CAHN
 AP +! 10MG/10ML (1MG/ML) N204078 002 May 31, 2013 Feb CAHN
 NEOSTIGMINE METHYLSULFATE
 AP LUITPOLD PHARMS INC 5MG/10ML (0.5MG/ML) A209182 001 May 04, 2018 Apr NEWA
 AP 10MG/10ML (1MG/ML) A209182 002 May 04, 2018 Apr NEWA

NEVIRAPINE

TABLET;ORAL
NEVIRAPINE

@ APOTEX INC 200MG A203021 001 May 22, 2012 Mar DISC
 TABLET, EXTENDED RELEASE;ORAL
 NEVIRAPINE
 @ APOTEX INC 400MG A205258 001 Apr 03, 2014 Jan DISC
 @ TECH ORGANIZED 100MG A207467 001 Jul 31, 2017 Mar DISC
 @ 400MG A207467 002 Jul 31, 2017 Mar DISC

NIACIN

TABLET, EXTENDED RELEASE;ORAL
NIACIN

AB AUROBINDO PHARMA LTD 500MG A209236 001 Feb 01, 2018 Jan NEWA
 AB 750MG A209236 002 Feb 01, 2018 Jan NEWA
 AB 1GM A209236 003 Feb 01, 2018 Jan NEWA
 AB JUBILANT GENERICS 500MG A209156 001 May 14, 2018 Apr NEWA
 AB 750MG A209156 002 May 14, 2018 Apr NEWA
 AB 1GM A209156 003 May 14, 2018 Apr NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION
CARDENE

>D> AP +! CHIESI USA INC 25MG/10ML (2.5MG/ML) N019734 001 Jan 30, 1992 May DISC
 >A> + @ 25MG/10ML (2.5MG/ML) N019734 001 Jan 30, 1992 May DISC
 NICARDIPINE HYDROCHLORIDE
 >D> AP EXELA PHARMA SCIENCE 25MG/10ML (2.5MG/ML) N022276 001 Jul 24, 2008 May CTEC
 >A> 25MG/10ML (2.5MG/ML) N022276 001 Jul 24, 2008 May CTEC
 >D> AP LUITPOLD PHARMS INC 25MG/10ML (2.5MG/ML) A090534 001 Nov 17, 2009 May DISC
 >A> @ 25MG/10ML (2.5MG/ML) A090534 001 Nov 17, 2009 May DISC
 >D> AP MYLAN INSTITUTIONAL 25MG/10ML (2.5MG/ML) A090664 001 Nov 17, 2009 May DISC
 >A> @ 25MG/10ML (2.5MG/ML) A090664 001 Nov 17, 2009 May DISC
 >D> AP NAVINTA LLC 25MG/10ML (2.5MG/ML) A090125 001 Nov 17, 2009 May DISC
 >A> @ 25MG/10ML (2.5MG/ML) A090125 001 Nov 17, 2009 May DISC
 >D> AP SUN PHARMA GLOBAL 25MG/10ML (2.5MG/ML) N078405 001 Nov 17, 2009 May DISC
 >A> @ 25MG/10ML (2.5MG/ML) N078405 001 Nov 17, 2009 May DISC
 >D> AP WEST-WARD PHARMS INT 25MG/10ML (2.5MG/ML) A078714 001 Dec 28, 2009 May DISC
 >A> @ 25MG/10ML (2.5MG/ML) A078714 001 Dec 28, 2009 May DISC
 >D> AP WOCKHARDT 25MG/10ML (2.5MG/ML) A090671 001 Nov 17, 2009 May DISC
 >A> @ 25MG/10ML (2.5MG/ML) A090671 001 Nov 17, 2009 May DISC
 INJECTABLE;INTRAVENOUS
 CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER
 + @ CHIESI USA INC 40MG/200ML (0.2MG/ML) N019734 005 Nov 07, 2008 Mar DISC

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE;ORAL
TASIGNA

+ NOVARTIS EQ 50MG BASE N022068 003 Mar 22, 2018 Mar NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>A> AB SUNNY PHARMTECH INC 75MG;25MG A208516 001 May 24, 2018 May NEWA

NITROGLYCERIN

OINTMENT;INTRA-ANAL
RECTIV

+! ALLERGAN SALES LLC 0.4% N021359 001 Jun 21, 2011 Jan CAHN

TABLET;SUBLINGUAL
NITROGLYCERIN

AB GLENMARK PHARMS SA 0.3MG A206391 001 Sep 19, 2017 Jan CAHN
 AB 0.4MG A206391 002 Sep 19, 2017 Jan CAHN
 AB 0.6MG A206391 003 Sep 19, 2017 Jan CAHN
 AB SIGMAPHARM LABS LLC 0.3MG A207745 001 May 07, 2018 Apr NEWA
 AB 0.4MG A207745 002 May 07, 2018 Apr NEWA
 AB 0.6MG A207745 003 May 07, 2018 Apr NEWA

NORETHINDRONE ACETATE

TABLET;ORAL
AYGESTIN

>D> AB +! DURAMED RES 5MG N018405 001 Apr 21, 1982 May DISC
 >A> + @ 5MG N018405 001 Apr 21, 1982 May DISC

NORETHINDRONE ACETATE

>D> AB BARR 5MG A075951 001 May 25, 2001 May CHRS
 >A> AB ! 5MG A075951 001 May 25, 2001 May CHRS

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

AB MAYNE PHARMA EQ 10MG BASE A073556 002 Mar 30, 1992 Mar CMS1
 AB EQ 25MG BASE A073556 003 Mar 30, 1992 Mar CMS1
 AB EQ 50MG BASE A073556 004 Mar 30, 1992 Mar CMS1

NYSTATIN

OINTMENT;TOPICAL
NYSTATIN

>A> AT @ G AND W LABS INC 100,000 UNITS/GM A209114 001 Oct 06, 2017 Jan DISC
 >A> AT LYNE 100,000 UNITS/GM A209082 001 May 21, 2018 May NEWA
 >A> AT ZYDUS PHARMS USA INC 100,000 UNITS/GM A207767 001 May 25, 2018 May NEWA

POWDER;TOPICAL
NYSTATIN

AT EPIC PHARMA LLC 100,000 UNITS/GM A210532 001 Apr 30, 2018 Apr NEWA

SUSPENSION;ORAL
NYSTATIN

>A> AA @ G AND W LABS INC 100,000 UNITS/ML A062349 001 Jul 14, 1982 Jan DISC
 >D> AA LANNETT CO INC 100,000 UNITS/ML A065148 001 Jun 28, 2005 May CAHN
 >D> AA VINTAGE PHARMS 100,000 UNITS/ML A065148 001 Jun 28, 2005 May CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT AMNEAL PHARMS LLC 100,000 UNITS/GM;0.1% A209990 001 Feb 15, 2018 Feb NEWA
 >A> AT LUPIN LTD 100,000 UNITS/GM;0.1% A208205 001 May 31, 2018 May NEWA

OINTMENT;TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT STRIDES PHARMA 100,000 UNITS/GM;0.1% A210077 001 Jan 29, 2018 Jan NEWA

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

@ AJANTA PHARMA LTD 5MG A204320 001 May 30, 2017 Mar DISC
 @ 10MG A204320 002 May 30, 2017 Mar DISC
 @ 15MG A204320 003 May 30, 2017 Mar DISC
 @ 20MG A204320 004 May 30, 2017 Mar DISC

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

>D>	AT	MICRO LABS LTD INDIA	EQ 0.1% BASE	A204392	001	Mar 21, 2018	May CAHN
	AT		EQ 0.1% BASE	A204392	001	Mar 21, 2018	Mar NEWA
>A>	AT	MYLAN PHARMS INC	EQ 0.1% BASE	A204392	001	Mar 21, 2018	May CAHN
	@	ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015	Mar DISC

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

>A>	AB	ZYDUS PHARMS USA INC	20MG;1.1GM	A203290	001	May 25, 2018	May NEWA
>A>	AB		40MG;1.1GM	A203290	002	May 25, 2018	May NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

	@	CHARTWELL MOLECULES	4MG	A077406	003	Dec 26, 2006	Mar CMS1
	@		8MG	A077406	004	Dec 26, 2006	Mar CMS1

ONDANSETRON HYDROCHLORIDE

TABLET;ORAL
ONDANSETRON HYDROCHLORIDE

AB		CASI PHARMS INC	EQ 4MG BASE	A077517	001	Jun 25, 2007	Mar CAHN
AB			EQ 8MG BASE	A077517	002	Jun 25, 2007	Mar CAHN
AB			EQ 24MG BASE	A077517	003	Jun 25, 2007	Mar CAHN

ORITAVANCIN DIPHOSPHATE

POWDER;IV (INFUSION)
ORBACTIV

+	!	MELINTA	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Jan CAHN
+	!	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Mar CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

AB		HETERO LABS LTD III	EQ 30MG BASE	A209438	001	Feb 23, 2018	Feb NEWA
AB			EQ 45MG BASE	A209438	002	Feb 23, 2018	Feb NEWA
AB			EQ 75MG BASE	A209438	003	Feb 23, 2018	Feb NEWA
>A>	AB	STRIDES PHARMA	EQ 30MG BASE	A209421	001	Jun 08, 2018	May NEWA
>A>	AB		EQ 45MG BASE	A209421	002	Jun 08, 2018	May NEWA
>A>	AB		EQ 75MG BASE	A209421	003	Jun 08, 2018	May NEWA

FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE

AB		LUPIN ATLANTIS	EQ 6MG BASE/ML	A208347	001	Feb 20, 2018	Feb NEWA
----	--	----------------	----------------	---------	-----	--------------	----------

OXACILLIN SODIUM

INJECTABLE;INJECTION
OXACILLIN SODIUM

>D>	AP	!	SANDOZ	EQ 1GM BASE/VIAL	A061490	003	May DISC
>A>		@		EQ 1GM BASE/VIAL	A061490	003	May DISC
>D>	AP	!		EQ 2GM BASE/VIAL	A061490	004	May DISC
>A>		@		EQ 2GM BASE/VIAL	A061490	004	May DISC
>D>	AP	!		EQ 10GM BASE/VIAL	A061490	006	May 09, 1991
>A>		@		EQ 10GM BASE/VIAL	A061490	006	May 09, 1991
>D>			POWDER;INTRAVENOUS				
>D>			OXACILLIN SODIUM				
>D>	AP	!	SANDOZ	EQ 1GM BASE/VIAL	A062737	001	Dec 23, 1986
>A>		@		EQ 1GM BASE/VIAL	A062737	001	Dec 23, 1986
>D>	AP	!		EQ 2GM BASE/VIAL	A062737	002	Dec 23, 1986
>A>		@		EQ 2GM BASE/VIAL	A062737	002	Dec 23, 1986

OXALIPLATIN

INJECTABLE;IV (INFUSION)
OXALIPLATIN

AP		ACTAVIS LLC	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Feb NEWA
AP			100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Feb NEWA
AP		EUGIA PHARMA	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Apr CAHN
AP			100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Apr CAHN

OXICONAZOLE NITRATE

CREAM;TOPICAL
OXICONAZOLE NITRATE

>D>	AB	TARO	EQ 1% BASE	A205076	001	Mar 07, 2016	May	CAHN
>A>	AB	TARO PHARMS	EQ 1% BASE	A205076	001	Mar 07, 2016	May	CAHN

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL
GELNIQUE

>D>		+!	ALLERGAN SALES LLC	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	May	CFTG
>A>	AB	+!		10% (100MG/PACKET)	N022204	001	Jan 27, 2009	May	CFTG

OXYBUTYNIN CHLORIDE

>A>	AB		PAR PHARM INC	10% (100MG/PACKET)	A207329	001	May 31, 2018	May	NEWA
-----	----	--	---------------	--------------------	---------	-----	--------------	-----	------

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

>A>	AA		LANNETT CO INC	5MG/5ML	A076682	001	Dec 28, 2004	May	CAHN
>D>	AA		VINTAGE PHARMS	5MG/5ML	A076682	001	Dec 28, 2004	May	CAHN

TABLET, EXTENDED RELEASE;ORAL

DITROPAN XL

+ @ JANSSEN PHARMS 15MG

N020897	003	Jun 22, 1999	Feb	DISC
---------	-----	--------------	-----	------

OXYBUTYNIN CHLORIDE

AB ! MYLAN PHARMS INC 15MG

A076644	002	May 10, 2007	Feb	CHRS
---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB +! GENUS LIFESCIENCES 5MG

N200534	001	Oct 20, 2010	Apr	CAHN
---------	-----	--------------	-----	------

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA + GENUS LIFESCIENCES 5MG/5ML

N200535	002	Aug 22, 2013	Apr	CAHN
---------	-----	--------------	-----	------

AA +! 100MG/5ML

N200535	001	Oct 20, 2010	Apr	CAHN
---------	-----	--------------	-----	------

AA SPECGX LLC 5MG/5ML

A210758	001	Apr 30, 2018	Apr	NEWA
---------	-----	--------------	-----	------

AA 100MG/5ML

A210758	002	Apr 30, 2018	Apr	NEWA
---------	-----	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB ASCENT PHARMS INC 5MG

A210175	001	Feb 02, 2018	Jan	NEWA
---------	-----	--------------	-----	------

AB 10MG

A210175	002	Feb 02, 2018	Jan	NEWA
---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

@ SUN PHARM INDS LTD 5MG

A203506	001	Apr 24, 2015	Mar	DISC
---------	-----	--------------	-----	------

@ 7.5MG

A203506	002	Apr 24, 2015	Mar	DISC
---------	-----	--------------	-----	------

@ 10MG

A203506	003	Apr 24, 2015	Mar	DISC
---------	-----	--------------	-----	------

@ 15MG

A203506	004	Apr 24, 2015	Mar	DISC
---------	-----	--------------	-----	------

@ 20MG

A203506	005	Apr 24, 2015	Mar	DISC
---------	-----	--------------	-----	------

@ 30MG

A203506	006	Apr 24, 2015	Mar	DISC
---------	-----	--------------	-----	------

@ 40MG

A203506	007	Apr 24, 2015	Mar	DISC
---------	-----	--------------	-----	------

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

! CASPER PHARMA LLC EQ 5MG BASE/GM;10,000 UNITS/GM

N061015	001		Feb	CMS2
---------	-----	--	-----	------

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

AB SUN PHARMA GLOBAL 1.5mg

A205618	001	Apr 06, 2018	Mar	NEWA
---------	-----	--------------	-----	------

AB 3MG

A205618	002	Apr 06, 2018	Mar	NEWA
---------	-----	--------------	-----	------

AB 6MG

A205618	003	Apr 06, 2018	Mar	NEWA
---------	-----	--------------	-----	------

AB 9MG

A205618	004	Apr 06, 2018	Mar	NEWA
---------	-----	--------------	-----	------

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP TEVA PHARMS USA EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

A090713	002	Mar 23, 2018	Mar	NEWA
---------	-----	--------------	-----	------

AP EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

A090713	001	Mar 23, 2018	Mar	NEWA
---------	-----	--------------	-----	------

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL
PANCREAZE

	+	JANSSEN PHARMS	24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523 001	Apr 12, 2010	Mar CPOT
	+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523 002	Apr 12, 2010	Mar CPOT
	+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523 004	Apr 12, 2010	Mar CPOT
	+!		98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523 003	Apr 12, 2010	Mar CPOT

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)
PANTOPRAZOLE SODIUM

AP		MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580 001	May 04, 2018	Apr NEWA
			TABLET, DELAYED RELEASE;ORAL			
			PANTOPRAZOLE SODIUM			
		@ SUN PHARM INDS LTD	EQ 20MG BASE	A200794 001	May 02, 2012	Apr DISC
		@	EQ 40MG BASE	A200794 002	May 02, 2012	Apr DISC

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PAROXETINE HYDROCHLORIDE

>A>	AB	SCIECURE PHARMA INC	EQ 12.5MG BASE	A209293 001	Jun 12, 2018	May NEWA
>A>	AB		EQ 25MG BASE	A209293 002	Jun 12, 2018	May NEWA
>A>	AB		EQ 37.5MG BASE	A209293 003	Jun 12, 2018	May NEWA

PEMOLINE

TABLET;ORAL
PEMOLINE

	@	FOSUN PHARMA	18.75MG	A075286 001	Dec 27, 1999	Jan CAHN
	@		37.5MG	A075286 002	Jun 30, 1999	Jan CAHN
	@		75MG	A075286 003	Jun 30, 1999	Jan CAHN

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION
PERMAPEN

BC		CASPER PHARMA LLC	600,000 UNITS/ML	N060014 001		Feb CMS2
----	--	-------------------	------------------	-------------	--	----------

PERINDOPRIL ERBUMINE

TABLET;ORAL
PERINDOPRIL ERBUMINE

	@	APOTEX	2MG	A090463 001	Aug 30, 2010	Jan DISC
	@		4MG	A090463 002	Aug 30, 2010	Jan DISC
	@		8MG	A090463 003	Aug 30, 2010	Jan DISC
AB		AUROBINDO PHARMA	2MG	A079070 001	Nov 10, 2009	Mar CHRS
AB			4MG	A079070 002	Nov 10, 2009	Mar CHRS

PHENDIMETRAZINE TARTRATE

CAPSULE;ORAL
PHENDIMETRAZINE TARTRATE

>D>	@	SANDOZ	35MG	A085695 001		May CAHN
>A>	@	VIRTUS PHARMS	35MG	A085695 001		May CAHN

CAPSULE, EXTENDED RELEASE;ORAL
PHENDIMETRAZINE TARTRATE

>D>	@	SANDOZ	105MG	A087378 001		May CAHN
>A>	@	VIRTUS PHARMS	105MG	A087378 001		May CAHN
	+!		105MG	N018074 001		Mar CAHN

TABLET;ORAL
PHENDIMETRAZINE TARTRATE

>D>	@	SANDOZ	35MG	A085497 001		May CAHN
>D>	@		35MG	A086365 001		May CAHN
>A>	@	VIRTUS PHARMS	35MG	A085497 001		May CAHN
AA			35MG	A085588 001		Mar CAHN
>A>	@		35MG	A086365 001		May CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

@ ELITE LABS INC 15MG A040460 001 Jan 14, 2003 Jan CAHN

PHENYL BUTAZONE

CAPSULE;ORAL

PHENYL BUTAZONE

@ FOSUN PHARMA 100MG A087774 001 Jun 16, 1982 Jan CAHN

TABLET;ORAL

PHENYL BUTAZONE

@ FOSUN PHARMA 100MG A084339 001 Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IV (INFUSION)

PHENYLEPHRINE HYDROCHLORIDE

AP CIPLA LTD 10MG/ML (10MG/ML) A210334 001 Apr 27, 2018 Apr NEWA

AP 100MG/10ML (10MG/ML) A210333 002 Apr 27, 2018 Apr NEWA

AP +! WEST WARD PHARM CORP 10MG/ML (10MG/ML) N203826 001 Dec 20, 2012 Apr CFTG

PHENYLEPHRINE HYDROCHLORIDE

AP CIPLA LTD 50MG/5ML (10MG/ML) A210333 001 Apr 27, 2018 Apr NEWA

VAZCULEP

AP + AVADEL LEGACY 50MG/5ML (10MG/ML) N204300 002 Jun 27, 2014 Apr CFTG

AP +! 100MG/10ML (10MG/ML) N204300 003 Jun 27, 2014 Apr CFTG

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA ! VINTAGE 5MG/5ML;6.25MG/5ML A040654 001 Dec 07, 2006 Jan CHRS

PROMETH VC PLAIN

@ G AND W LABS INC 5MG/5ML;6.25MG/5ML A088761 001 Nov 08, 1984 Jan DISC

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

AB WOCKHARDT BIO AG 125MG/5ML A040420 001 Apr 19, 2002 Jan CAHN

PHYTONADIONE

TABLET;ORAL

MEPHYTON

AB +! VALEANT PHARMS 5MG N010104 003 Apr CFTG

PHYTONADIONE

AB AMNEAL PHARMS CO 5MG A209373 001 May 11, 2018 Apr NEWA

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB PRINSTON INC EQ 15MG BASE A207806 001 Apr 17, 2018 Apr NEWA

AB EQ 30MG BASE A207806 002 Apr 17, 2018 Apr NEWA

AB EQ 45MG BASE A207806 003 Apr 17, 2018 Apr NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

>A> AP FRESENIUS KABI EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL A203719 001 May 18, 2018 May NEWA

>A> AP EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL A203719 002 May 18, 2018 May NEWA

>A> AP EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL A203719 003 May 18, 2018 May NEWA

AP EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL A203720 001 May 11, 2018 Apr NEWA

AP FRESENIUS KABI USA EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL A206204 001 May 11, 2018 Apr NEWA

AP SANDOZ INC EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL A203557 001 Oct 29, 2014 Apr CDFR

AP WOCKHARDT BIO AG EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL A207146 001 Mar 17, 2017 Jan CPOT

PIROXICAM

	CAPSULE;ORAL						
	PIROXICAM						
AB	LABORATORIOS CINFA	10MG	A208991	001	Feb 21, 2018	Feb	NEWA
AB		20MG	A208991	002	Feb 21, 2018	Feb	NEWA
AB	MICRO LABS	10MG	A206152	001	Dec 29, 2017	Feb	CRLD
AB		20MG	A206152	002	Dec 29, 2017	Feb	CRLD
AB	STRIDES PHARMA	10MG	A210347	001	Jan 26, 2018	Jan	NEWA
AB		20MG	A210347	002	Jan 26, 2018	Jan	NEWA

POLIDOCANOL

	SOLUTION;INTRAVENOUS						
	VARITHENA						
	+!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	Jan CDFR

POTASSIUM CHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL						
	MICRO-K						
	+ @	NESHER PHARMS	8MEQ	N018238	001		Apr DISC
		MICRO-K 10					
	+ @	NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	Apr DISC
	TABLET, EXTENDED RELEASE;ORAL						
	K-TAB						
AB3	+ ABBVIE	10MEQ	N018279	001		Jan	CTEC
AB2	+!	20MEQ	N018279	003	Nov 25, 2013	Jan	CTEC
	POTASSIUM CHLORIDE						
AB3	PADDOCK LLC	10MEQ	A209688	001	Jan 12, 2018	Jan	NEWA
AB2		20MEQ	A209688	002	Jan 12, 2018	Jan	NEWA

POTASSIUM CITRATE

	TABLET, EXTENDED RELEASE;ORAL						
	POTASSIUM CITRATE						
AB	MOUNTAIN	5MEQ	A077440	001	Jun 09, 2006	Jan	CAHN
AB		10MEQ	A077440	002	Jun 09, 2006	Jan	CAHN
AB	TEVA PHARMS USA INC	5MEQ	A209758	001	Mar 05, 2018	Feb	NEWA
AB		10MEQ	A209758	002	Mar 05, 2018	Feb	NEWA
AB		15MEQ	A209758	003	Mar 05, 2018	Feb	NEWA

PRASUGREL HYDROCHLORIDE

	TABLET;ORAL						
	PRASUGREL						
AB	ACCORD HLTHCARE	EQ 5MG BASE	A205987	001	Feb 02, 2018	Jan	NEWA
AB		EQ 10MG BASE	A205987	002	Feb 02, 2018	Jan	NEWA
AB	USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Jan	CAHN
AB		EQ 10MG BASE	A205790	002	Oct 16, 2017	Jan	CAHN

PRAVASTATIN SODIUM

	TABLET;ORAL						
	PRAVASTATIN SODIUM						
AB	APPCO PHARMA LLC	10MG	A209869	001	Apr 13, 2018	Apr	NEWA
AB		20MG	A209869	002	Apr 13, 2018	Apr	NEWA
AB		40MG	A209869	003	Apr 13, 2018	Apr	NEWA
AB		80MG	A209869	004	Apr 13, 2018	Apr	NEWA

PREDNISOLONE

	SYRUP;ORAL						
	PREDNISOLONE						
>A>	AA	LANNETT CO INC	15MG/5ML	A040775	001	Sep 21, 2007	May CAHN
>D>	AA	VINTAGE	15MG/5ML	A040775	001	Sep 21, 2007	May CAHN
	TABLET;ORAL						
	PREDNISOLONE						
	@	FOSUN PHARMA	5MG	A080339	001		Jan CAHN

PREDNISOLONE SODIUM PHOSPHATE

	SOLUTION;ORAL						
	PREDNISOLONE SODIUM PHOSPHATE						
AA	!	WOCKHARDT BIO AG	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Jan CAHN
	SOLUTION/DROPS;OPHTHALMIC						
	PREDNISOLONE SODIUM PHOSPHATE						
	@	BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065	001	Jul 29, 1994	Apr CAHN

PREDNISONE

TABLET;ORAL
PREDNISONE

>D>	AB	HIKMA PHARMS	2.5MG	A 040538	001	Jan 08, 2004	May DISC
>A>		@	2.5MG	A 040538	001	Jan 08, 2004	May DISC

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CITANEST PLAIN DENTAL

>D>		@ DENTSPLY PHARM	4%	N 021382	001		May CRLD
>A>		+ @	4%	N 021382	001		May CRLD

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
ALCAINE

>D>	AT	!	ALCON LABS INC	0.5%	A 080027	001	May DISC
>A>			@	0.5%	A 080027	001	May DISC
	AT	!		0.5%	A 080027	001	Feb CAHN

PROPARACAINE HYDROCHLORIDE

>D>	AT		AKORN INC	0.5%	A 040277	001	Mar 16, 2000	May CHRS
>A>	AT	!		0.5%	A 040277	001	Mar 16, 2000	May CHRS

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
PROPRANOLOL HYDROCHLORIDE

@ FOSUN PHARMA 1MG/ML

A 076400 001 Feb 26, 2003 Jan CAHN

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

>A>	AB		IMPAX LABS INC	20MG	A 071972	002	Apr 06, 1988	May CMS1
>A>	AB			40MG	A 071972	003	Apr 06, 1988	May CMS1
>A>	AB			60MG	A 071976	002	May 13, 1986	May CMS1
			@ YAOPHARMA CO LTD	10MG	A 070663	001	Jun 13, 1986	Jan CAHN
			@	20MG	A 070664	001	Jun 13, 1986	Jan CAHN
			@	40MG	A 070665	001	Jun 13, 1986	Jan CAHN
			@	60MG	A 070666	001	Oct 10, 1986	Jan CAHN
			@	80MG	A 070667	001	Jun 13, 1986	Jan CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET;ORAL

CORPHED

@ FOSUN PHARMA 60MG;2.5MG

A 088602 001 Apr 11, 1985 Jan CAHN

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

+! VYERA PHARMS LLC 25MG

N 008578 001 Jan CAHN

QUAZEPAM

TABLET;ORAL

DORAL

@ GALT PHARMS 7.5MG

N 018708 003 Feb 26, 1987 Feb CAHN

+! 15MG

N 018708 001 Dec 27, 1985 Feb CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 5MG BASE

A 076607 001 Dec 15, 2004 Apr DISC

@ EQ 10MG BASE

A 076607 002 Dec 15, 2004 Apr DISC

@ EQ 20MG BASE

A 076607 003 Dec 15, 2004 Apr DISC

@ EQ 40MG BASE

A 076607 004 Dec 15, 2004 Apr DISC

@ YAOPHARMA CO LTD EQ 5MG BASE

A 076803 001 Mar 02, 2005 Jan CAHN

@ EQ 10MG BASE

A 076803 002 Mar 02, 2005 Jan CAHN

@ EQ 20MG BASE

A 076803 003 Mar 02, 2005 Jan CAHN

@ EQ 40MG BASE

A 076803 004 Mar 02, 2005 Jan CAHN

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE SULFATE

@ G AND W LABS INC 300MG

A 040045 001 Jun 30, 1994 Jan DISC

RABEPRAZOLE SODIUMCAPSULE, DELAYED RELEASE;ORAL
ACIPHEX SPRINKLE

	+	CERECOR INC	5MG	N204736	001	Mar 26, 2013	Feb CAHN
	+	!	10MG	N204736	002	Mar 26, 2013	Feb CAHN

TABLET, DELAYED RELEASE;ORAL
RABEPRAZOLE SODIUM

AB		ALKEM LABS LTD	20MG	A208644	001	Apr 24, 2018	Apr NEWA
----	--	----------------	------	---------	-----	--------------	----------

RALTEGRAVIR POTASSIUMTABLET;ORAL
ISENTRESS HD

>D>	+	MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017	May CHRS
>A>	+	!	EQ 600MG BASE	N022145	002	May 26, 2017	May CHRS

RAMELTEONTABLET;ORAL
RAMELTEON

AB		DR REDDYS LABS SA	8MG	A091693	001	Jul 26, 2013	Mar CAHN
----	--	-------------------	-----	---------	-----	--------------	----------

RAMIPRILCAPSULE;ORAL
RAMIPRIL

	@	WATSON LABS	5MG	A076549	003	Oct 24, 2005	Mar DISC
	@	YAOPHARMA CO LTD	1.25MG	A077514	001	Jun 18, 2008	Jan CAHN
	@		2.5MG	A077514	002	Jun 18, 2008	Jan CAHN
	@		5MG	A077514	003	Jun 18, 2008	Jan CAHN
	@		10MG	A077514	004	Jun 18, 2008	Jan CAHN

>D> TABLET;ORAL

RAMIPRIL

>D>		APOTEX INC	1.25MG	A091069	001	Dec 02, 2015	May DISC
>A>	@		1.25MG	A091069	001	Dec 02, 2015	May DISC
>D>			2.5MG	A091069	002	Dec 02, 2015	May DISC
>A>	@		2.5MG	A091069	002	Dec 02, 2015	May DISC
>D>			5MG	A091069	003	Dec 02, 2015	May DISC
>A>	@		5MG	A091069	003	Dec 02, 2015	May DISC
>D>	!		10MG	A091069	004	Dec 02, 2015	May DISC
>A>	@		10MG	A091069	004	Dec 02, 2015	May DISC

RANITIDINE HYDROCHLORIDE

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

>A>	AA	LANNETT CO INC	EQ 15MG BASE/ML	A078890	001	Jul 01, 2010	May CAHN
>D>	AA	VINTAGE PHARMS	EQ 15MG BASE/ML	A078890	001	Jul 01, 2010	May CAHN

TABLET;ORAL

ZANTAC 150

	+	@	GLAXO GRP LTD	EQ 150MG BASE	N018703	001	Jun 09, 1983	Apr DISC
--	---	---	---------------	---------------	---------	-----	--------------	----------

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

	@	APOTEX INC	EQ 0.5MG BASE	A201950	001	Sep 12, 2013	Mar DISC
	@		EQ 1MG BASE	A201950	002	Sep 12, 2013	Mar DISC

REMIFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

REMIFENTANIL HYDROCHLORIDE

AP		FRESENIUS KABI USA	EQ 1MG BASE/VIAL	A206223	001	Jan 16, 2018	Jan NEWA
AP			EQ 2MG BASE/VIAL	A206223	002	Jan 16, 2018	Jan NEWA
AP			EQ 5MG BASE/VIAL	A206223	003	Jan 16, 2018	Jan NEWA

ULTIVA

AP	+	MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N020630	001	Jul 12, 1996	Jan CFTG
AP	+		EQ 2MG BASE/VIAL	N020630	002	Jul 12, 1996	Jan CFTG
AP	+	!	EQ 5MG BASE/VIAL	N020630	003	Jul 12, 1996	Jan CFTG

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB	CASI PHARMS INC	0.5MG	A 078555	001	Nov 22, 2013	Mar	CAHN
AB		1MG	A 078555	002	Jan 22, 2014	Mar	CAHN
AB		2MG	A 078555	003	Jan 22, 2014	Mar	CAHN

RIBAVIRIN

CAPSULE;ORAL

RIBAVIRIN

AB	CASI PHARMS INC	200MG	A 076192	001	Apr 06, 2004	Mar	CAHN
----	-----------------	-------	----------	-----	--------------	-----	------

TABLET;ORAL

COPEGUS

@ ROCHE

		200MG	N 021511	001	Dec 03, 2002	Apr	DISC
--	--	-------	----------	-----	--------------	-----	------

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

>A>	AA	LANNETT CO INC	1MG/ML	A 079158	001	Dec 03, 2010	May	CAHN
-----	----	----------------	--------	----------	-----	--------------	-----	------

@ PRECISION DOSE

		1MG/ML	A 076797	001	Jun 28, 2010	Mar	DISC
--	--	--------	----------	-----	--------------	-----	------

>D>	AA	VINTAGE	1MG/ML	A 079158	001	Dec 03, 2010	May	CAHN
-----	----	---------	--------	----------	-----	--------------	-----	------

TABLET;ORAL

RISPERIDONE

AB	CHARTWELL MOLECULAR	0.25MG	A 077543	001	May 18, 2011	Mar	CAHN
AB		0.5MG	A 077543	002	May 18, 2011	Mar	CAHN
AB		1MG	A 077543	003	May 18, 2011	Mar	CAHN
AB		2MG	A 077543	004	May 18, 2011	Mar	CAHN
AB		3MG	A 077543	005	May 18, 2011	Mar	CAHN
AB		4MG	A 077543	006	May 18, 2011	Mar	CAHN
AB	RENATA	0.25MG	A 078707	001	Dec 29, 2008	Jan	CAHN
AB		0.5MG	A 078707	002	Dec 29, 2008	Jan	CAHN
AB		1MG	A 078707	003	Dec 29, 2008	Jan	CAHN
AB		2MG	A 078707	004	Dec 29, 2008	Jan	CAHN
AB		3MG	A 078707	005	Dec 29, 2008	Jan	CAHN
AB		4MG	A 078707	006	Dec 29, 2008	Jan	CAHN

RITONAVIR

CAPSULE;ORAL

NORVIR

	+ @ ABBVIE	100MG	N 020945	001	Jun 29, 1999	Apr	DISC
--	------------	-------	----------	-----	--------------	-----	------

RIZATRIPTAN BENZOATE

TABLET;ORAL

MAXALT

	+ @ MERCK	EQ 5MG BASE	N 020864	001	Jun 29, 1998	Apr	DISC
--	-----------	-------------	----------	-----	--------------	-----	------

RIZATRIPTAN BENZOATE

@ APOTEX INC

		EQ 5MG BASE	A 202244	001	Dec 31, 2012	Mar	DISC
--	--	-------------	----------	-----	--------------	-----	------

@

		EQ 10MG BASE	A 202244	002	Dec 31, 2012	Mar	DISC
--	--	--------------	----------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING;ORAL

MAXALT-MLT

	+ @ MERCK	EQ 5MG BASE	N 020865	001	Jun 29, 1998	Apr	DISC
--	-----------	-------------	----------	-----	--------------	-----	------

RIZATRIPTAN BENZOATE

@ APOTEX INC

		EQ 5MG BASE	A 202477	001	Jul 01, 2013	Mar	DISC
--	--	-------------	----------	-----	--------------	-----	------

@

		EQ 10MG BASE	A 202477	002	Jul 01, 2013	Mar	DISC
--	--	--------------	----------	-----	--------------	-----	------

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP	GLAND CHEMS PVT	50MG/5ML (10MG/ML)	A 205656	001	Apr 04, 2018	Mar	NEWA
AP		100MG/10ML (10MG/ML)	A 205656	002	Apr 04, 2018	Mar	NEWA
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A 205656	001	Apr 04, 2018	Apr	CAHN
AP		100MG/10ML (10MG/ML)	A 205656	002	Apr 04, 2018	Apr	CAHN

ROFLUMILAST

TABLET;ORAL

DALIRESP

	+ ASTRAZENECA PHARMS	250MCG	N 022522	002	Jan 23, 2018	Jan	NEWA
--	----------------------	--------	----------	-----	--------------	-----	------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

	@ G AND W LABS INC	EQ 0.25MG BASE	A 077460	001	May 05, 2008	Jan	DISC
	@	EQ 0.5MG BASE	A 077460	002	May 05, 2008	Jan	DISC
	@	EQ 1MG BASE	A 077460	003	May 05, 2008	Jan	DISC
	@	EQ 2MG BASE	A 077460	004	May 05, 2008	Jan	DISC
	@	EQ 3MG BASE	A 077460	005	May 05, 2008	Jan	DISC
	@	EQ 4MG BASE	A 077460	006	May 05, 2008	Jan	DISC
	@	EQ 5MG BASE	A 077460	007	May 19, 2008	Jan	DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

AP	+	FRESENIUS KABI USA	400MG/200ML (2MG/ML)	N 020533	007	Sep 24, 1996	Mar	CTEC
>D>	+		500MG/100ML (5MG/ML)	N 020533	009	Jan 04, 2011	May	CTEC
>A>	AP	+	500MG/100ML (5MG/ML)	N 020533	009	Jan 04, 2011	May	CTEC
>D>	+		1GM/200ML (5MG/ML)	N 020533	010	Jan 04, 2011	May	CTEC
>A>	AP	+	1GM/200ML (5MG/ML)	N 020533	010	Jan 04, 2011	May	CTEC

ROPIVACAINE HYDROCHLORIDE

AP		AKORN	200MG/100ML (2MG/ML)	A 204636	001	Mar 16, 2018	Mar	NEWA
AP			400MG/200ML (2MG/ML)	A 204636	002	Mar 16, 2018	Mar	NEWA
>A>	AP	INFORLIFE	200MG/100ML (2MG/ML)	A 206166	001	Jun 11, 2018	May	NEWA
>A>	AP		400MG/200ML (2MG/ML)	A 206166	002	Jun 11, 2018	May	NEWA
>A>	AP		500MG/100ML (5MG/ML)	A 206166	003	Jun 11, 2018	May	NEWA
>A>	AP		1GM/200ML (5MG/ML)	A 206166	004	Jun 11, 2018	May	NEWA

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL

SERTRALINE HYDROCHLORIDE

>A>	@	ACI HEALTHCARE LTD	EQ 20MG BASE/ML	A 076934	001	Jun 30, 2006	May	CAHN
>D>	@	ALLIED PHARMA INC	EQ 20MG BASE/ML	A 076934	001	Jun 30, 2006	May	CAHN

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

	@	CHARTWELL MOLECULAR	EQ 25MG BASE	A 077162	001	Feb 06, 2007	Mar	CAHN
	@		EQ 50MG BASE	A 077162	002	Feb 06, 2007	Mar	CAHN
	@		EQ 100MG BASE	A 077162	003	Feb 06, 2007	Mar	CAHN
	@	FOSUN PHARMA	EQ 25MG BASE	A 077713	001	Feb 06, 2007	Jan	CAHN
	@		EQ 50MG BASE	A 077713	002	Feb 06, 2007	Jan	CAHN
	@		EQ 100MG BASE	A 077713	003	Feb 06, 2007	Jan	CAHN

SEVELAMER CARBONATE

TABLET;ORAL

SEVELAMER CARBONATE

AB		SANDOZ INC	800MG	A 200959	001	Mar 20, 2018	Mar	NEWA
----	--	------------	-------	----------	-----	--------------	-----	------

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB		AJANTA PHARMA LTD	EQ 20MG BASE	A 210394	001	May 04, 2018	Apr	NEWA
	@	APOTEX CORP	EQ 20MG BASE	A 091379	001	Nov 06, 2012	Mar	DISC
>A>	AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A 203962	001	Jun 11, 2018	May	NEWA
>A>	AB		EQ 50MG BASE	A 203962	002	Jun 11, 2018	May	NEWA
>A>	AB		EQ 100MG BASE	A 203962	003	Jun 11, 2018	May	NEWA
>A>	AB	HETERO LABS LTD V	EQ 25MG BASE	A 202659	001	Jun 11, 2018	May	NEWA
>A>	AB		EQ 50MG BASE	A 202659	002	Jun 11, 2018	May	NEWA
>A>	AB		EQ 100MG BASE	A 202659	003	Jun 11, 2018	May	NEWA
>A>	AB	RUBICON RES PVT LTD	EQ 25MG BASE	A 204882	001	Jun 11, 2018	May	NEWA
>A>	AB		EQ 50MG BASE	A 204882	002	Jun 11, 2018	May	NEWA
>A>	AB		EQ 100MG BASE	A 204882	003	Jun 11, 2018	May	NEWA
>A>	AB	TORRENT PHARMS LTD	EQ 25MG BASE	A 091448	001	Jun 11, 2018	May	NEWA
>A>	AB		EQ 50MG BASE	A 091448	002	Jun 11, 2018	May	NEWA
>A>	AB		EQ 100MG BASE	A 091448	003	Jun 11, 2018	May	NEWA

>D> SIMEPREVIR SODIUM

>D> CAPSULE;ORAL

>D> OLYSIO

>D>	+	JANSSEN PRODS	EQ 150MG BASE	N 205123	001	Nov 22, 2013	May	DISC
>A>	+	@	EQ 150MG BASE	N 205123	001	Nov 22, 2013	May	DISC

SIMVASTATIN

TABLET; ORAL
SIMVASTATIN

>D>	AB	HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	May	DISC
>A>	@		10MG	A206557	001	Nov 13, 2017	May	DISC
>D>	AB		20MG	A206557	002	Nov 13, 2017	May	DISC
>A>	@		20MG	A206557	002	Nov 13, 2017	May	DISC
>D>	AB		40MG	A206557	003	Nov 13, 2017	May	DISC
>A>	@		40MG	A206557	003	Nov 13, 2017	May	DISC
>D>	AB		80MG	A206557	004	Nov 13, 2017	May	DISC
>A>	@		80MG	A206557	004	Nov 13, 2017	May	DISC
	@	YAOPHARMA CO LTD	5MG	A077766	001	Dec 20, 2006	Jan	CAHN
	@		10MG	A077766	002	Dec 20, 2006	Jan	CAHN
	@		20MG	A077766	003	Dec 20, 2006	Jan	CAHN
	@		40MG	A077766	004	Dec 20, 2006	Jan	CAHN
	@		80MG	A077766	005	Dec 20, 2006	Jan	CAHN

SINECATECHINS

OINTMENT; TOPICAL
VEREGEN

+!	FOUGERA PHARMS INC	15%	N021902	001	Oct 31, 2006	Jan	CAHN
----	--------------------	-----	---------	-----	--------------	-----	------

SODIUM BENZOATE; SODIUM PHENYLACETATE

>A>		SOLUTION; INTRAVENOUS						
>A>		AMMONUL						
>A>	AP	+! MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	May	CDFR
>A>		SODIUM PHENYLACETATE AND SODIUM BENZOATE						
>A>	AP	AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	May	CDFR
>A>	AP	MAIA PHARMS INC	10%;10% (5GM/50ML;5GM/50ML)	A208521	001	May 08, 2017	May	CDFR
>A>	AP	NAVINTA LLC	10%;10% (5GM/50ML;5GM/50ML)	A205880	001	Aug 04, 2016	May	CDFR
>D>		SOLUTION; IV (INFUSION)						
>D>		AMMONUL						
>D>	AP	+! MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	May	CDFR
>D>		SODIUM PHENYLACETATE AND SODIUM BENZOATE						
>D>	AP	AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	May	CDFR
>D>	AP	MAIA PHARMS INC	10%;10% (5GM/50ML;5GM/50ML)	A208521	001	May 08, 2017	May	CDFR
>D>	AP	NAVINTA LLC	10%;10% (5GM/50ML;5GM/50ML)	A205880	001	Aug 04, 2016	May	CDFR

SODIUM BICARBONATE

INJECTABLE; INJECTION
SODIUM BICARBONATE

@	HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Mar	DISC
@		0.5MEQ/ML	A202981	001	Mar 04, 2016	Mar	DISC

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ @	ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984	Apr	DISC	
AP	+!	9MG/ML	N019217	001	Jul 13, 1984	Feb	CAHN	
		SOLUTION; IRRIGATION						
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AT	+!	B BRAUN	900MG/100ML	N016733	001		Mar	CRLD

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

AP		SOFIE	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb	CAHN
----	--	-------	--------------	---------	-----	--------------	-----	------

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
SODIUM NITROPRUSSIDE

AP		MYLAN LABS LTD	25MG/ML	A210763	001	Apr 17, 2018	Apr	NEWA
----	--	----------------	---------	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

AA		APNAR PHARMA LP	454GM/BOT	A206815	001	Feb 18, 2016	Mar	CAHN
----	--	-----------------	-----------	---------	-----	--------------	-----	------

>A>	<u>SODIUM ZIRCONIUM CYCLOSILICATE</u>				
>A>	FOR SUSPENSION; ORAL				
>A>	LOKELMA				
>A>	+	ASTRAZENECA PHARMS	5GM/PACKET	N207078 001	May 18, 2018 May NEWA
>A>	+	!	10GM/PACKET	N207078 002	May 18, 2018 May NEWA
 <u>SOMATROPIN</u>					
INJECTABLE; INJECTION					
BIO-TROPIN					
	@	FERRING	4.8MG/VIAL	N019774 001	May 25, 1995 Feb CAHN
ZOMACTON					
BX	+	!	FERRING	5MG/VIAL	N019774 002 Jan 04, 2002 Feb CAHN
	+			10MG/VIAL	N019774 003 Mar 07, 2012 Feb CAHN
 <u>SPIRONOLACTONE</u>					
TABLET; ORAL					
SPIRONOLACTONE					
AB		CASI PHARMS INC	25MG	A086809 001	Mar CAHN
 <u>STERILE WATER FOR IRRIGATION</u>					
LIQUID; IRRIGATION					
STERILE WATER IN PLASTIC CONTAINER					
AT	+	B BRAUN	100%	N016734 001	Mar CRLD
 <u>SUCCINYLCHOLINE CHLORIDE</u>					
INJECTABLE; INJECTION					
SUCCINYLCHOLINE CHLORIDE					
>A>	AP	RENAISSANCE SSA LLC	20MG/ML	A210231 001	Jun 04, 2018 May NEWA
	AP	ZYDUS PHARMS USA INC	20MG/ML	A209467 001	May 04, 2018 Apr NEWA
 <u>SUCRALFATE</u>					
SUSPENSION; ORAL					
CARAFATE					
	+	!	ALLERGAN SALES LLC	1GM/10ML	N019183 001 Dec 16, 1993 Jan CAHN
TABLET; ORAL					
CARAFATE					
AB	+	!	ALLERGAN SALES LLC	1GM	N018333 001 Jan CAHN
 <u>SULFAMETHOXAZOLE; TRIMETHOPRIM</u>					
SUSPENSION; ORAL					
SULFAMETHOXAZOLE AND TRIMETHOPRIM					
>A>	AB	LANNETT CO INC	200MG/5ML; 40MG/5ML	A077785 001	Jan 24, 2007 May CAHN
>D>	AB	VINTAGE	200MG/5ML; 40MG/5ML	A077785 001	Jan 24, 2007 May CAHN
TABLET; ORAL					
SULFAMETHOXAZOLE AND TRIMETHOPRIM					
	@	FOSUN PHARMA	400MG; 80MG	A070889 001	Nov 13, 1986 Jan CAHN
	@		400MG; 80MG	N018598 003	May 19, 1982 Jan CAHN
	@		800MG; 160MG	A070890 001	Nov 13, 1986 Jan CAHN
	@	SUN PHARM INDUSTRIES	400MG; 80MG	A071017 002	Aug 25, 1986 Apr CMS1
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH					
	@	FOSUN PHARMA	800MG; 160MG	N018598 004	May 19, 1982 Jan CAHN
 <u>SULINDAC</u>					
TABLET; ORAL					
SULINDAC					
	@	FOSUN PHARMA	150MG	A072712 001	Aug 30, 1991 Jan CAHN
	@		200MG	A072713 001	Aug 30, 1991 Jan CAHN
 <u>SUMATRIPTAN SUCCINATE</u>					
INJECTABLE; SUBCUTANEOUS					
SUMAVEL DOSEPRO					
	+	@	ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239 002 Nov 26, 2013 Mar DISC
	+	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239 001 Jul 15, 2009 Mar DISC
TABLET; ORAL					
SUMATRIPTAN SUCCINATE					
	@	FOSUN PHARMA	EQ 25MG BASE	A076976 001	Aug 10, 2009 Jan CAHN
	@		EQ 50MG BASE	A076976 002	Aug 10, 2009 Jan CAHN
	@		EQ 100MG BASE	A076976 003	Aug 10, 2009 Jan CAHN

TACROLIMUS

>A> FOR SUSPENSION;ORAL
 >A> PROGRAF
 >A> + ASTELLAS EQ 0.2MG BASE/PACKET N210115 001 May 24, 2018 May NEWA
 >A> +! EQ 1MG BASE/PACKET N210115 002 May 24, 2018 May NEWA
 OINTMENT;TOPICAL
 TACROLIMUS
 AB GLENMARK PHARMS LTD 0.1% A210393 001 Apr 16, 2018 Apr NEWA

TADALAFIL

TABLET;ORAL
 CIALIS
 >D> + LILLY 2.5MG N021368 004 Jan 07, 2008 May CFTG
 >A> AB + 2.5MG N021368 004 Jan 07, 2008 May CFTG
 >D> + 5MG N021368 001 Nov 21, 2003 May CFTG
 >A> AB + 5MG N021368 001 Nov 21, 2003 May CFTG
 >D> + 10MG N021368 002 Nov 21, 2003 May CFTG
 >A> AB + 10MG N021368 002 Nov 21, 2003 May CFTG
 >D> +! 20MG N021368 003 Nov 21, 2003 May CFTG
 >A> AB +! 20MG N021368 003 Nov 21, 2003 May CFTG
 >A> TADALAFIL
 >A> AB TEVA PHARMS USA 2.5MG A090141 001 May 22, 2018 May NEWA
 >A> AB 5MG A090141 002 May 22, 2018 May NEWA
 >A> AB 10MG A090141 003 May 22, 2018 May NEWA
 >A> AB 20MG A090141 004 May 22, 2018 May NEWA

TALC

AEROSOL;INTRAPLEURAL
 SCLEROSOL
 +! LYMOL MEDCL 4GM/SPRAY N020587 001 Dec 24, 1997 Mar CPOT

TAMOXIFEN CITRATE

SOLUTION;ORAL
 SOLTAMOX
 MIDATECH PHARMA US EQ 20MG BASE/10ML N021807 001 Oct 29, 2005 Mar CPOT

TAPENTADOL HYDROCHLORIDE

>D> SOLUTION;ORAL
 >D> NUCYNTA
 >D> +! DEPOMED INC EQ 20MG BASE/ML N203794 001 Oct 15, 2012 May DISC
 >A> + @ EQ 20MG BASE/ML N203794 001 Oct 15, 2012 May DISC

TAZAROTENE

CREAM;TOPICAL
 TAZAROTENE
 >D> AB TARO 0.1% A208258 001 Apr 03, 2017 May CAHN
 >A> AB TARO PHARMS 0.1% A208258 001 Apr 03, 2017 May CAHN

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE;INJECTION
 PULMOLITE
 + @ JUBILANT DRAXIMAGE N/A N017776 001 Feb DISC

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION
 CIS-MDP
 PHARMALUCENCE N/A N018124 001 Jan CTEC
 MDP-BRACCO
 @ CARDINAL HEALTH 414 N/A N018107 001 Jan DISC

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE;INJECTION
 DTPA
 +! JUBILANT DRAXIMAGE N/A N018511 001 Dec 29, 1989 Jan CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC
RADIOGENIX SYSTEM

+ NORTHSTAR MEDICAL 30-1153mCi/GENERATOR N202158 001 Feb 08, 2018 Feb NEWA

TEMOZOLOMIDE

CAPSULE;ORAL
TEMOZOLOMIDE

@ MYLAN PHARMS INC 5MG A205227 001 Jun 29, 2016 Apr DISC
@ 20MG A205227 002 Jun 29, 2016 Apr DISC
@ 100MG A205227 003 Jun 29, 2016 Mar DISC
@ 140MG A205227 004 Jun 29, 2016 Mar DISC
@ 180MG A205227 005 Jun 29, 2016 Mar DISC
@ 250MG A205227 006 Jun 29, 2016 Mar DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE

AB AUROBINDO PHARMA LTD 150MG A090647 001 Jan 26, 2018 Jan NEWA
AB 200MG A090647 002 Jan 26, 2018 Jan NEWA
AB 250MG A090647 003 Jan 26, 2018 Jan NEWA
AB 300MG A090647 004 Jan 26, 2018 Jan NEWA
AB CIPLA LTD 300MG A078800 001 Jan 26, 2018 Jan NEWA
AB HETERO LABS LTD III 300MG A090636 001 Jan 26, 2018 Jan NEWA
AB LAURUS LABS PVT 300MG A209550 001 Feb 26, 2018 Feb NEWA
AB MACLEODS PHARMS LTD 300MG A203232 001 Jan 26, 2018 Jan NEWA
AB STRIDES PHARMA 300MG A090742 001 Jan 26, 2018 Jan NEWA
AB TEVA PHARMS USA 150MG A091612 002 Jan 26, 2018 Jan NEWA
AB 200MG A091612 003 Jan 26, 2018 Jan NEWA
AB 250MG A091612 004 Jan 26, 2018 Jan NEWA

VIREAD
AB + GILEAD SCIENCES INC 150MG N021356 002 Jan 18, 2012 Jan CFTG
AB + 200MG N021356 003 Jan 18, 2012 Jan CFTG
AB + 250MG N021356 004 Jan 18, 2012 Jan CFTG

TERCONAZOLE

CREAM;VAGINAL
TERAZOL 7

+ @ JANSSEN PHARMS 0.4% N019579 001 Dec 31, 1987 Feb DISC
TERCONAZOLE
AB ! TARO 0.4% A076043 001 Jan 19, 2005 Feb CHRS
SUPPOSITORY;VAGINAL
TERAZOL 3
+ @ JANSSEN PHARMS 80MG N019641 001 May 24, 1988 Feb DISC
TERCONAZOLE
AB ! PERRIGO NEW YORK 80MG A077149 001 Mar 17, 2006 Feb CHRS

TESTOSTERONE

GEL;TRANSDERMAL
TESTOSTERONE

@ ANI PHARMS INC 25MG/2.5GM PACKET N202763 001 Feb 14, 2012 Jan DISC
@ 50MG/5GM PACKET N202763 002 Feb 14, 2012 Jan DISC
SOLUTION, METERED;TRANSDERMAL
TESTOSTERONE
AT CIPLA LTD 30MG/1.5ML ACTUATION A209533 001 Jan 29, 2018 Jan NEWA

TETRABENAZINE

TABLET;ORAL
TETRABENAZINE

AB LUPIN LTD 12.5MG A210544 001 Apr 20, 2018 Apr NEWA
AB 25MG A210544 002 Apr 20, 2018 Apr NEWA

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC
TETRACAINE HYDROCHLORIDE

+! ALCON LABS 0.5% N208135 001 Feb 29, 2016 Mar CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
THEOCHRON

AB	NOSTRUM PHARMS LLC	100MG	A 087400	003	Feb 21, 1985	Jan	CTEC
AB		200MG	A 087400	004	Feb 21, 1985	Jan	CTEC

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

@	FOSUN PHARMA	10MG	A 088131	001	Aug 30, 1983	Jan	CAHN
@		15MG	A 088132	001	Aug 30, 1983	Jan	CAHN
@		25MG	A 088133	001	Aug 30, 1983	Jan	CAHN
@		50MG	A 088134	001	Aug 30, 1983	Jan	CAHN
@		100MG	A 088135	001	Nov 20, 1984	Jan	CAHN
@		150MG	A 088136	001	Sep 17, 1986	Jan	CAHN
@		200MG	A 088137	001	Sep 17, 1986	Jan	CAHN

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

AP	DR REDDYS LABS LTD	15MG/VIAL	A 210337	001	May 04, 2018	Apr	NEWA
AP	JIANGSU HENGRUI MED	15MG/VIAL	A 209150	001	May 04, 2018	Apr	NEWA
AP	! WEST-WARD PHARMS INT	15MG/VIAL	A 075547	001	Apr 02, 2001	Apr	CTEC

THIOTHIXENE

CAPSULE;ORAL

NAVANE

+	@ PFIZER	1MG	N 016584	001		Jan	CRLD
+	@	2MG	N 016584	002		Jan	CRLD
+	@	5MG	N 016584	003		Jan	CRLD
+	@	10MG	N 016584	004		Jan	CRLD
+	@	20MG	N 016584	005		Jan	CRLD

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL

TICLOPIDINE HYDROCHLORIDE

@	YAOPHARMA CO LTD	250MG	A 075318	001	Aug 20, 1999	Jan	CAHN
@		250MG	A 075326	001	Aug 20, 1999	Jan	CAHN

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOPTIC

AT	+	ATON	EQ 0.25% BASE	N 018086	001		Jan	CMFD
AT1	+		EQ 0.5% BASE	N 018086	002		Jan	CMFD

TABLET;ORAL

TIMOLOL MALEATE

@	YAOPHARMA CO LTD	5MG	A 072550	001	Apr 13, 1989	Jan	CAHN
@		10MG	A 072551	001	Apr 13, 1989	Jan	CAHN
@		20MG	A 072552	001	Apr 13, 1989	Jan	CAHN

TIZANIDINE HYDROCHLORIDE

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	CASI PHARMS INC	EQ 2MG BASE	A 076280	001	Nov 26, 2002	Mar	CAHN
AB		EQ 4MG BASE	A 076280	002	Jun 27, 2002	Mar	CAHN
AB	ZYDUS PHARMS USA INC	EQ 2MG BASE	A 208187	001	Mar 09, 2018	Feb	NEWA
AB		EQ 4MG BASE	A 208187	002	Mar 09, 2018	Feb	NEWA

TOFACITINIB CITRATE

TABLET;ORAL

XELJANZ

>A>	+	! PF PRISM CV	EQ 10MG BASE	N 203214	002	May 30, 2018	May	NEWA
-----	---	---------------	--------------	----------	-----	--------------	-----	------

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

@	YAOPHARMA CO LTD	100MG	A 071633	001	Dec 09, 1987	Jan	CAHN
@		250MG	A 070289	001	Mar 13, 1986	Jan	CAHN
@		500MG	A 070290	001	Mar 13, 1986	Jan	CAHN

TOLBUTAMIDE

TABLET;ORAL
 TOLBUTAMIDE
 @ YAOPHARMA CO LTD 500MG A 086574 001 Jan CAHN

TOLMETIN SODIUM

CAPSULE;ORAL
 TOLMETIN SODIUM
 @ FOSUN PHARMA EQ 400MG BASE A 073462 001 Apr 30, 1992 Jan CAHN
 TABLET;ORAL
 TOLMETIN SODIUM
 @ FOSUN PHARMA EQ 200MG BASE A 073588 001 Jul 31, 1992 Jan CAHN
 @ EQ 600MG BASE A 074002 001 Sep 27, 1993 Jan CAHN

TOLTERODINE TARTRATE

TABLET;ORAL
 TOLTERODINE TARTRATE
 @ APOTEX CORP 1MG A 200164 001 Sep 25, 2012 Mar DISC
 @ 2MG A 200164 002 Sep 25, 2012 Mar DISC

TOLVAPTAN

TABLET;ORAL
 JYNARQUE
 + OTSUKA PHARM CO LTD 15MG N 204441 001 Apr 23, 2018 Apr NEWA
 + 30MG N 204441 002 Apr 23, 2018 Apr NEWA
 + 45MG N 204441 003 Apr 23, 2018 Apr NEWA
 + 60MG N 204441 004 Apr 23, 2018 Apr NEWA
 +! 90MG N 204441 005 Apr 23, 2018 Apr NEWA

TOPIRAMATE

CAPSULE;ORAL
 TOPIRAMATE
 @ FOSUN PHARMA 15MG A 079206 001 Oct 14, 2009 Jan CAHN
 @ 25MG A 079206 002 Oct 14, 2009 Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL
 TRAMADOL HYDROCHLORIDE
 @ FOSUN PHARMA 50MG A 075968 001 Jun 25, 2002 Jan CAHN

TRANDOLAPRIL

TABLET;ORAL
 MAVIK
 + @ ABBVIE 1MG N 020528 001 Apr 26, 1996 Mar DISC
 + @ 2MG N 020528 002 Apr 26, 1996 Mar DISC
 + @ 4MG N 020528 003 Apr 26, 1996 Mar DISC
 TRANDOLAPRIL
 AB ! LUPIN 4MG A 077522 003 Jun 12, 2007 Mar CHRS
 >D> AB WATSON LABS 1MG A 077805 001 Jun 12, 2007 May DISC
 >A> @ 1MG A 077805 001 Jun 12, 2007 May DISC
 >D> AB 2MG A 077805 002 Jun 12, 2007 May DISC
 >A> @ 2MG A 077805 002 Jun 12, 2007 May DISC
 >D> AB 4MG A 077805 003 Jun 12, 2007 May DISC
 >A> @ 4MG A 077805 003 Jun 12, 2007 May DISC

TRANEXAMIC ACID

INJECTABLE;INJECTION
 TRANEXAMIC ACID
 >D> AP ACIC FINE CHEMS 100MG/ML A 202436 001 Feb 11, 2014 May CAHN
 >A> AP ACIC PHARMS 100MG/ML A 202436 001 Feb 11, 2014 May CAHN

TRANLYCPROMINE SULFATE

TABLET;ORAL
 TRANLYCPROMINE SULFATE
 AB KINEDEXE UK EQ 10MG BASE A 206856 001 Apr 17, 2018 Apr NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

@ FOSUN PHARMA 100MG A072483 001 Apr 30, 1990 Jan CAHN

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

>A> AT LANNETT CO INC 0.025% A040671 001 Jun 09, 2006 May CAHN
 >A> AT 0.1% A040671 002 Jun 09, 2006 May CAHN
 >A> AT MACLEODS PHARMS LTD 0.025% A209535 001 May 18, 2018 May NEWA
 >A> AT 0.1% A209535 002 May 18, 2018 May NEWA
 >A> AT 0.5% A209535 003 May 18, 2018 May NEWA
 AT PERRIGO NEW YORK 0.025% A086413 002 Mar CMS1
 AT 0.1% A086413 003 Mar CMS1
 >D> AT TARO 0.1% A040039 001 Nov 26, 1997 May CAHN
 >A> AT TARO PHARM INDS LTD 0.1% A040039 001 Nov 26, 1997 May CAHN
 >D> AT VINTAGE 0.025% A040671 001 Jun 09, 2006 May CAHN
 >D> AT 0.1% A040671 002 Jun 09, 2006 May CAHN

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

>A> AT LANNETT CO INC 0.1% A040672 002 Dec 13, 2006 May CAHN
 >D> AT VINTAGE 0.1% A040672 002 Dec 13, 2006 May CAHN

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

>D> AT TARO 0.1% A040037 001 Sep 30, 1994 May CAHN
 >A> AT TARO PHARM INDS LTD 0.1% A040037 001 Sep 30, 1994 May CAHN

SPRAY;TOPICAL

KENALOG

AT +! SUN PHARM INDS INC 0.147MG/GM N012104 001 Feb CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

SYPRINE

AB +! ATON 250MG N019194 001 Nov 08, 1985 Jan CFTG
 AB TRIENTINE HYDROCHLORIDE 250MG A207567 001 Feb 07, 2018 Jan NEWA
 AB WATSON LABS TEVA 250MG

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

@ FOSUN PHARMA EQ 10MG BASE/ML A085787 001 Apr 15, 1982 Jan CAHN

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

TROPICAMIDE

AT BAUSCH AND LOMB 0.5% A040067 001 Jul 27, 1994 Apr CAHN

URSODIOL

CAPSULE;ORAL

URSODIOL

>A> AB ABHAI LLC 300MG A210707 001 May 17, 2018 May NEWA
 TABLET;ORAL
 URSO 250
 AB + ALLERGAN SALES LLC 250MG N020675 001 Dec 10, 1997 Apr CAHN
 URSO FORTE
 AB +! ALLERGAN SALES LLC 500MG N020675 002 Jul 21, 2004 Apr CAHN

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

>A> AA LANNETT CO INC 250MG/5ML A077960 001 Oct 13, 2006 May CAHN
 >D> AA VINTAGE 250MG/5ML A077960 001 Oct 13, 2006 May CAHN

VALSARTAN

TABLET;ORAL

VALSARTAN

AB SQUARE PHARMS LTD 40MG A205347 001 Apr 09, 2018 Mar NEWA
 AB 80MG A205347 002 Apr 09, 2018 Mar NEWA
 AB 160MG A205347 003 Apr 09, 2018 Mar NEWA

TABLET;ORAL
VALSARTAN

AB		320MG	A205347	004	Apr 09, 2018	Mar	NEWA
AB	UNICHEM LABS LTD	40MG	A209261	001	May 04, 2018	Apr	NEWA
AB		80MG	A209261	002	May 04, 2018	Apr	NEWA
AB		160MG	A209261	003	May 04, 2018	Apr	NEWA
AB		320MG	A209261	004	May 04, 2018	Apr	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

@	FRESENIUS KABI USA	EQ 125MG BASE	A065453	001	Jun 18, 2012	Feb	DISC
@		EQ 250MG BASE	A065453	002	Jun 18, 2012	Feb	DISC

FOR SOLUTION;ORAL

FIRVANQ KIT

+!	RXMTM THERAPS LLC	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Jan	NEWA
+!		EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Jan	NEWA

INJECTABLE;INJECTION

VANCOVIN HYDROCHLORIDE IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Apr	NEWA
@	MYLAN LABS LTD	EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011	Mar	DISC

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

LEVITRA

+	@ BAYER HLTHCARE	2.5MG	N021400	003	Aug 19, 2003	Apr	DISC
---	------------------	-------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING;ORAL

STAXYN

+	@ BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr	DISC
---	------------------	------	---------	-----	--------------	-----	------

VARENICLINE TARTRATE

TABLET;ORAL

CHANTIX

+	PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Feb	CAHN
+!		EQ 1MG BASE	N021928	002	May 10, 2006	Feb	CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

@	FOSUN PHARMA	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan	CAHN
@		EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan	CAHN
@		EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan	CAHN
@		EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan	CAHN
@		EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan	CAHN

VERAPAMIL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

>A>	AP	EXELA PHARMA SCS LLC	10MG/4ML (2.5MG/ML)	N018925	002	Apr 05, 2018	May	NEWA
AP	!	HOSPIRA	5MG/2ML (2.5MG/ML)	A070738	001	May 06, 1987	Jan	CPOT

TABLET;ORAL

ISOPTIN

+	@ MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr	CRLD
+	@	80MG	N018593	001	Mar 08, 1982	Apr	CRLD
+	@	120MG	N018593	002	Mar 08, 1982	Apr	CRLD

VERAPAMIL HYDROCHLORIDE

@	YAOPHARMA CO LTD	40MG	A073168	001	Jul 31, 1992	Jan	CAHN
@		80MG	A071423	001	May 24, 1988	Jan	CAHN
@		120MG	A071424	001	May 25, 1988	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

@	APOTEX CORP	120MG	A200878	001	Apr 20, 2012	Mar	DISC
@		180MG	A200878	002	Apr 20, 2012	Mar	DISC
@		240MG	A200878	003	Apr 20, 2012	Mar	DISC

VIGABATRINFOR SOLUTION;ORAL
VIGABATRIN

AA	AMNEAL PHARMS	500MG/PACKET	A210155	001	Mar 13, 2018	Feb	NEWA
AA	TEVA PHARMS USA	500MG/PACKET	A209824	001	Apr 23, 2018	Apr	NEWA

VILAZODONE HYDROCHLORIDETABLET;ORAL
VIIBRYD

+	!	ALLERGAN SALES LLC	10MG	N022567	001	Jan 21, 2011	Jan	CAHN
+			20MG	N022567	002	Jan 21, 2011	Jan	CAHN
+			40MG	N022567	003	Jan 21, 2011	Jan	CAHN

VINBLASTINE SULFATEINJECTABLE;INJECTION
VELBAN

+	@	LILLY	10MG/VIAL	N012665	001		Apr	CRLD
---	---	-------	-----------	---------	-----	--	-----	------

WARFARIN SODIUMTABLET;ORAL
WARFARIN SODIUM

@	YAOPHARMA CO LTD	1MG	A040196	001	Sep 30, 1997	Jan	CAHN
@		2MG	A040196	002	Sep 30, 1997	Jan	CAHN
@		2.5MG	A040196	003	Sep 30, 1997	Jan	CAHN
@		3MG	A040196	008	Jul 26, 2000	Jan	CAHN
@		4MG	A040196	004	Sep 30, 1997	Jan	CAHN
@		5MG	A040196	005	Sep 30, 1997	Jan	CAHN
@		6MG	A040196	009	Jul 26, 2000	Jan	CAHN
@		7.5MG	A040196	006	Sep 30, 1997	Jan	CAHN
@		10MG	A040196	007	Sep 30, 1997	Jan	CAHN

ZIPRASIDONE HYDROCHLORIDECAPSULE;ORAL
ZIPRASIDONE HYDROCHLORIDE

@	MYLAN PHARMS INC	EQ 20MG BASE	A202395	001	Oct 10, 2013	Mar	DISC
@		EQ 40MG BASE	A202395	002	Oct 10, 2013	Mar	DISC
@		EQ 60MG BASE	A202395	003	Oct 10, 2013	Mar	DISC

ZOLEDRONIC ACIDINJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Jan	CAHN
AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Jan	CAHN

ZOLMITRIPTANTABLET;ORAL
ZOLMITRIPTAN

@	APOTEX INC	2.5MG	A202078	001	May 14, 2013	Mar	DISC
@		5MG	A202078	002	May 14, 2013	Mar	DISC

TABLET, ORALLY DISINTEGRATING;ORAL
ZOLMITRIPTAN

@	APOTEX INC	2.5MG	A202476	001	May 14, 2013	Mar	DISC
@		5MG	A202476	002	May 14, 2013	Mar	DISC

ZOLPIDEM TARTRATETABLET;ORAL
ZOLPIDEM TARTRATE

@	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr	DISC
@		10MG	A078055	002	Apr 23, 2007	Apr	DISC

ZONISAMIDECAPSULE;ORAL
ZONISAMIDE

@	AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006	Feb	CAHN
@		50MG	A077645	003	Sep 29, 2006	Feb	CAHN
@		100MG	A077645	001	Dec 22, 2005	Feb	CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ G AND W LABS

325MG

N018060 003 Dec 18, 1986

Jan DISC

@

650MG

N018060 002

Jan DISC

ACETAMINOPHEN

>A>	+	TARO PHARM INDS LTD	120MG	N018337	003	Sep 12, 1983	May	CAHN
>A>	+		325MG	N018337	002		May	CAHN
>A>	+		650MG	N018337	001		May	CAHN
>D>	+	TARO PHARMS NORTH	120MG	N018337	003	Sep 12, 1983	May	CAHN
>D>	+		325MG	N018337	002		May	CAHN
>D>	+		650MG	N018337	001		May	CAHN

INFANTS' FEVERALL

>A>	+	TARO PHARM INDS LTD	80MG	N018337	004	Aug 26, 1992	May	CAHN
>D>	+	TARO PHARMS NORTH	80MG	N018337	004	Aug 26, 1992	May	CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

>A>		HERITAGE PHARMA	650MG	A207035	001	May 31, 2018	May	NEWA
-----	--	-----------------	-------	---------	-----	--------------	-----	------

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL

GAVISCON

>D>	+	SANOFI AVENTIS US	160MG;40MG	N018685	002	Dec 09, 1983	May	DISC
>A>	+	@	160MG;40MG	N018685	002	Dec 09, 1983	May	DISC

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

BUTENAFINE HYDROCHLORIDE

>D>		TARO	1%	A205181	001	Nov 16, 2017	May	CAHN
>A>		TARO PHARMS	1%	A205181	001	Nov 16, 2017	May	CAHN

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

PLD ACQUISITIONS

5MG

A077946 001 Dec 27, 2007

Feb CAHN

10MG

A077946 002 Dec 27, 2007

Feb CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

PLD ACQUISITIONS

5MG;120MG

A077991 001 Mar 05, 2008

Feb CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+	!	BECTON DICKINSON CO	2%;70% (1ML)	N020832	008	Oct 23, 2008	Feb	NEWA
---	---	---------------------	--------------	---------	-----	--------------	-----	------

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

PLD ACQUISITIONS LLC

1.34MG

A073458 001 Oct 31, 1993

Jan CAHN

CLOTTRIMAZOLE

CREAM;VAGINAL

MYCELEX-7

@ BAYER HEALTHCARE LLC

1%

N018230 002 Dec 26, 1991

Mar DISC

CREAM, TABLET;TOPICAL, VAGINAL

MYCELEX-7 COMBINATION PACK

@ BAYER HEALTHCARE LLC

1%,100MG

N020389 002 Jun 23, 1994

Feb DISC

TABLET;VAGINAL

MYCELEX-7

@ BAYER HEALTHCARE LLC

100MG

N018182 002 Dec 26, 1991

Mar DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

PERRIGO R AND D

30MG;600MG

A207602 002 Mar 05, 2018

Apr NEWA

60MG;1.2GM

A207602 001 Mar 05, 2018

Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM

DR REDDYS LABS LTD EQ 20MG BASE A207673 001 May 15, 2018 Apr NEWA

IBUPROFEN

CAPSULE;ORAL
IBUPROFEN

STRIDES PHARMA EQ 200MG FREE ACID AND POTASSIUM A204469 001 Mar 28, 2018 Mar NEWA
SALT

SUSPENSION;ORAL
IBUPROFEN

AUROBINDO PHARMA LTD 100MG/5ML A209179 001 Apr 17, 2018 Apr NEWA

TABLET;ORAL
IBUPROFEN

@ P AND L DEV LLC 200MG A070733 001 Sep 19, 1986 Jan CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE
DR REDDYS LABS LTD 5MG

A210375 001 Jan 19, 2018 Jan NEWA

LORATADINE

TABLET;ORAL
LORATADINE

AUROBINDO PHARMA LTD 10MG A208314 001 Apr 16, 2018 Apr NEWA
PLD ACQUISITIONS LLC 10MG A075209 001 Jan 21, 2003 Jan CAHN

TABLET, CHEWABLE;ORAL
LORATADINE

SUN PHARMA GLOBAL 5MG A210088 001 Apr 16, 2018 Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
LORATADINE

AUROBINDO PHARMA LTD 10MG A208477 001 Apr 11, 2018 Mar NEWA

MICONAZOLE NITRATE

CREAM;VAGINAL
MICONAZOLE NITRATE

>D> TARO 2% A074444 001 Jan 13, 1997 May CAHN
>A> TARO PHARMS 2% A074444 001 Jan 13, 1997 May CAHN

CREAM, SUPPOSITORY;TOPICAL, VAGINAL
MICONAZOLE 7 COMBINATION PACK

@ G AND W LABS 2%,100MG A076585 001 Mar 26, 2004 Jan DISC

NAPROXEN SODIUM

TABLET;ORAL
NAPROXEN SODIUM

@ PLD ACQUISITIONS LLC EQ 200MG BASE A074646 001 Jan 13, 1997 Jan CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL
THRIVE

@ GLAXOSMITHKLINE CONS EQ 2MG BASE A077658 001 Jun 19, 2007 Mar DISC
EQ 2MG BASE A077658 001 Jun 19, 2007 Feb CAHN
EQ 4MG BASE A077656 001 Jun 19, 2007 Feb CAHN

TROCHE/LOZENGE;ORAL
NICORETTE

+ GLAXOSMITHKLINE CONS EQ 2MG BASE N021330 001 Oct 31, 2002 Feb CTNA
+! EQ 4MG BASE N021330 002 Oct 31, 2002 Feb CTNA

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM

>A> AUROBINDO PHARMA LTD EQ 20MG BASE A206877 001 Jun 06, 2018 May NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE
ZYDUS PHARMS USA INC 20MG;1.1GM

A203345 001 Mar 16, 2018 Mar NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

APNAR PHARMA LP	17GM/SCOOPFUL
AUROBINDO PHARMA LTD	17GM/SCOOPFUL

A202071	001	Dec 28, 2012	Mar CAHN
A209017	001	Apr 09, 2018	Mar NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

VIVIMED GLOBAL	EQ 75MG BASE
	EQ 150MG BASE

A209160	001	Mar 05, 2018	Feb NEWA
A209161	001	Feb 22, 2018	Feb NEWA

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1%

N021958	001	Jul 24, 2006	Feb CAHN
---------	-----	--------------	----------

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1%

N021124	001	Mar 17, 2000	Feb CAHN
---------	-----	--------------	----------

SPRAY;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1%

N021124	002	Mar 17, 2000	Feb CAHN
---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 5 MAY 2018

NO MAY 2018 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2018 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Dec 15, 2029	DS DP U-1981		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001	8822438	Aug 24, 2027	U-1579		I-765	Feb 07, 2021
	8822438	Aug 24, 2027	U-1580			
	8822438	Aug 24, 2027	U-2235			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027	U-1579		I-765	Feb 07, 2021
	8822438	Aug 24, 2027	U-1580			
	8822438	Aug 24, 2027	U-2235			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	7459554	Nov 24, 2026	DS		>A> ODE-175	Oct 31, 2024
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	9399012	Sep 11, 2031	U-2261			
	9399012	Sep 11, 2031	U-2262			
	9399012*PED	Mar 11, 2032				
	9610265	Nov 13, 2028	U-2263			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 001	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	RE46417	Feb 10, 2025	DS DP U-1263			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 001					I-763	Jan 12, 2021
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 002					I-763	Jan 12, 2021
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 003					I-763	Jan 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	9861771	Oct 11, 2020	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001 >A>	9956205	Dec 28, 2031	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002 >A>	9956205	Dec 28, 2031	U-2104			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	9867791	Dec 02, 2030	U-2106		I-769	Aug 24, 2020
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	9867791	Dec 02, 2030	U-2106		I-769	Aug 24, 2020
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001					I-766	Mar 09, 2021
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001					>A> NC	May 31, 2021
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002					>A> NC	May 31, 2021
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003					>A> NC	May 31, 2021
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	9220745	Dec 18, 2034	U-2217		NCE	Dec 21, 2022
	9220745	Dec 18, 2034	U-2218			
	9572856	Sep 20, 2030	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	9220745	Dec 18, 2034	U-2217		NCE	Dec 21, 2022
	9220745	Dec 18, 2034	U-2218			
	9572856	Sep 20, 2030	U-2221			
	9867863	Dec 16, 2029	U-2231			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	8445507	Sep 15, 2030	DS DP U-2237		NCE	Feb 14, 2023
	8802689	Mar 27, 2027	U-2237			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9884054	Sep 23, 2033	U-2237			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	7427638	Feb 16, 2028	DS DP			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	7427638	Feb 16, 2028	DS DP			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	7427638	Feb 16, 2028	DS DP			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	9941931	Nov 04, 2030	DP			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	6723351	Nov 10, 2018	U-2204		ODE-167	Jan 12, 2025
	6723351	Nov 10, 2018	U-2229			
	6723351	Nov 10, 2018	U-573			
	6855339	Nov 10, 2018	U-2204			
	6855339	Nov 10, 2018	U-2229			
	6855339	Nov 10, 2018	U-617			
	6861076	Nov 10, 2018	U-2204			
	6861076	Nov 10, 2018	U-2229			
	6861076	Nov 10, 2018	U-617			
	6884439	Nov 10, 2018	U-2204			
	6884439	Nov 10, 2018	U-2229			
	6884439	Nov 10, 2018	U-651			
	6982096	Nov 10, 2018	U-2204			
	6982096	Nov 10, 2018	U-2229			
	6982096	Nov 10, 2018	U-651			
	8273379	Nov 10, 2018	U-1291			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002	6723351	Nov 10, 2018	U-2204		ODE-167	Jan 12, 2025
	6723351	Nov 10, 2018	U-2229			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002	6855339	Nov 10, 2018	U-2204			
	6855339	Nov 10, 2018	U-2229			
	6861076	Nov 10, 2018	U-2204			
	6861076	Nov 10, 2018	U-2229			
	6884439	Nov 10, 2018	U-2204			
	6884439	Nov 10, 2018	U-2229			
	6982096	Nov 10, 2018	U-2204			
	6982096	Nov 10, 2018	U-2229			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	>A> 8999313	Sep 10, 2033	DP		>A> NP	May 04, 2021
	>A> 9326969	Sep 10, 2033	U-2310			
	>A> 9592252	Aug 11, 2032	DP U-2310			
	>A> 9707297	Sep 10, 2033	DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001					M-158 NPP PED PED	Mar 12, 2018 Mar 12, 2018 Sep 12, 2018 Sep 12, 2018
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002					M-158 NPP PED PED	Mar 12, 2018 Mar 12, 2018 Sep 12, 2018 Sep 12, 2018
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001					>A> NCE	May 21, 2023
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-2244			
	7112592	Feb 24, 2022	DS DP U-282			
	8178554	Jul 24, 2021	DS DP U-2245			
	8178554	Jul 24, 2021	DS DP U-282			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9211259	Feb 28, 2029	U-1796			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 002	9919050	Nov 22, 2025	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	9901585	Jun 13, 2023	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001					>A> NCE	May 31, 2023
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2019	DS DP U-594			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	8791270	Jan 12, 2026	DP U-1790			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9877974	Aug 31, 2030	DP U-1858			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	6642245	Nov 04, 2020	U-257		NCE	Feb 07, 2023
	6703396	Mar 09, 2021	DS DP			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9216996	Dec 19, 2033	DS DP			
	9296769	Aug 15, 2032	DS DP U-257			
	9708342	Jun 19, 2035	DS DP			
	9732092	Dec 19, 2033	DS DP			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001					ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002					ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003					ODE-163	Dec 19, 2024
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	>A> 9687443	Jul 10, 2021	DP			
	>A> 9687443*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	9861631	Mar 25, 2031	U-1428			
	9861632	Mar 25, 2031	U-1428			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	8293742	Jul 14, 2030	U-2222			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	9907801	Apr 19, 2022	DP U-2239			
	9907802	Apr 19, 2022	DP U-2240			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	>A> 6784197	Feb 21, 2021	DS DP U-2295			
	>A> 6911461	Feb 21, 2021	DS DP U-2295			
	>A> 8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	>A> 6784197	Feb 21, 2021	DS DP U-2295			
	>A> 6911461	Feb 21, 2021	DS DP U-2295			
	>A> 8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	>A> 6784197	Feb 21, 2021	DS DP U-2295			
	>A> 6911461	Feb 21, 2021	DS DP U-2295			
	>A> 8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	>A> 6784197	Feb 21, 2021	DS DP U-2295			
	>A> 6911461	Feb 21, 2021	DS DP U-2295			
	>A> 8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	>A> 6784197	Feb 21, 2021	DS DP U-2295			
	>A> 6911461	Feb 21, 2021	DS DP U-2295			
	>A> 8492416	Feb 21, 2021	U-2295			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	>A> 6784197	Feb 21, 2021	DS DP U-2295			
	>A> 6911461	Feb 21, 2021	DS DP U-2295			
	>A> 8492416	Feb 21, 2021	U-2295			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9895422	Jun 07, 2030	U-2114			
	9895422	Jun 07, 2030	U-2116			
	9895422	Jun 07, 2030	U-2281			
	9895422	Jun 07, 2030	U-2282			
	9895422	Jun 07, 2030	U-2283			
	9895422	Jun 07, 2030	U-2284			
	9895422	Jun 07, 2030	U-2285			
	9895422	Jun 07, 2030	U-2286			
	9895422	Jun 07, 2030	U-2287			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001					I-771	Apr 06, 2021
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002					I-771	Apr 06, 2021
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001					NP	Nov 30, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002					NP	Nov 30, 2020
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	9931305	Feb 14, 2022	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	9931305	Feb 14, 2022	DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	>A> 8426391	Aug 27, 2028	U-1872			
	9861644	Mar 14, 2034	DP			
	>A> 9925147	Apr 25, 2028	DP U-2255			
	>A> 9925147	Apr 25, 2028	DP U-2256			
	>A> 9925147	Apr 25, 2028	DP U-2257			
	>A> 9925147	Apr 25, 2028	DP U-2258			
	>A> 9925147	Apr 25, 2028	DP U-2259			
	9943530	Feb 02, 2027	U-2274			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	>A> 8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	>A> 8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	>A> 8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	>A> 8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	>A> 8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	>A> 8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	>A> 8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	>A> 8222219	Apr 11, 2025	U-493			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	6114313	Dec 11, 2018	DP U-1715			
	6130208	Jun 29, 2019	DP U-1715			
	9925265	May 13, 2029	U-2260			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9872906	Mar 14, 2034	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWAB</u>						
N 021524 001					M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWABSTICK</u>						
N 021524 002					M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524 003					M-221	Feb 14, 2021
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9603796	Apr 21, 2029	DS DP U-2252		I-770	Mar 02, 2021
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	>A> 9956231	Aug 31, 2030	DP U-1408			
	>A> 9956231	Aug 31, 2030	DP U-1761			
	>A> 9956231	Aug 31, 2030	DP U-1858			
	>A> 9956231	Aug 31, 2030	DP U-193			
	>A> 9956231	Aug 31, 2030	DP U-742			
	>A> 9956231	Aug 31, 2030	DP U-88			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	9889115	Jun 23, 2019	U-1660			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	9891239	Sep 03, 2029	DP U-257			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	9891239	Sep 03, 2029	DP U-257			
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	9867815	Feb 07, 2037	U-2225		NCE	Dec 14, 2022
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9925156	Jan 26, 2027	DS DP U-1399		ODE-162	Dec 22, 2024
	9925157	Jan 26, 2027	DS DP U-1399			
	9925158	Jan 26, 2027	DS DP U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9925156	Jan 26, 2027	DS DP U-1399		ODE-162	Dec 22, 2024
	9925157	Jan 26, 2027	DS DP U-1399			
	9925158	Jan 26, 2027	DS DP U-1399			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	9925174	Jun 14, 2023	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	9925174	Jun 14, 2023	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	9925174	Jun 14, 2023	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	>A> 7994185	Jan 20, 2030	DS DP U-1406		I-778	Apr 30, 2021
	>A> 7994185	Jan 20, 2030	DS DP U-2031		>A> I-781	May 04, 2021
	>A> 7994185	Jan 20, 2030	DS DP U-2032			
	>A> 7994185	Jan 20, 2030	DS DP U-2296			
	>A> 8415345	Jan 20, 2030	DS DP U-1406			
	>A> 8415345	Jan 20, 2030	DS DP U-2031			
	>A> 8415345	Jan 20, 2030	DS DP U-2032			
	>A> 8415345	Jan 20, 2030	DS DP U-2296			
	>A> 8703781	Oct 15, 2030	DS DP U-1713			
	>A> 8703781	Oct 15, 2030	DS DP U-2032			
	>A> 8703781	Oct 15, 2030	DS DP U-2296			
	>A> 8703781	Oct 15, 2030	DS DP U-2297			
	>A> 8703781	Oct 15, 2030	DS DP U-2298			
	>A> 8835443	Jun 10, 2025	U-2026			
	>A> 8835443	Jun 10, 2025	U-2027			
	>A> 8835443	Jun 10, 2025	U-2296			
	>A> 8835443	Jun 10, 2025	U-2298			
	>A> 9233956	May 04, 2029	U-1811			
	>A> 9233956	May 04, 2029	U-2031			
	>A> 9233956	May 04, 2029	U-2032			
	>A> 9233956	May 04, 2029	U-2296			
	>A> 9233956	May 04, 2029	U-2297			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	>A> 7994185	Jan 20, 2030	DS DP U-1406		I-778	Apr 30, 2021
	>A> 7994185	Jan 20, 2030	DS DP U-2031		>A> I-781	May 04, 2021
	>A> 7994185	Jan 20, 2030	DS DP U-2032			
	>A> 7994185	Jan 20, 2030	DS DP U-2296			
	>A> 8415345	Jan 20, 2030	DS DP U-1406			
	>A> 8415345	Jan 20, 2030	DS DP U-2031			
	>A> 8415345	Jan 20, 2030	DS DP U-2032			
	>A> 8415345	Jan 20, 2030	DS DP U-2296			
	>A> 8703781	Oct 15, 2030	DS DP U-1713			
	>A> 8703781	Oct 15, 2030	DS DP U-2032			
	>A> 8703781	Oct 15, 2030	DS DP U-2296			
	>A> 8703781	Oct 15, 2030	DS DP U-2297			
	>A> 8703781	Oct 15, 2030	DS DP U-2298			
	>A> 8835443	Jun 10, 2025	U-2026			
	>A> 8835443	Jun 10, 2025	U-2027			
	>A> 8835443	Jun 10, 2025	U-2296			
	>A> 8835443	Jun 10, 2025	U-2298			
	>A> 9233956	May 04, 2029	U-1811			
	>A> 9233956	May 04, 2029	U-2031			
	>A> 9233956	May 04, 2029	U-2032			
	>A> 9233956	May 04, 2029	U-2296			
	>A> 9233956	May 04, 2029	U-2297			
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	9918973	Dec 13, 2024	U-1030			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	9884044	Jun 13, 2022	DP U-1546			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	9889115	Jun 23, 2019	U-1305			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 006					ODE-164	Nov 09, 2024
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	>A> 9949986	Feb 21, 2028	U-1940			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001					M-222	Feb 06, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002					M-222	Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003					M-222	Feb 06, 2021
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	6960346	Jul 03, 2023	DP		NP	Feb 09, 2021
	7560120	Sep 05, 2022	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Apr 01, 2019	DP			
	7320999	Oct 20, 2019		U-1384		
	7619001	Apr 01, 2019		U-1384		
	7803840	Apr 01, 2019		U-1385		
	8399514	Feb 07, 2028		U-1384		
	8759393	Jul 04, 2018	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Apr 01, 2019	DP			
	7320999	Oct 20, 2019		U-1384		
	7619001	Apr 01, 2019		U-1384		
	7803840	Apr 01, 2019		U-1385		
	8399514	Feb 07, 2028		U-1384		
	8759393	Jul 04, 2018	DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9861607	May 18, 2027		U-620		
	9907780	Apr 11, 2028	DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9861607	May 18, 2027		U-620		
	9907780	Apr 11, 2028	DP			
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661 001	9937132	Feb 18, 2033	DP	U-1382		
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 001					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 002					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 003					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 091471 001					PC	Feb 14, 2018
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9877955	Jan 03, 2028		U-1969		
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	6916802	Apr 29, 2022	DS	U-1571		
	7253185	Apr 29, 2022	DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	9949997	May 17, 2034		U-2292		
	9949998	Jun 11, 2034		U-2290		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	9949997	May 17, 2034	U-2292			
	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	9949998	Jun 11, 2034	U-2290			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	>A> 9968553	Nov 06, 2032	U-1723			
	>A> 9968553	Nov 06, 2032	U-185			
	>A> 9968553	Nov 06, 2032	U-1892			
	>A> 9968553	Nov 06, 2032	U-3			
	>A> 9968553	Nov 06, 2032	U-71			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 001	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 003	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 004	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 207920 001	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001					>A> NP	May 29, 2021
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002					>A> NP	May 29, 2021
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	8778962	Feb 18, 2022	U-1541		I-773	Apr 10, 2021
	8778962	Feb 18, 2022	U-2280		ODE-169	Apr 10, 2025
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	8778962	Feb 18, 2022	U-1541		I-773	Apr 10, 2021
	8778962	Feb 18, 2022	U-2280		ODE-169	Apr 10, 2025
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	8778962	Feb 18, 2022	U-1541		I-773	Apr 10, 2021
	8778962	Feb 18, 2022	U-2280		ODE-169	Apr 10, 2025
	8778962*PED	Aug 18, 2022				
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6872700	Jan 14, 2020	U-2288		M-224	Apr 02, 2021
	6872700	Jan 14, 2020	U-654			
	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6872700	Jan 14, 2020	U-2288		M-224	Apr 02, 2021
	6872700	Jan 14, 2020	U-654			
	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9814705	Jan 08, 2024	DP			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001					I-767	Feb 02, 2021
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	5604229	Feb 18, 2019	DS U-1086		>A> NPP	May 11, 2021
	5604229*PED	Aug 18, 2019			>A> PED	Nov 11, 2021
	8324283	Mar 29, 2026	DP			
	8324283*PED	Sep 29, 2026				
	9187405	Jun 25, 2027	U-1086			
	9187405*PED	Dec 25, 2027				
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 002					>A> NS >A> PED	May 11, 2021 Nov 11, 2021
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	8534281	Mar 08, 2030	DP		>A> NPP	May 17, 2021
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	8534281	Mar 08, 2030	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 003					>A> NS	May 17, 2021
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	8534281	Mar 08, 2030	DP		I-775	Apr 24, 2021
	9750726	Nov 29, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	8534281	Mar 08, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	8534281	Mar 08, 2030	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 002	9861771	Oct 11, 2020	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	9861771	Oct 11, 2020	DP			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	9730890	Jun 22, 2021	DP			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001	5691336	Mar 04, 2019	DS DP		NPP	Apr 03, 2021
	5691336*PED	Sep 04, 2019			PED	Oct 03, 2021
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002	5691336	Mar 04, 2019	DS DP U-2265		NPP	Apr 03, 2021
	5691336*PED	Sep 04, 2019			PED	Oct 03, 2021
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	>A> 8426450	May 23, 2032	DS DP		>A> NCE	Apr 19, 2023
	>A> 8895586	May 23, 2032		U-2301		
	>A> 9186357	Nov 18, 2030		U-2301		
	>A> 9403772	May 23, 2032	DS	U-2301		
	>A> 9908907	May 23, 2032	DS DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001	>A> 7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	>A> 7538108	Mar 28, 2026	DS	U-2294	ODE-174	Apr 17, 2025
	>A> 7989448	Jun 12, 2026	DS	U-2294		
	>A> 8163902	Jun 17, 2026	DS	U-2294		
	>A> 8211889	Jan 19, 2026	DS			
	>A> 8263122	Nov 24, 2030	DP			
	>A> 8445485	Jun 17, 2026	DP			
	>A> 8652492	Nov 06, 2028	DP			
	>A> 8771648	Jul 27, 2032	DP			
	>A> 8912170	Jun 17, 2026		U-2294		
	>A> 8951504	Jul 27, 2032		U-2294		
	>A> 9266912	Jan 19, 2026		U-2294		
	>A> 9283238	Jun 17, 2026		U-2294		
	>A> 9737554	Jan 19, 2026	DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	>A> 7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	>A> 7538108	Mar 28, 2026	DS	U-2294	ODE-174	Apr 17, 2025
	>A> 7989448	Jun 12, 2026	DS	U-2294		
	>A> 8163902	Jun 17, 2026	DS	U-2294		
	>A> 8211889	Jan 19, 2026	DS			
	>A> 8263122	Nov 24, 2030	DP			
	>A> 8445485	Jun 17, 2026	DP			
	>A> 8652492	Nov 06, 2028	DP			
	>A> 8771648	Jul 27, 2032	DP			
	>A> 8912170	Jun 17, 2026		U-2294		
	>A> 8951504	Jul 27, 2032		U-2294		
	>A> 9266912	Jan 19, 2026		U-2294		
	>A> 9283238	Jun 17, 2026		U-2294		
	>A> 9737554	Jan 19, 2026	DP			
<u>GADOXETATE DISODIUM - FOVIST</u>						
N 022090 002	>A> 6039931	Nov 13, 2021		U-1239		
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 001	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 002	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 004	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 005	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	9931304	Jun 27, 2021	DP			
	>A> 9962338	Jun 27, 2021	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	9931304	Jun 27, 2021	DP			
	>A> 9962338	Jun 27, 2021	DP			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	9913910	Sep 28, 2024	U-2253			
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
N 210566 001					>A> NDF	May 24, 2021
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	7348361	Nov 06, 2020	DP U-1087		M-220	Feb 15, 2021
	7348361	Nov 06, 2020	DP U-2250			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9872837	Dec 21, 2031	DP			
<u>HYDROCORTISONE BUTYRATE - HYDROCORTISONE BUTYRATE</u>						
A 209556 001					PC	Aug 11, 2018
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 001	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 002	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 003	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 004	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 005	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9789257	Feb 11, 2034	DP			
	9844558	May 02, 2036	U-2236			
	RE44846	Aug 10, 2019	DP			
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 001					>A> ODE-177	Dec 21, 2024
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 002					>A> ODE-177	Dec 21, 2024
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026		U-1456		
	8476284	Dec 28, 2026		U-1650		
	8476284	Dec 28, 2026		U-1946		
	8476284	Dec 28, 2026		U-1947		
	8497277	Dec 28, 2026		U-1456		
	8497277	Dec 28, 2026		U-1491		
	8497277	Dec 28, 2026		U-1650		
	8497277	Dec 28, 2026		U-1946		
	8497277	Dec 28, 2026		U-1947		
	8563563	Apr 26, 2027		U-1491		
	8563563	Apr 26, 2027		U-1946		
	8563563	Apr 26, 2027		U-2219		
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026		U-1491		
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031		U-1456		
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026		U-1456		
	8952015	Dec 28, 2026		U-1491		
	8952015	Dec 28, 2026		U-1650		
	8952015	Dec 28, 2026		U-1946		
	8952015	Dec 28, 2026		U-1947		
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031		U-1491		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	89999999	Jun 03, 2031	U-1946			
	89999999	Jun 03, 2031	U-2228			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026		U-1456		
	8476284	Dec 28, 2026		U-1650		
	8476284	Dec 28, 2026		U-1946		
	8476284	Dec 28, 2026		U-1947		
	8476284	Dec 28, 2026		U-2241		
	8497277	Dec 28, 2026		U-1456		
	8497277	Dec 28, 2026		U-1491		
	8497277	Dec 28, 2026		U-1650		
	8497277	Dec 28, 2026		U-1946		
	8497277	Dec 28, 2026		U-1947		
	8497277	Dec 28, 2026		U-2241		
	8497277	Dec 28, 2026		U-2242		
	8563563	Apr 26, 2027		U-1491		
	8563563	Apr 26, 2027		U-1946		
	8563563	Apr 26, 2027		U-2241		
	8563563	Apr 26, 2027		U-2242		
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026		U-1491		
	8703780	Dec 28, 2026		U-2242		
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031		U-1456		
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026		U-1456		
	8952015	Dec 28, 2026		U-1491		
	8952015	Dec 28, 2026		U-1650		
	8952015	Dec 28, 2026		U-1946		
	8952015	Dec 28, 2026		U-1947		
	8952015	Dec 28, 2026		U-2241		
	8952015	Dec 28, 2026		U-2242		
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031		U-1491		
	8999999	Jun 03, 2031		U-1946		
	8999999	Jun 03, 2031		U-2241		
	8999999	Jun 03, 2031		U-2242		
	9125889	Jun 03, 2031		U-1650		
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034		U-2150		
	9801881	Jun 03, 2031		U-1491		
	9801881	Jun 03, 2031		U-2242		
	9801883	Jun 03, 2031		U-2159		
	9801883	Jun 03, 2031		U-2243		
	9814721	Jun 03, 2031		U-1947		
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026		U-1456		
	8476284	Dec 28, 2026		U-1650		
	8476284	Dec 28, 2026		U-1946		
	8476284	Dec 28, 2026		U-1947		
	8476284	Dec 28, 2026		U-2241		
	8497277	Dec 28, 2026		U-1456		
	8497277	Dec 28, 2026		U-1491		
	8497277	Dec 28, 2026		U-1650		
	8497277	Dec 28, 2026		U-1946		
	8497277	Dec 28, 2026		U-1947		
	8497277	Dec 28, 2026		U-2241		
	8497277	Dec 28, 2026		U-2242		
	8563563	Apr 26, 2027		U-1491		
	8563563	Apr 26, 2027		U-1946		
	8563563	Apr 26, 2027		U-2241		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	8563563	Apr 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026			U-1491	
	8703780	Dec 28, 2026			U-2242	
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031			U-1456	
	8754091	Dec 28, 2026		DP		
	8952015	Dec 28, 2026			U-1456	
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	
	8952015	Dec 28, 2026			U-1947	
	8952015	Dec 28, 2026			U-2241	
	8952015	Dec 28, 2026			U-2242	
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031			U-1491	
	8999999	Jun 03, 2031			U-1946	
	8999999	Jun 03, 2031			U-2241	
	8999999	Jun 03, 2031			U-2242	
	9125889	Jun 03, 2031			U-1650	
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036		DP		
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034			U-2150	
	9801881	Jun 03, 2031			U-1491	
	9801881	Jun 03, 2031			U-2242	
	9801883	Jun 03, 2031			U-2159	
	9801883	Jun 03, 2031			U-2243	
	9814721	Jun 03, 2031			U-1947	
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026			U-1456	
	8476284	Dec 28, 2026			U-1650	
	8476284	Dec 28, 2026			U-1946	
	8476284	Dec 28, 2026			U-1947	
	8476284	Dec 28, 2026			U-2241	
	8497277	Dec 28, 2026			U-1456	
	8497277	Dec 28, 2026			U-1491	
	8497277	Dec 28, 2026			U-1650	
	8497277	Dec 28, 2026			U-1946	
	8497277	Dec 28, 2026			U-1947	
	8497277	Dec 28, 2026			U-2241	
	8497277	Dec 28, 2026			U-2242	
	8563563	Apr 26, 2027			U-1491	
	8563563	Apr 26, 2027			U-1946	
	8563563	Apr 26, 2027			U-2241	
	8563563	Apr 26, 2027			U-2242	
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026			U-1491	
	8703780	Dec 28, 2026			U-2242	
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031			U-1456	
	8754091	Dec 28, 2026		DP		
	8952015	Dec 28, 2026			U-1456	
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	
	8952015	Dec 28, 2026			U-1947	
	8952015	Dec 28, 2026			U-2241	
	8952015	Dec 28, 2026			U-2242	
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031			U-1491	
	8999999	Jun 03, 2031			U-1946	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9072661	Mar 16, 2032	U-2264			
	9072710	Mar 16, 2032	U-2266			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	9861603	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	9861603	Dec 18, 2026	U-1440			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	9884094	May 01, 2033	U-2238			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR</u>						
N 206538 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP	U-1832		
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP	U-1855		
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP	U-2146		
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9950039	Dec 10, 2035	U-2277			
	9950039	Dec 10, 2035	U-2278			
	9950039	Dec 10, 2035	U-2279			
<u>INSULIN LISPRO - ADMELOG SOLOSTAR</u>						
N 209196 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP	U-1832		
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN LISPRO - ADMELOG SOLOSTAR</u>						
N 209196 002	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 04, 2024	DP U-2146			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	9943571	Aug 11, 2029	U-1537			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	9943571	Aug 11, 2029	U-1537			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	9943571	Aug 11, 2029	U-1537			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8629162	Jun 24, 2025	U-2234			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	8629162	Jun 24, 2025	U-2234			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	8629162	Jun 24, 2025	U-2234			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	7495103	May 20, 2027	DS DP		NCE	Feb 12, 2023
	7645789	May 01, 2027	DS DP		ODE-173	Feb 12, 2025
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2246			
	8598181	May 01, 2027	U-2246			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2247			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2248			
	9670163	Dec 28, 2026	DP U-2246			
	9931334	Dec 28, 2026	DP U-2275			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9931334	Dec 28, 2026	DP U-2276		M-218	Jan 25, 2021
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	9931334	Dec 28, 2026	DP U-2276		M-218	Jan 25, 2021
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 001	9901546	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 002	9901546	May 17, 2019	DP			
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001 >A>	9956205	Dec 28, 2031	U-2311			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002					ODE-165	Nov 08, 2024
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001 >A>	9868739	Nov 09, 2031	U-1981			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9914802	Nov 13, 2020	DS DP U-1666			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7723390	Mar 14, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 013	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	9283174	May 10, 2031	DP		NP	Feb 28, 2021
	9925264	May 10, 2031	DP U-2267			
	9931403	May 10, 2031	DP			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	9890141	Oct 21, 2030	DS			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001 >A>	9968659	Jan 09, 2037	U-2313			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	9440029	Jan 30, 2032	DP			
	9855388	Apr 24, 2029	DP U-1881			
	>A> 9981013	Aug 30, 2030	U-2297			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	9440029	Jan 30, 2032	DP			
	9855388	Apr 24, 2029	DP U-1881			
	>A> 9981013	Aug 30, 2030	U-2297			
<u>LOFEXIDINE HYDROCHLORIDE - LUCEMYRA</u>						
N 209229 001					>A> NCE	May 16, 2023
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	9861622	Mar 07, 2025	U-1316			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001					M-225	Apr 26, 2021
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002					M-225	Apr 26, 2021
<u>LULICONAZOLE - LUZU</u>						
N 204153 001					NPP	Feb 20, 2021
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001					NCE ODE-166	Jan 26, 2023 Jan 26, 2025
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001	6861409	Aug 01, 2022	DS DP U-2220		ODE-170	Dec 20, 2024
	8192719	Oct 12, 2027	U-2220			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	7094781	Dec 05, 2025	DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 002	8323692	Mar 30, 2023	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9855215	Jan 02, 2033	DP			
<u>METOPROLOL SUCCINATE - METOPROLOL SUCCINATE</u>						
N 210428 001	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - METOPROLOL SUCCINATE</u>						
N 210428 002	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - METOPROLOL SUCCINATE</u>						
N 210428 003	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - METOPROLOL SUCCINATE</u>						
N 210428 004	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	9943526	Apr 20, 2036	U-1643			
<u>MIRABEGRON - MYRBETRIQ</u>						
N 202611 001	>A> 8772315	Oct 30, 2028	U-2300		I-777	Apr 27, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	>A> 8772315	Oct 30, 2028	U-2300		I-777	Apr 27, 2021
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310 001	7544192	Nov 29, 2026	U-2272			
	7662141	Mar 12, 2024	U-2272			
	7713255	Mar 12, 2024	U-2272			
	7951130	Mar 12, 2024	U-2272			
	7951131	Mar 12, 2024	U-2272			
	7951133	Mar 12, 2024	U-2272			
	8025635	Jun 12, 2027	DP U-2272			
	8109918	Mar 12, 2024	U-2272			
	8763222	Feb 08, 2032	DP			
	9585681	Apr 04, 2026	U-2272			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 001	9907793	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 002	9907793	Apr 04, 2023	DP U-1556			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	9931336	Mar 14, 2034	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	>A> 8623826	Nov 18, 2030	U-2293			
	>A> 9186357	Nov 18, 2030	U-2293			
	>A> 9271975	Sep 09, 2031	U-2293			
	>A> 9943515	Nov 18, 2030	U-2293			
	>A> 9951016	Sep 25, 2035	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 003	7169791	Jul 04, 2023	DS DP U-836		NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
	8293756	Sep 25, 2027	DP		ODE-172	Mar 22, 2025
	8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2021
	8415363	Jul 18, 2026	DS DP U-1407		PED	Sep 22, 2025
	8501760	Jul 18, 2026	DS DP		PED	Sep 22, 2025
	9061029	Apr 07, 2032	DS DP U-1374			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	9907756	Jun 07, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	9907756	Jun 07, 2029	DP			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003					M-167	Oct 09, 2018
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	9926559	Jan 09, 2034	U-1943	>A>	M-226	May 14, 2021
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001					I-762	Jan 12, 2021
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002					I-762	Jan 12, 2021
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2019	DP			
	5948818	May 13, 2019	DP			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	>A> 8946235	Aug 08, 2032	DS DP U-1777		I-774	Apr 18, 2021
	>A> 8946235	Aug 08, 2032	DS DP U-2289		>A> ODE-176	Apr 18, 2025
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	>A> 8946235	Aug 08, 2032	DS DP U-1777		I-774	Apr 18, 2021
	>A> 8946235	Aug 08, 2032	DS DP U-2289		>A> ODE-176	Apr 18, 2025
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	>A> 9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	>A> 9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	>A> 9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	>A> 9968598	Sep 02, 2036	DP U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005 >A>	9968598	Sep 02, 2036	DP U-1556			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001 >A>	9974773	Jun 11, 2035	U-2306			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2019	DS			
	9180200	Jan 29, 2032	DP U-805			
	9399014	Dec 15, 2029	U-805			
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 090713 002					PC	Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 001					PC	Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 002					PC	Sep 19, 2018
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739 001	9925212	Oct 08, 2033	U-1766			
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739 002	9925212	Oct 08, 2033	U-1766			
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739 003	9925212	Oct 08, 2033	U-1766			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	8420674	Dec 18, 2027	U-2079			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	7566729	Apr 22, 2029	U-2269			
	7566729	Apr 22, 2029	U-2270			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2054			
	8084475	Jan 08, 2030	U-2268			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8420674	Dec 18, 2027	U-2079			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	9610321	Sep 15, 2031	U-1999		I-764	Jan 24, 2021
	9610321	Sep 15, 2031	U-2230			
	9919024	Sep 15, 2031	U-1999			
	9919024	Sep 15, 2031	U-2230			
	9925231	Sep 15, 2031	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
<u>PREGABALIN - LYRICA</u>						
N 021446 001					>A> NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 002					>A> NPP	May 03, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u> N 021446 003					>A> NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u> N 021446 004					>A> NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u> N 021446 005					>A> NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u> N 021446 006					>A> NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u> N 021446 007					>A> NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u> N 021446 008					>A> NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u> N 022488 001					>A> NPP	May 03, 2021
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u> N 203971 001	6635234	Nov 17, 2022	U-2271			
<u>REGORAFENIB - STIVARGA</u> N 203085 001	>A> 9957232	Jul 09, 2032	DS			
<u>RIBOCICLIB SUCCINATE - KISOALI</u> N 209092 001	>A> 9868739	Nov 09, 2031	U-1981			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u> N 202022 001					M-223	Feb 01, 2021
<u>RIOCIQUAT - ADEMPAS</u> N 204819 001	>A> 7173037	Dec 04, 2026	DS DP			
<u>RIOCIQUAT - ADEMPAS</u> N 204819 002	>A> 7173037	Dec 04, 2026	DS DP			
<u>RIOCIQUAT - ADEMPAS</u> N 204819 003	>A> 7173037	Dec 04, 2026	DS DP			
<u>RIOCIQUAT - ADEMPAS</u> N 204819 004	>A> 7173037	Dec 04, 2026	DS DP			
<u>RIOCIQUAT - ADEMPAS</u> N 204819 005	>A> 7173037	Dec 04, 2026	DS DP			
<u>RITONAVIR - RITONAVIR</u> A 202573 001					PC	Sep 16, 2018
<u>RIVAROXBAN - XARELTO</u> N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-2142			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9539218	Feb 17, 2034	U-2143			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	>A> 7592339	Dec 11, 2020	U-1167			
	>A> 7592339	Dec 11, 2020	U-1200			
	>A> 7592339	Dec 11, 2020	U-1301			
	>A> 7592339	Dec 11, 2020	U-1302			
	>A> 7592339	Dec 11, 2020	U-1303			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001				>A> D-171		Jan 23, 2021
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 002	5712298	Jan 27, 2020	DS DP U-1115		NS	Jan 23, 2021
	8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024	U-1115			
	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			
	9468598	Feb 19, 2023	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 002	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 003	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 004	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	9925150	Mar 01, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	9925150	Mar 01, 2032	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	7351701	Jul 23, 2024	U-2012		I-772	Apr 06, 2021
	7351701	Jul 23, 2024	U-2101		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	7351701	Jul 23, 2024	U-2012		I-772	Apr 06, 2021
	7351701	Jul 23, 2024	U-2101		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	7351701	Jul 23, 2024	U-2012		I-772	Apr 06, 2021
	7351701	Jul 23, 2024	U-2101		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9856265	Jul 28, 2026	DS DP U-1467			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	>A> 6332985	Mar 29, 2019	U-2312		>A> NCE	May 18, 2023
	>A> 8802152	Apr 19, 2032	DS			
	>A> 8808750	Feb 10, 2032	U-2312			
	>A> 8877255	Oct 22, 2033	DS			
	>A> 9592253	Oct 14, 2035	DS U-2312			
	>A> 9844567	Feb 10, 2032	U-2312			
	>A> 9861658	Feb 10, 2032	U-2312			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	>A> 6332985	Mar 29, 2019	U-2312		>A> NCE	May 18, 2023
	>A> 8802152	Apr 19, 2032	DS			
	>A> 8808750	Feb 10, 2032	U-2312			
	>A> 8877255	Oct 22, 2033	DS			
	>A> 9592253	Oct 14, 2035	DS U-2312			
	>A> 9844567	Feb 10, 2032	U-2312			
	>A> 9861658	Feb 10, 2032	U-2312			
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	9868745	Nov 16, 2032	DS DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 001					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 002					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 003					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 004					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9855241	Jan 25, 2033	U-2149			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	>A> 9968655	Nov 01, 2025	U-2308			
	>A> 9968656	Nov 01, 2025	U-2308			
	>A> 9968658	Nov 01, 2025	U-1320			
	>A> 9974835	Nov 01, 2025	U-1320			
	>A> 9974837	Nov 01, 2025	U-1320			
	>A> 9981014	Nov 01, 2025	U-1320			
	>A> 9981016	Nov 01, 2025	U-1320			
	>A> 9987334	Nov 01, 2025	U-1320			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	001				>A> I-780	May 30, 2021
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	002				>A> I-780	May 30, 2021
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246	001	9937181	Mar 14, 2034	DP		
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	001	>A> 5753677	May 19, 2020	U-2307	>A> I-779	Apr 23, 2021
		>A> 5972882	Dec 14, 2018	U-2307	>A> ODE-178	Apr 23, 2025
		>A> 8501730	Sep 01, 2026	DS		
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	002	>A> 5753677	May 19, 2020	U-2307	>A> I-779	Apr 23, 2021
		>A> 5972882	Dec 14, 2018	U-2307	>A> ODE-178	Apr 23, 2025
		>A> 8501730	Sep 01, 2026	DS		
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	003	>A> 5753677	May 19, 2020	U-2307	>A> I-779	Apr 23, 2021
		>A> 5972882	Dec 14, 2018	U-2307	>A> ODE-178	Apr 23, 2025
		>A> 8501730	Sep 01, 2026	DS		
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	004	>A> 5753677	May 19, 2020	U-2307	>A> I-779	Apr 23, 2021
		>A> 5972882	Dec 14, 2018	U-2307	>A> ODE-178	Apr 23, 2025
		>A> 8501730	Sep 01, 2026	DS		
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	005	>A> 5753677	May 19, 2020	U-2307	>A> I-779	Apr 23, 2021
		>A> 5972882	Dec 14, 2018	U-2307	>A> ODE-178	Apr 23, 2025
		>A> 8501730	Sep 01, 2026	DS		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	001	7378423	May 29, 2027	DS DP	I-778	Apr 30, 2021
		>A> 8835443	Jun 10, 2025	U-1581	>A> I-781	May 04, 2021
		>A> 8835443	Jun 10, 2025	U-1582		
		>A> 8835443	Jun 10, 2025	U-2020		
		>A> 8835443	Jun 10, 2025	U-2037		
		>A> 8835443	Jun 10, 2025	U-2302		
		>A> 8835443	Jun 10, 2025	U-2305		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	002	7378423	May 29, 2027	DS DP	I-778	Apr 30, 2021
		>A> 8835443	Jun 10, 2025	U-1581	>A> I-781	May 04, 2021
		>A> 8835443	Jun 10, 2025	U-1582		
		>A> 8835443	Jun 10, 2025	U-2020		
		>A> 8835443	Jun 10, 2025	U-2037		
		>A> 8835443	Jun 10, 2025	U-2302		
		>A> 8835443	Jun 10, 2025	U-2305		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	003	7378423	May 29, 2027	DS DP	I-778	Apr 30, 2021
		>A> 8835443	Jun 10, 2025	U-1581	>A> I-781	May 04, 2021
		>A> 8835443	Jun 10, 2025	U-1582		
		>A> 8835443	Jun 10, 2025	U-2020		
		>A> 8835443	Jun 10, 2025	U-2037		
		>A> 8835443	Jun 10, 2025	U-2302		
		>A> 8835443	Jun 10, 2025	U-2305		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	>A> 8497393	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	>A> 8497393	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	>A> 8497393	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	>A> 8497393	Dec 15, 2028	DS	Y		
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	8534281	Mar 08, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8534281	Mar 08, 2030	DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	7173038	Aug 14, 2021	DS DP			
	8642608	Feb 06, 2022			U-1490	
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	7173038	Aug 14, 2021	DS DP			
	8642608	Feb 06, 2022			U-1490	
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	9937223	Jan 30, 2035			U-1857	
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7713999	May 30, 2024	DS DP	U-2291		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	>A> 9125908	Jun 15, 2027		U-2309	>A> M-227	May 02, 2021
	>A> 9125909	Jun 15, 2027		U-2309		
	>A> 9125910	Jun 15, 2027		U-2309		
	9861630	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	>A> 9125908	Jun 15, 2027		U-2309	>A> M-227	May 02, 2021
	>A> 9125909	Jun 15, 2027		U-2309		
	>A> 9125910	Jun 15, 2027		U-2309		
	9861630	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	>A> 9125908	Jun 15, 2027		U-2309	>A> M-227	May 02, 2021
	>A> 9125909	Jun 15, 2027		U-2309		
	>A> 9125910	Jun 15, 2027		U-2309		
	9861630	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	>A> 9125908	Jun 15, 2027		U-2309	>A> M-227	May 02, 2021
	>A> 9125909	Jun 15, 2027		U-2309		
	>A> 9125910	Jun 15, 2027		U-2309		
	9861630	Jun 15, 2027		U-1668		

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as

described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 38th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm